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Preface  
One of the main hurdles in medicinal chemistry is the presence of the blood-brain 
barrier. This mono-layer of cerebral endothelial cells prevents passage of basically all 
molecules into the brain parenchyma, except for a few low molecular weight lipophilic 
molecules. Small polar molecules and proteins can only cross the blood-brain barrier via 
receptor mediated transcytosis (Figure 1). Most potent drugs, developed for brain and 
central nervous system related diseases, lack the ability to cross the blood-brain barrier. 
Furthermore, since most drugs are hydrophobic they also suffer from low 
bioavailability1. Both hurdles might be tackled by the development of drug formulations 
in the form of nano-carriers. A specific group of nano-carriers are polymeric vesicles or 
polymersomes which have gained much attention over the past 10 years. 
 
 
Figure 1. a) The blood brain barrier is 
formed by a monolayer of cerebral 
endothelial cells, forming a barrier that 
physically separates the blood stream from 
the brain parenchyma. b) Cerebral endo-
thelial cells are connected via tight 
junctions that effectively seal the 
paracellular pathway. Small polar 
molecules and larger proteins can only 
enter the brain by receptor mediated 
transport, specifically designed to regulate 
the microenvironment of the brain. 
Reprinted with permission (Ref. 1) 
 
 
Polymersomes are spherical vesicles that are composed of amphiphilic block 
copolymers. The amphiphilic polymers form a bilayered structure, enclosing a aqueous 
lumen, while the bilayered membrane forms a hydrophobic compartment of 10 – 20 nm 
in thickness2,3 (Figure 2). When the overall structure is regarded the resemblance with 
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liposomes is clear, yet there are also some major differences. Polymersomes are formed 
from amphiphilic block copolymers with a molecular weight of 5-100 kDa, whereas 
liposomes are assembled from phospholipids with an average weight of 500-800 Da. 
The higher molecular weight of the building blocks establishes itself in a lower critical 
micelle concentration, resulting in a more robust and stable membrane. Furthermore, 
the membrane is thicker, which allows for a more efficient storage and transport of 
hydrophobic drugs. These features render polymersomes as potent nonocariers for 
biomedical applications, like (targeted) drug delivery4 and in vivo imaging5. 
 
 
Figure 2. Schematic presentation of 
polymersomes formed from a bilayer of 
amphiphilic block copolymers. The surface 
is tagged with peptides as which mediate 
transport over the blood-brain barrier. 
Furthermore, tracking moieties are 
included for visualization and radio-
isotope labelling. 
 
 
 The research described herein aims at the development of polymersomes as smart 
nano-carriers to target and accommodate transport over the blood-brain barrier (Figure 
2). In order to design such a carrier we need to develop a good understanding of factors 
like size, stability and stealth character that will influence in vivo behaviour. 
Furthermore, a reliable synthetic platform is needed to be able to synthesize 
biocompatible amphiphilic polymers that self-assemble in polymersomes of controlled 
size. These arguments form the basic design criteria of polymersome for biomedical 
applications. In order to target the vesicles to the brain, or any tissue of interest, there is 
also a need to introduce targeting and/or tracking moieties at the periphery. Therefore 
reliable chemistry is essential to modify the periphery of vesicles, while keeping good 
control over the overall stability. Finally, with the chemistry available there is a need for 
efficient and specific targeting moieties, which are still active after they have been 
coupled to the periphery of polymersomes.  
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 In Chapter 16 recent literature on the design and use of polymeric vesicles in 
biomedical application was reviewed. Next, in Chapter 2 the platform chemistry to 
synthesise block copolymers, self-assemble polymersomes of well defined size and 
functionalize the periphery with peptides and fluorescent tracers was developed. In 
Chapter 37 the effect of polymersome size on in vivo circulation was evaluated via the 
quantitative method of radio-isotope labelling. Furthermore these polymersomes were 
applied in SPECT/CT imaging. In Chapter 48, polymersomes tagged with a small peptide 
(G23) that recognizes gangliosides GM1 and GT1b were developed. These vesicles were 
shown to accommodate blood-brain barrier transport both in vitro and in vivo. Next, in 
Chapter 59 a more quantitative study after the biodistribution of G23 tagged 
polymersomes was performed. For that purpose, polymersomes were both targeted and 
labelled with a radio-isotope. 
  In the final two chapters a more fundamental study after the controlled modification 
of the surface topology of polymersomes was performed. In Chapter 610 block 
copolymer analogues were prepared of which the blocks were connected via a 
hydrazone bond. By mixing in this polymer, and applying acidic conditions, it was shown 
that the degree of surface PEGylation can be controlled from 100 to 5 percent. Below 5 
percent PEGylation the colloidal stability was lost in a pH dependent rate. Finally, in 
Chapter 711 polymersomes from hydrazone-coupled block copolymers were shown to 
exchange surface PEG chains between vesicles and the enviroment via the aniline 
catalyzed transimination equilibrium. This method allowed to modify the polymersome-
periphery to form complex (asymmetrically)-functionalized vesicles. 
 
(1) Cecchelli, R.; Berezowski, V.; Lundquist, S.; Culot, M.; Renftel, M.; Dehouck, M. P.; Fenart, L. Nat Rev Drug Discov 2007, 6, 
650. 
(2) Discher, B. M.; Won, Y. Y.; Ege, D. S.; Lee, J. C. M.; Bates, F. S.; Discher, D. E.; Hammer, D. A. Science 1999, 284, 1143. 
(3) Discher, D. E.; Eisenberg, A. Science 2002, 297, 967. 
(4) Ahmed, F.; Pakunlu, R. I.; Srinivas, G.; Brannan, A.; Bates, F.; Klein, M. L.; Minko, T.; Discher, D. E. Mol Pharmaceut 2006, 
3, 340. 
(5) Christian, D. A.; Garbuzenko, O. B.; Minko, T.; Discher, D. E. Macromol Rapid Comm 2010, 31, 135. 
(6) Brinkhuis, R. P.; Rutjes, F. P. J. T.; van Hest, J. C. M. Polym Chem-Uk 2011, 2, 1449. 
(7) Brinkhuis, R. P.; Stojanov, K.; Laverman, P.; Eilander, J.; Zuhorn, I. S.; Rutjes, F. P. J. T.; van Hest, J. C. M. Bioconjugate 
Chemistry 2012, 23, 958. 
(8) Georgieva, J.; Brinkhuis, R. P.; Stojanov, K.; Weijers, C. A. G. M.; Zuilhof, H.; Rutjes, F. P. J. T.; Hoekstra, D.; van Hest, J. C. 
M.; Zuhorn, I. S. Angewandte Chemie int. ed. 2012, 51, 8339. 
(9) Stojanov, K.; Georgieva, J.; Brinkhuis, R. P.; van Hest, J. C. M.; Rutjes, F. P. J. T.; Dierckx, R. A. J. O.; de Vries, E. F. J., Mol. 
Pharm. 2012, 9, 1620. 
(10) Brinkhuis, R. P.; Visser, T. R.; Rutjes, F. P. J. T.; van Hest, J. C. M. Polym Chem-Uk 2011, 2, 550. 
(11) Brinkhuis, R. P.; de Graaf, F.; Borre Hansen, M.; visser, T. R.; Rutjes, F. P. J. T.; van Hest, J. C. M., Polym Chem-UK, 
accepted. 
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Polymeric Vesicles in Biomedical Applications 
 
 
 
 
 
 
 
 
 
 
Polymeric vesicles, or polymersomes, are nano- to micrometer sized polymeric capsules with a bilayered 
membrane. Applications of these vesicles are foreseen in nano medicine, in vivo imaging and drug 
delivery. Such applications put many restrictions on the choice of polymer, the size and the surface of the 
vesicle. In this respect much can be learned and translated to polymersome science from lines of 
research with a longer history of practical knowledge such as liposomal formulation and polymer drug 
conjugation. The dimensions of a vesicle, such as size and shape can be controlled for polymersomes and 
will influence the in vivo circulation time. The surface can be adjusted to induce stealth character, or 
chemically modified to introduce targeting moieties. And last but not least the choice of block 
copolymers - the building blocks of a polymersome - can introduce features like biocompatibility, 
inherent or induced permeability and triggered release. In this Chapter we will discuss the recent 
advances in polymersome science with regard to biomedical applications and will specifically address 
the abovementioned features which affect their biological behaviour 
 
 
 
 
 
 
 
 
 
René P. Brinkhuis, Floris P.J.T. Rutjes and Jan C.M. van Hest, Polymer Chemistry 2011, 2, 1449-1462 
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1.1 Introduction 
Polymeric vesicles, or polymersomes, are nano- to micro- meter-sized polymeric 
capsules with a bilayered membrane which is comprised of amphiphilic block 
copolymers. Although the aggregation behaviour of amphiphilic polymers was 
noticed before1-4, the first systematic study after the formation of polymersomes was 
reported by Discher et al.5. In this paper the name polymersomes was coined, in 
analogy to liposomes. With regard to the bilayer membrane architecture, the 
similarity between polymersomes and liposomes is obvious in the sense that both 
species are composed of a bilayer of amphiphiles enclosing an aqueous compartment. 
There are however also major differences. The building blocks of liposomes are in 
most cases naturally occurring phospholipids with a molecular weight well below 1 
kDa; a polymersome is constructed of amphiphilic block copolymers with a 
molecular weight of up to 100 kDa. This higher molecular weight of the building 
blocks manifests itself in a tougher, less permeable and less fluidic membrane and as 
a result superior physical and chemical stability. With regard to the use of high 
molecular weight building blocks and the resulting robustness of the capsule 
structure one can argue that polymersomes resemble to a certain extent viral 
capsids6-7 and therefore can be interesting candidates for in vivo and cellular 
delivery.  
 
 Amphiphilic block copolymers have not only been found to form vesicular 
structures; in fact, the formation of a bilayered vesicular structure puts quite some 
restrictions on the overall block copolymer composition. Depending on the ratio 
between the hydrophobic and hydrophilic part of the polymer, spherical micelles, 
rods and vesicles have been found to form spontaneously8. The morphology that is 
observed is dependent on the geometry of the amphiphile, which can vary between 
cylindrical and conical depending on the ratio of the hydrophobic and hydrophilic 
segments. For small molecular weight amphiphiles this geometry is captured in the 
dimensionless packing parameter9-10 - depicted in Figure 1 - which to some extent 
can also be translated to polymeric amphiphiles. More intuitively, however, the 
hydrophilic fraction (f) is better suited to predict the expected morphology 6-8. 
Polymeric Vesicles in Biomedical Applications 
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Figure 1. Several structures formed by the self assembly of amphiphilic block copolymers as determined 
by the geometry of the amphiphile. The geometry is captured by the dimensionless packing parameter 
p=V/(a0lc). Reprinted with permission (ref. 10)10. 
Block copolymers with a hydrophilic fraction of more than 45 – 50 percent will 
mostly yield micelles. In the region where f is around 35 ± 10% in many cases 
polymersomes are observed and in case the hydrophilic fraction is less than 25 
percent, inverted structures can be expected. Finally, there is a small region where 
worm-like micelles have been reported, when the hydrophilic fraction is around 50 
percent. Although this basic empirical rule holds quite well in most cases, the exact 
aggregation behaviour can depend strongly on the type of block copolymer and the 
conditions applied.  
 
 Polymersomes have been prepared in a variety of ways. Among them two 
methods seem to be favoured. First of all the “solvent switch” method is broadly 
applied11-12. The block copolymer is dissolved in an organic solvent which is a good 
solvent for both blocks. The organic solvent is diluted with or injected in a non-
solvent of one of the blocks, mostly water or a buffered solution, until the desired 
aggregates are formed. Residual organic solvents are removed by dialysis or are 
allowed to evaporate. One of the major drawbacks is the need of an organic solvent 
which is not always compatible with applications in which bioactive compounds have 
to be encapsulated. Furthermore, traces of the organic solvents tend to stay behind 
which is not desirable for in vivo applications. The second general method is a 
Chapter 1 
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technique based on rehydration12. A polymer film is cast on a substrate and an 
aqueous solution is used to rehydrate the polymer to form vesicles. Furthermore, 
methods like electro formation, bulk rehydration and rehydration from pre-treated 
substrates have been applied. The choice of the method of formation has a big 
influence on the properties such as size of the obtained vesicles.  
 
 Vesicles are thought to form in a two-step procedure. In an early stage of 
formation a flat bilayer is formed from micelles or polymer clusters, as depicted in 
Figures 2a-b. Thereafter under the influence of a curvature change, and therefore a 
change in packing parameter, this sheet will form a closed structure or a vesicle 13-14. 
This mechanism is depicted in the cartoon presented in Figure 3.  This sequence of 
events leads to statistical encapsulation of compounds dissolved in the water layer, 
but does not provide an explanation for the many fascinating shapes found 
experimentally13. More recent simulation studies show the possibility of an 
alternative, more complex, mechanism in which vesicles do not evolve from the 
closing of a bilayer membrane, but evolve from micelles that grow and change 
morphology14-15. It should be noted that for the second pathway the loading 
efficiency of hydrophilic compounds would be lower compared to the former one 
since there is no closure, and hence encapsulation step involved. Experimentally, 
polymersome formation along path I is supported by Du et al.16 (Figure 2). They were 
able to trap and visualize transition states like micelles and lamellae that eventually 
formed polymersomes by systematically adjusting the solvent polarity and 
chemically locking the structure prior to transmission electron microscope (TEM) 
imaging. Experimental evidence for the second route was found by Adams et al.17 
They showed that indeed poor loading efficiencies for hydrophilic compounds were 
found. These two seemingly contradictive experimental results show that it is 
possible that multiple mechanisms of formation do exist, depending on the exact 
conditions applied14. 
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Figure 2. Several stages of polymersome formation captured by Du and co-workers16 as a function of the 
water/organic solvent ratio. First spheres and rods are formed that transform into lamella which close to 
form polymersomes due to an increase in water content. Reprinted with permission (ref. 16). 
 
Figure 3. Cartoon of polymersome formation along path I as described by Antonietti et al.13. First spheres 
transforming into sheets are formed which close in a second step to form polymersomes. Reprinted with 
permission (ref. 13). 
 The field of polymersome research has been reviewed extensively in the past 
6,10,12,18-25 and often the potential of polymersomes for biomedical applications such 
as smart drug delivery systems, in vivo imaging vehicles or artificial organelles is 
mentioned. Many of these applications involve cell specific interactions and/or 
require non-toxic and tuneable in vivo behaviour, and these criteria put quite some 
restrictions on e.g. the choice of polymer and the polymersome dimensions. In the 
remainder of this chapter we specifically address the factors that affect the use of 
polymersomes in biomedical applications. In the next sections we will focus on 
suitable components for the construction of polymeric vesicles for this specific field 
Chapter 1 
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of application. We will furthermore address the importance of size, topology, 
tuneable stability and permeability. Finally, a selection of functionalization methods 
will be discussed. In addition we will illustrate these topics with recent research and 
try to extrapolate facts from liposomal research to polymersomes.  
 
1.2 Block Copolymers 
The starting point of formation for any polymersome are the amphiphilic diblock or 
triblock copolymers that are the building blocks of the membrane. More than a 
decade of research into polymeric vesicles not only yielded some understanding 
underlying the formation of block copolymer nanostructures, but also allowed 
researchers to use their full creativity in the synthesis of new amphiphilic polymers. 
This resulted in an extensive library of block copolymers known today to form 
aggregates. For a comprehensive overview of polymers used for polymersome 
formation, one is referred to recent reviews on biohybrid amphiphiles24 and 
synthetic amphiphilic block copolymers10,26. This section will focus on the most 
common types of polymers used in biomedical polymersome research.  
 For biomedical applications it is obligatory to use biodegradable or at least 
biocompatible polymers as building blocks. The field of polymer drug conjugates has 
already a long history of practical knowledge on suitable polymers that are in clinical 
use/evaluation nowadays27-28. These polymers include synthetic polymers such as 
poly(ethylene glycol) (PEG), poly(N-(2-hydroxypropyl)methacrylamide) (pHPMA), 
poly(vinyl pyrrolidone) (PVP) and poly(ethylene-imine) (PEI), but also natural 
polymers like dextran, dextrin and pseudosynthetic polymers such as poly L-
glutamic acid (PGA) and poly(L-lysine) are commonly used. The translation from 
polymer drug conjugates to polymersome-forming amphiphilic block copolymers is 
not always straightforward, but many examples can be found in literature in which 
biocompatible and bio-inspired block copolymers have been employed to form 
polymeric vesicles. 
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1.2.1 Synthetic polymers 
The first well-studied polymersome-forming system was based on the biocompatible 
block copolymer poly (ethylene-oxide)-b-poly (ethyl-ethylene) (PEO-b-PEE)5. 
Although the PEE block is highly biocompatible, it is the PEO block that gives these 
polymersomes useful in vivo characteristics. The water-soluble poly (ethylene-oxide) 
(PEO) or poly (ethylene-glycol) (PEG) is a polymer which is generally known for 
good biocompatibility and excellent in vivo behaviour. Application of a PEG mantle is 
used in liposome formulations to strongly reduce in vivo and in vitro non-specific 
protein adsorption, resulting in stealth behaviour and therefore prolonged 
circulation times29-30. PEG has been coupled to many hydrophobic blocks such as the 
non-degradable polystyrene (PS) and polybutadiene (PBd)31, or biodegradable 
polymers such as polycaprolactone (PCL) or poly(lactic acid) (PLA)32-34. Each 
hydrophobic polymer introduces specifically desired characteristics in the 
polymersome. Polystyrene as an example has a relatively high glass transition 
temperature (Tg) and will yield after removal of the organic solvent a rigid semi-
crystalline membrane. Polybutadiene on the other hand has a Tg well below room 
temperature which will result in a flexible and fluidic membrane allowing for 
extrusion and therefore size control after polymersome formation. Polymersomes of 
polybutadiene-b-polyethylene glycol (PBd-b-PEG) are generally considered as fully 
biocompatible and therefore popular in research towards in vivo applications like 
drug delivery. However, polybutadiene is not biodegradable, at least not on the 
timescale of days. PCL and PLA on the other hand are biodegradable and bio-
compatible and are therefore also often encountered as the hydrophobic block 31-34.  
 Instead of using the neutral and inert PEG block as hydrophilic element, also 
some more functional moieties can be applied. The most straightforward way is to 
introduce ionic character in a block copolymer. In this way the water-soluble PEG 
block was replaced for poly acrylic acid (PAA) to introduce negatively charged acid 
residues35, but also the zwitterionic, phospholipid mimic, poly(2-methacryloyloxy-
ethyl phosphorylcholine) (PMPC) has been applied as the hydrophilic block by Armes 
and co-workers36-38. They furthermore showed that polymersomes with interesting 
pH-dependent properties are obtained if both blocks contain zwitter-ionic or 
ionisable monomers as is the case with vesicles prepared from poly(2-
(diisopropylamino)ethyl methacrylate) (PDPA) as the hydrophobic and PMPC36 as 
Chapter 1 
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the hydrophilic block. The PDPA block is hydrophobic at a pH above 6.4, but readily 
becomes hydrophilic and protonated below this pH. This results in a sharp transition 
from polymersomes to free dissolved block copolymers upon lowering the pH, which 
can be used as a drug release mechanism.  
 The previous example involved an external stimulus (pH change) to release 
content from the vesicle, but also amphiphilic block copolymers with inherently 
leaky properties have been reported. Polymersomes of polystyrene-b-poly 3-
(isocyano-L-alanyl-aminoethyl) thiophene (PS-PIAT) turned out to be excellent 
candidates for nanoreactors, since these polymersomes are permeable for small 
molecules while large molecules such as enzymes stay trapped inside3, 39. Although 
not fully understood, this permeability is probably a result of the helical rodlike 
secondary structure of the hydrophilic PIAT block, which frustrates the packing of 
the polymers in a closed bilayer.  
 These selected examples already show a few of the many possibilities to alter 
and tune the characteristics of the polymersomes, like robustness, charge and 
permeability. One crucial property however remains biocompatibility and/or 
biodegradability. It is therefore a logical step that many researchers have developed 
amphiphilic block copolymers capable of forming polymersomes which are partly 
based on naturally occurring building blocks such as amino acids, nucleotides and 
carbohydrates. 
 
1.2.2 Bio(hybrid) polymers 
Oligo- and polypeptides are highly versatile and biodegradable polymersome 
building blocks, since their properties can be varied in many different ways. A wide  
variety of secondary structures can be created based on the primary sequence of 
amino acids. By selecting the correct amino acid residues stimulus-responsive 
behaviour is introduced, such as pH dependent charge and hence solubility 40. One of 
the first reports on the formation of vesicular structures from peptide hybrids made 
use of an antibacterial hydrophobic helical peptide, Gramicidin A. By coupling 
Gramicidin A with PEG an amphiphilic block copolymer was obtained41 which readily 
formed a variety of aggregated structures in aqueous solution. Among the obtained 
structures a vesicle-like aggregate was found, which was called a peptosome2,42. 
Since then the name peptosome has been more generally used for peptide-containing 
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polymersomes. This early example involved a hydrophobic peptide which was buried 
under a PEG mantle. However, in most other cases the peptide moiety is the 
hydrophilic part, forming the periphery of the vesicles. This was for example 
demonstrated by Dirks et al.43 who coupled a tripeptide, Gly-Gly-Arg-AMC, via the 
copper-catalysed azide-alkyne Huisgen (3+2) cycloaddition to polystyrene. Even 
more common than the use of oligopeptides is the application of polypeptides as 
building blocks in polymersome-forming block copolymers. Peptides consisting of a 
repetition of the same amino acid, and block copolymers of homopolypeptides can 
nowadays be obtained in a controlled fashion by the polymerisation of N-
carboxyanhydrides (NCA) with a nickel catalyst and an amine initiator44-45. In this 
way PBd was used as the amine functional initiator to polymerize for example PBd-
poly(L-glutamate)46-49 and PBd-poly(L-lysine)50 which both have been extensively 
studied with respect to their aggregation behaviour. These examples involve a 
combination of synthetic polymers and polypeptides, but also block copolymers of 
which both the hydrophobic and the hydrophilic part are composed of polypeptides 
have been designed to form polymersomes.40,51-52 In two recent examples Kimura et 
al. showed the usefulness of peptosomes for in vivo cancer imaging53. They 
constructed peptosomes out of a block copolymer composed of poly(N-
methylglycine) and poly(γ-methyl-L-glutamate) (PMLG) in which a near infrared dye 
was encapsulated. These peptosomes showed good in vivo circulation times and low 
recognition by the reticuloendothelial system RES (blood clearance mostly by liver 
and spleen). 
 
 Another group of naturally occurring building blocks which have recently gained 
more attention are carbohydrates or polysaccharides23,54-56. In natural systems 
saccharides are conjugated to the surface of cells via lipids constituting the cell 
membrane (glycolipids), and they are also found conjugated to proteins 
(glycoproteins). These glycoconjugates play an important role in biological processes 
such as cellular recognition and pathogen infection. In many cases these processes 
are mediated via interactions between saccharides and receptor proteins, called 
lectins. In general lectins have only a low affinity for saccharides, so this needs to be 
compensated by multivalent interactions via the so-called cluster glycoside effect. 
Application of (poly)saccharides in polymersomes as hydrophilic part of block 
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copolymers or as the end group of block copolymer amphiphiles allows for the 
construction of highly functionalised and multivalent vesicle surfaces.  
 Although quite some research has focused on the synthesis of polysaccharide 
block copolymers not many examples have been reported that actually form 
polymersomes23. An example which also demonstrates specific recognition is a fairly 
simple rod-coil amphiphile, tetra(p-phenylene)-block-PEG12-α-D-mannopyranoside57 
This molecule formed small polymersomes which specifically interacted with the pili 
of a specific Escherichia coli bacterial strain as depicted in Figure 4. When the head 
group was replaced for galactose, polymersomes were still formed, but without the 
binding properties. Another example involved a β-cyclodextrin head group coupled 
to PS which also formed vesicles58. The hydrophobic interior of β-cyclodextrin was 
used to attach hydrophobic fluorescent dyes and the adamantane-coupled enzyme 
horse radish peroxidise (HRP) to the surface.  
 
 
Figure 4. Rod coil amphiphile which forms 
small vesicles. The manno-pyranoside 
head group induces recognition and 
binding to the pili of Escherichia coli. 
Replacing this moiety for galactose had no 
influence on the aggregate formation, but 
resulted in loss of recognition57. Reprinted 
with permission (ref. 57). 
 
 Block copolymers comprising polysaccharides such as dextran-b-poly(benzyl-L-
glutamate) (PBLG)54 dextran-b-PS and hyaluronan-b-PBLG59 have also been used for 
vesicle formation. Dextran-b-PS was found to form both micelles and vesicles, 
depending on the PS length. The usefulness of these peptide-carbohydrate hybrid 
polymersomes in drug delivery was nicely demonstrated in a series of recent papers 
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by Lecommandoux et al.60-62 They prepared docetaxel loaded hyaluronan-b-PBLG 
polymersomes and showed both in vivo and in vitro (tumour-) targeting by the 
hyaluronan periphery as well as release and shrinkage of the tumours in animal 
models. Finally, an elegant first example of a thermoresponsive saccharide-
containing block copolymer was reported by Otsuka et al.63. They coupled 
maltoheptaose (mal7) to poly(N-isopropylacrylamide) (PNIPAM) via click chemistry 
to obtain polymersomes. They showed that above the lower critical solution 
temperature (LCST) of PNIPAM polymersomes were spontaneously formed whereas 
below the LCST the assemblies were dissolved again. 
 
1.2.3 Polymeric vesicles with non-bilayer structures 
A group of vesicle-forming polymers exists which don’t yield a bilayer structure. An 
interesting example is the self-assembly into vesicles of ABA or ABC triblock 
copolymers64. Although the overall composition is similar to a vesicle bilayer, namely 
two hydrophilic outer blocks separated by a hydrophobic inner domain, the entire 
structure is a single layered vesicle. By changing the blocks A, B or C one can even 
direct the orientation of the polymers in the membrane, thereby obtaining 
asymmetric membranes that display different functional groups on the inside and 
outside as was elegantly demonstrated by Wolfgang Meier and co-workers. Very 
recently Percec et al.65 reported an in depth investigation into a variety of 
amphiphilic, or Janus dendrimers that formed a variety of aggregates, among them a 
vesicular structure that was named dendrimersomes. A peptidic-dendron 
polymersome was also reported to form polymersome-like structures66. Another 
interesting system comprises the so-called polyion polymer complexes or 
PICsomes67-71. They are based on two polymers with opposite charges that self-
assemble and phase separate into vesicular structures This is an example of a series 
of polymers that recognize each other and form recognition-induced aggregates, so-
called RIP’s72-74. A final example of vesicles that do not exhibit a bilayered membrane 
was developed by Caruso and Möhwald75. They showed that enzymes can be 
entrapped in vesicles that were formed by a layer-by-layer deposition of anionic and 
cationic polymers.  
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1.3 Structural Factors 
For in vivo and biomedical applications of polymersomes it is important to ascertain 
that particles circulate sufficiently long to reach the desired place. This can be 
achieved by protecting the particle from interactions with the immune system. We 
have already mentioned examples of polymers that exhibit such stealth-like 
behaviour which was attributed to the PEG surface of the particles. It should be noted 
however that although PEGylation is a good start to rule out non-specific 
interactions, it is by itself not enough to escape clearance by the RES. Not all factors 
influencing in vivo circulation times have been fully investigated yet, but in case of 
polymersomes, the analogy between polymersomes and liposomes allows for some 
extrapolation.  
 From liposome research it is known that factors like stealth-like behaviour, size 
and shape play an important role76-77. Therefore this section will review how these 
parameters can be controlled. Furthermore, we will highlight research where these 
effects have been observed.  
 
1.3.1 Stealth-like behaviour 
To prolong blood circulation times and prevent recognition by the RES a PEG mantle 
is applied in liposomal formulations by introducing up to ten percent PEGylated 
phospholipids. PEG has very useful characteristics in the sense that it blocks (almost 
all) non-specific protein adsorption and induces no immune response, basically 
giving a vessel stealth characteristics29-30. These stealth liposomes have blood 
circulation half times in the order of 15 hours and will circulate in traceable amounts 
for many days. Discher and co-workers investigated the in vivo fate of polymersomes 
formed from PBd-b-PEG by preparing polymersomes with a fluorescent dye 
entrapped78-79. These polymersomes were inherently hundred percent PEGylated. 
The blood circulation half life was determined by counting fluorescent dots in blood 
samples derived at different time points. Compared to PEGylated liposomes the 
circulation half life appeared even longer and polymersomes could still be found 
after several days. These results show that PEGylated polymersomes also display 
stealth-like behaviour. It should be noted that not only PEG has the useful 
characteristics of reducing interactions with opsonins and preventing clearance by 
Polymeric Vesicles in Biomedical Applications 
 
21 
the reticuloendothelial system (RES). Also the zwitterionic polymer PMPC has been 
recognized to reduce the adsorption of opsonins80. Other possibilities include use of 
pHPMA, and oligosaccharides such as cyclodextrin, which might be used since these 
polymers are already under investigation as polymer-conjugated therapeutics27. 
Finally in liposomal formulations poly(oxazoline) conjugates also showed prolonged 
circulation times81. The non-adsorptive character and hydration shell of the 
hydrophilic mantle is obligatory to create stealth-like particles, but it is certainly not 
enough.  
 
1.3.2 Size  
Although not fully investigated for polymeric vesicles it is known from liposome 
science that size has a big influence on blood circulation times, RES recognition, 
biodistribution and the mechanism of cell uptake76,82. Figure 5 shows a literature 
compilation by Harashima et al. on the influence of the size of liposomes on the 
circulation time. What is not clear from this picture is that there is also a lower limit 
for prolonged circulation times. The junctions in vascular endothelium of healthy 
tissue vary depending on the tissue type. In most tissues these openings are below 2-
6 nm, so too small for liposomes and polymersomes to enter. Organs and tissue with 
discontinuous endothelium like the fenestrated endothelium of kidney glomerulus or 
sinusoidal endothelium of the liver and spleen can have pores of 40-60 and up to 150 
nm83. Particles with a size below these values will therefore be excreted or trapped 
within the tissue resulting in clearance from the circulation. It is notable that 
tumours can have discontinuous microvasculature with pore sizes above 100 nm. In 
fact, this is the basis for non targeted delivery to tumours since particles that are 
small enough to enter will accumulate in the tumour. Taking these mechanisms into 
account the optimum size for circulation in the blood stream is expected to be 
around 80-150 nm. It might be expected that a similar trend is valid for 
polymersomes and the polymersome size should be controlled to achieve optimal 
blood circulation half lives. 
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Figure 5. Compilation of literature by 
Harashima et al.76 on the effect of particle 
size on the blood clearance of liposomes. 
Reprinted with permission (ref. 76). 
 For polymersomes the eventual vesicle size can be influenced at different points 
in the process of preparation. The first level to exert influence is on the polymer 
level. For example, it has been shown that there is correlation between amphiphile 
molecular weight and aggregate size84. Furthermore, the polydispersity11 of the block 
copolymer and the ratio between blocks can have an influence on the size 
distribution. 
 One stage further, one can influence the size using different methods of vesicle 
formation85. Rehydration methods and solvent displacement86 or injection87 methods 
have been applied and mostly yield 50 to 800 nanometre-sized polymersomes. On 
the other hand electroformation will yield micrometre-sized giant polymersomes. 
Howse et al.85 recently showed that they were able to use surface-directed 
templating with different mesh surfaces to influence the size of PEO-PBO vesicles. 
They were able to deposit block copolymer domains of predefined size on a grid and 
showed that rehydration from these grids yielded control over polymersome size as 
depicted in Figure 6. Smaller polymer domains yielded smaller polymersomes (5-10 
µm) with in all cases small size distributions. The presence of pH-responsive, 
ionizable groups can also allow control over size during vesicle formation by 
changing the pH or ionic strength49. A certain amount of control over polymersome 
size was shown by Shen et al.88 They were able to influence the vesicle size by 
changing the solvent nature and composition during solvent displacement formation 
of PS-PAA polymersomes. Luo et al.86 showed also that binary organic solvent 
systems can be used to influence size. Furthermore the presence of additives like 
dendrimers89, (homo)polymers11 and surfactants90 have been shown to influence the 
average polymersome size and polydispersity11.  
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Figure 6. Rehydration of amphiphilic block copolymers from a surface template. The dimensions of the 
polymer domain (L) dictate the eventual polymersome size (dmax)85. i) block copolymer domain of 
predefined dimensions, ii) hydration and phase separation, iii) further hydration and lamellae formation, 
iv) expansion, v) detachment, vi) energy minimisation resulting in polymersome formation. Reprinted 
with permission (ref. 85) 
 Finally polymersomes can be resized after they have been formed. In this respect 
the most straightforward way to obtain polymersomes of a predefined size is by 
extrusion. This basically means that a preformed sample of polymersomes is pressed 
through a filter with nanopores79. This procedure has also been proven to be 
applicable on larger scale by the use of hollow nano-fibers91. The only restriction is 
that the polymeric membrane should remain fluidic till the end of the procedure, 
therefore polymers with a low Tg are needed. In the stage after formation it is also 
possible to exert influence on the size via more sophisticated methods than 
extrusion. Eisenberg and co-workers reported that membrane fusion and fission 
driven by a change in dioxane/water content (change of interfacial energy) allowed 
vesicles to grow and shrink reversibly86,88.  
 Another example involves the swelling of the membrane by an external stimulus. 
In this way pH-responsive blocks have been introduced in the corona to trigger size 
change, but also a change in secondary structure of polypeptides has been 
employed46. In a recent example by Yu and Eisenberg92 the formation of so-called 
“breathing vesicles” from PEO-PS-PDEAEMA was reported. By variation of the pH 
they were able to swell and shrink the polymersome (membrane) with a factor of 
~1.9 changing simultaneously the membrane permeability as depicted in  Figure 7. 
This approach shows that a well-chosen balance between solubility and hydration 
will keep the aggregate together, but still allows considerable changes. If this balance 
is not carefully chosen, the polymersome will disassemble into its constituents.  
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Figure 7. Reversible change of the PEG-b-
PS-b-PDEAEMA membrane upon pH 
change. (A) Cryo-TEM images of the vesicle 
wall structure at several pH values. (B) 
Schematic illustration of the presumed 
membrane structure at corresponding pH 
values. Reprinted with permission (ref 92)
 
 
Figure 8. Morphologies possible for 
triblock copolymers as determined 
theoretically by Li et al.93 Reprinted with 
permission (ref. 93). 
1.3.3 Shape 
The influence of shape and topology on in vivo behaviour is not so well studied for 
liposomes and polymersomes. In fact, probably the most illustrative example for the 
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influence of shape in amphiphilic assemblies for in vivo behaviour comes from rod 
like micelles as studied by Geng et al.94 They showed that worm-like micelles, which 
are non spherical in nature, have blood circulation times exceeding those of spherical 
particles like liposomes and polymersomes by far; even if the persistence length at 
the moment of injection is several microns. Micelles or worm-like micelles95-97 do not 
have an aqueous lumen and therefore do not allow for delivery of hydrophilic 
compounds, but also worm-like polymersomes have been observed and described98-
99 that do enable the encapsulation of hydrophilic compounds, and which should 
have similar behaviour.  
 These cylindrical shapes are not the only non-spherical shaped vesicles that have 
been reported. In fact, a realm of non-spherical aggregates is possible13. This has 
already been demonstrated for giant phospholipid vesicles (10-50 um) of which it is 
known that they can transform shape from spherical into a variety of nonspherical 
shapes upon a change in environment100-101. Theoretical studies on triblock 
copolymers by Li et al.93 showed that this transformation should also be possible for 
polymersomes as depicted in the phase diagram in Figure 8.  
 Recently, experiments have been performed in which non-spherical polymeric 
assemblies were created chemically16 or via kinetic entrapment.102 It should 
therefore be possible in the near future to investigate the effect of shapes other than 
rodlike or spherical on in vivo behaviour 
 
1.4 Release and Permeabilisation Mechanisms 
One of the advantages of polymersomes over liposomes is their more robust and 
therefore less leaky membrane, which is very useful for improved circulation times 
and the prevention of uncontrolled release of drugs. However, at one point almost 
each in vivo application involves a disruption step to release the vesicle content or 
make the content accessible. Despite the fact that polymersomes display improved 
stability, many successful examples exist of stimuli-responsive vesicles, which 
release their contents upon action of an external trigger9,20,24. It is also possible to 
achieve permeability control, i.e. controlled pore formation, without complete 
disruption of the vesicular structure. In the next section we will highlight a few 
recent and illustrative examples.  
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1.4.1 Triggered Disruption 
The most straightforward example of a release mechanism is actually degradation of 
the biodegradable polymers of which the vesicle is composed. Polymersomes of PCL-
b-PEG released their cargo due to biodegradation based on (pH driven) hydrolysis of 
the polymers. During this process a transformation change from polymersomes to 
rods and eventually micelles was in some cases observed due to the change in 
hydrophilic fraction (f). By mixing in a stable PBd-b-PEG block copolymer it was 
possible to tune the speed of degradation6,31. Besides hydrolysis disruption based on 
chemical alteration of the block copolymer by oxidation99, or reduction have been 
reported20.  
pH-Triggered release mechanisms which in principle are reversible have also been 
reported. A nice example of a polymersome that can disassemble upon a pH change 
was already encountered in Section 1.2.1. Armes and co-workers used the 
biocompatible zwitterionic PMPC-b-PDPA block copolymer to form polymersomes at 
pH above six. By lowering the pH a sharp transition was observed from vesicles to 
molecularly dissolved polymers due to protonation of the PDPA block. The 
polymersome content was thereby instantaneously released. The driving force for 
polymersome formation is in most cases based on phase separation due to the 
amphiphilic character of the block copolymer. By switching the character of the 
hydrophobic block to hydrophilic it is possible to dissolve the whole polymersome 
and release the content. Recently Kim et al.103 reported a system based on this 
principle. They developed a stimulus-responsive amphiphilic polymer containing 
boronic acid moieties in the hydrophobic domain that, upon increase of pH and in the 
presence of monosaccharides such as D-glucose, became soluble in an aqueous 
environment. Another interesting example was reported by Lecommandoux. They 
prepared polymersomes of a block copolymer comprising two polypeptides, poly-L-
glutamate-b-poly-L-lysine (PGA-b-PLys). By changing the pH they were able to 
switch the solubility of both blocks, effectively flopping the whole membrane104. 
Those examples all involve a change in pH as the trigger, but there are more stimuli 
explored.  
 Also changes in temperature can be used for altering the hydrophilicity of a block 
copolymer20. From literature there are quite some polymers, peptides and proteins 
which demonstrate LCST behaviour as was mentioned before in Section 1.2.2 with 
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the example by Otsuka et al.63. Figure 9 shows another very versatile example based 
on P(DEAEMA98-b-NIPAM392), a so-called “schizophrenic” polymer105-106. This system 
was shown to reversibly dissolve and assemble into polymersomes, as well as 
transform micelles to polymersomes based on either a pH and/or a temperature 
trigger105. Based on a pH-induced conformational change Bellomo et al.40 reported a 
release mechanism for polymersomes composed of a dipeptide block copolymer 
which contained a stable hydrophilic α-helix of PEGylated poly-L-lysine and a 
hydrophobic α-helix of poly(L-leucine0.3-co-L-lysine0.7). Upon lowering the pH the 
alpha-helix of the hydrophobic block transformed into a random coil due to 
protonation of the lysine residues. This conformational change was found to disrupt 
the vesicle, allowing the transport of calcium ions and dyes in and out of the 
polymersome.  
 
 
Figure 9. Mechanism of aggregation and dissolution of schizophrenic vesicles as described by Smith et 
al.105 Reprinted with permission (ref. 105) 
 
Figure 10. Polymersome disruption by 
illuminating with UV light. A fraction of the 
polymeric building blocks is functionalized 
with azobenzene moieties. Illumination 
with light induced a conformational 
change, disrupting the polymersome and 
releasing its content107. Reprinted with 
permission (ref 107) 
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Figure 11. Polymersomes loaded with enzymes in the lumen and porphyrins in the membrane respond to 
light by a morphology change and eventually release of content108. Reprinted with permission (ref. 108) 
 Researchers also have developed methods of disruption, based on external 
stimuli such as ultrasound and light. An interesting system was reported by Mabrouk 
et al.107 as depicted in Figure 10. They described how the incorporation of 
azobenzene moieties allowed for a conformational change in the membrane upon 
illumination with UV light. Their polymersomes were disrupted within a second. 
Figure 11 shows another example of a light-driven vesicle shape transformation and 
release. Robbins et al108 reported that polymersomes formed from PBd-b-PEG with 
porphyrins entrapped in the membrane and proteins in the lumen disrupted in 
response to light. When either the protein or the porphyrin was left out this effect 
was negligible, indicating a synergy between the fluorophore and the encapsulated 
enzyme. 
 
1.4.2 Controlled Permeability 
For some applications a complete disruption of the vesicle is not desired. Rather, the 
polymersome should be semi-permeable. This is for example the case in enzyme 
therapeutics or artificial organelles, in which enzymes are encapsulated in the 
vesicle. The polymersome functions as a protective cage, i.e keeping the enzymes in 
and allowing substrate and products to diffuse in and out of the polymersome. 
Different strategies have been reported to create in a controlled fashion these semi-
permeable or leaky polymersomes. 
An example of an inherently leaky polymersome is based on the earlier mentioned 
PS-b-PIAT block copolymer system. These polymersomes have been used as 
biocatalytic reactors, by encapsulating enzymes in the lumen. It was shown that 
substrate diffused through pores in the membrane, and the encapsulated enzyme 
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was not able to escape, essentially making it a nano reactor with a semi permeable 
membrane39. This line of research was developed further by creating a nano 
reactor109 capable of performing a three-enzyme cascade reaction. The cascade 
scheme is depicted in Figure 12. and shows that one enzyme is entrapped in the 
lumen, a second is captured in the hydrophobic membrane and finally a third enzyme 
is coupled covalently to the surface via clickable anchors. Another system that has 
been reported by Kataoka to assemble a semi-permeable membrane is based on 
oppositely charged block copolypeptides which yield PICsomes71. These PICsomes 
have also been used as biocatalytic nanoreactors. Although these two examples show 
the usefulness of semi-permeable vesicles, in both cases the permeability was not 
tuneable.  
 
 
Figure 12. Polymersome nano-reactor 
performing a three enzyme cascade 
reaction. All three enzymes are associated 
with the PS-PIAT vesicle and leaving out 
one will stop the whole cascade109. 
Reprinted with permission (ref. 109) 
 
 Meier and co-workers followed a bio-inspired approach for the construction of 
semi-permeable vesicles.110 They nicely showed that bacterial transmembrane 
channel proteins OmpF and aquaporin111,112 could be successfully reconstituted into 
the membrane of polymersomes composed of the triblock copolymer poly(2-methyl 
oxazoline)-b-poly(dimethylsiloxane)-b-poly(2-methyloxazoline) (PMOXA-PDMS-
PMOXA), which made these vesicles selectively porous. In nature many 
transmembrane pores have a directed orientation, but upon reconstitution into 
liposomes or polymersomes they tend to adopt a random orientation, basically 
blocking out fifty percent of the channels. By using an asymmetric ABC type of 
triblock copolymer it is possible to form vesicles with either the A or the C block on 
the outside112, effectively constructing an asymmetric membrane as depicted in  
Figure 13. Meier and co-workers reconstituted aquaporin 0 in these membranes and 
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were able to tune the direction of insertion. An elegant approach towards the 
construction of semi-permeable polymersomes113 was the reconstitution of LamB 
protein in PDMS-b-PMOXA polymersomes. This protein was recognized by 
Bacteriophage lambda and used to dock the phage, after which it injected its DNA 
into the polymersome, as nicely captured by TEM imaging in Figure 14.  
  In another example Choi et al.114 showed that it is also possible to reconstitute 
two different proteins, bacteriorhodopsin and F1-ATP-ase, in a polymeric vesicle 
membrane, as depicted in Figure 15. ATP-ase can be regarded as a proton gradient 
driven motor that, while rotating, converts ADP into ATP. The required proton 
gradient is supplied by bacteriorhodopisin, which is activated by a light source. Choi 
and co-workers nicely showed that the enzymes worked together. If no light was 
applied there was no production of ATP. This research is one of the first systems 
reported where a complex biocatalytic process is performed in a polymersome 
nanoreactor.  
 Only few examples of synthetic approaches towards controlled semi-permeable 
polymersomes have been reported. One of the first of these approaches was reported 
by Tsourkas and co-workers115. They designed polymersomes based on PBd-b-PEG 
and mixed in phospholipids, 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-choline 
(POPC). After they crosslinked the PBd membrane, POPC was extracted leaving a 
porous vesicle. The same method was applied by exchanging POPC for the 
biodegradable block copolymer poly(caprolactone)-PEG. After crosslinking and 
hydrolysis a highly permeable polymersome was obtained116. Recently, another fully 
synthetic approach to controlled permeable polymersomes was reported by Kim et 
al.117 They used the boronic acid based block copolymers described in Section 1.4.1 
and mixed it in with PS-PEG, which forms a semi-crystalline membrane. Upon 
washing away the boronic acid polymer by applying sugar and base they were able to 
form pores in the membrane of which the size was tuneable by the ratio of boronic 
acid block copolymer and PS-PEG. This procedure could be used in combination with 
the encapsulation of CalB, allowing the substrate to pass the membrane while 
keeping CalB enclosed. They also showed that bigger pores allowed faster diffusion 
of substrate, as determined by the reaction rate.  
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Figure 13. Asymmetric polymersome membranes obtained from ABC triblock copolymers allow for the 
directed reconstitution of transmembrane channels.112 By changing the molecular weight of the A and C 
block either the A or the C block is directed outwards. Reprinted with permission (Ref. 112) 
 
 
 
Figure 14. Schematic and TEM image of a polymersome in which membrane protein LambB is 
reconstituted.113 This membrane protein is recognized by bacteriophage lambda which is shown to dock 
on the polymersome to inject its RNA. Reprinted with permission (ref. 113) 
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Figure 15. Light driven nano reactor. 
Under the influence of light 
bacteriorhodopisin (BR) establishes a 
proton gradient, which is used by ATP-ase 
to produce ATP from ADP 114. Reprinted 
with permission (ref. 114). 
  
 
1.5 Surface Functionality 
PEGylated liposomes are neutral and are considered to be long circulating vesicles, 
with circulation times up to days. When compared to natural systems there is 
however room for improvement. Red blood cells for example circulate up till 100 
days. Their cell surface has an overall negative charge due to the external glycocalyx 
moieties. The effect of surface charge of liposomes has therefore been studied, but 
the general trend is not so obvious and seems to be influenced by the size of the 
liposome, especially in rat and mice studies.76 In rabbits a clear trend was observed 
which was in favour of neutral PEGylated liposomes (t1/2 = 19.3h.), while negative 
and PEGylated negatively charged liposomes showed circulation half times of only 
9.6 and 16.5 hours respectively118. Charge is only one of the possible functionalities 
which affect the interaction of polymersomes with biological systems. Another aspect 
is surface topology. Research on both will be discussed in the next sections  
 
1.5.1 Surface topology 
Christan et al.119 recently reported on the synthesis and in vivo evaluation of 
polymersomes with a red blood cell like surface (i.e. negatively charged surface). 
They prepared polymersomes of PBd-b-PEG with a near infrared dye entrapped, and 
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compared them with polymersomes where a fraction of PBd-b-PAA was introduced 
to obtain a negative surface charge. After 24 hours they showed that polymersomes 
with negative surfaces predominantly accumulated in the liver. Liposomes often are 
covered with up to ten percent of PEG chains that induce stealth character. In general 
it is thought that the conformation of the surface PEG chains has an influence on the 
stealth effect. PEG chains can either adopt a mushroom conformation to cover the full 
surface or a fully stretched conformation depending on the available space. Smart et 
al.120 studied these conformations for polymersomes both theoretically and 
experimentally. For polymersomes it is not so straightforward to reduce the number 
of PEG chains in the corona. Often PEG is a part of the block copolymer, covalently 
linked to the hydrophobic block and needed to form and stabilize the polymersome 
in solution. By the introduction of a hydrazone bond between PS and PEG (PS-Hz-
PEG) He et al.121 showed that polymersomes constructed of this polymer were able to 
shed off their PEG mantle by adjusting the pH. Brinkhuis et al.122 (Chapter 6) used 
this concept on PBd-Hz-PEG vesicles and systematically mixed in a non-hydrolysable 
analogue. They showed that after vesicle formation the number of PEG chains could 
be reduced to five percent without losing colloidal stability. This is already an 
example where the surface structure is adapted, but more complex surface 
topologies have also been reported, involving domain formation. 
 In liposomes it is possible to create surface domains via micro-phase separation 
either assisted or not assisted by the addition of ions123. This domain formation was 
recently also described in polymersomes124. The effect of more complex surface 
topologies on cell interactions was shown by Battaglia et al.125. They were able to 
create domains within the polymersome surface by mixing different ratios of two 
triblock copolymers based on PMPC. They nicely showed how the ratio of polymers 
influenced the size and number of domains present in their polymersomes as 
depicted in Figure 16. Furthermore, this figure indicates how the cellular uptake is 
influenced by the surface topology and size of these patchy polymersomes, pointing 
out the importance of surface topology. 
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Figure 16. a)Effect of the ratio of PMPC-PDPA and PEG-PDPA on the domain size of patchy polymersomes. 
b) the number and size of domains influence the cell binding and uptake of patchy polymersomes125. 
Reprinted with permission (ref 125). 
1.5.2 Surface functionalization 
In many biomedical applications reported thus far, such as in vivo imaging, 
polymersomes have been used which contained a functional content, e.g. near 
infrared fluorescent dyes53,119,126 and MRI contrast agents115-116, but which did not 
have any surface functionality. In fact, they were mostly designed for prolonged in 
vivo circulation times, which means that they were predominantly PEGylated. 
However, for imaging and drug delivery it might be desirable to functionalize the 
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periphery with ligands or moieties that allow (specific) recognition. In principle two 
approaches can be followed for this purpose. In the first method the functional group 
is attached to the polymer prior to vesicle formation. One of the first examples of this 
approach was the preparation of a functionalized polymersome for cellular delivery 
via the conjugation of the cell penetrating peptide Tat to PBd-b-PEG. After the 
polymersomes were formed they showed good cellular uptake and were able to 
deliver a near infrared dye loaded polymersome to dendritic cells126. However this 
approach is not always trivial. If the functionality that needs to be introduced is too 
hydrophobic, the moiety might fold back in the membrane upon polymersome 
formation, reducing its availability. Furthermore, if bigger moieties need to be 
introduced, this will put quite some restrictions on the preparation methods and also 
the expected behaviour of the amphiphiles. Therefore researchers have also 
developed a second approach which entails post functionalization of polymersomes 
either via covalent or via strong non-covalent interactions, as recently reviewed by 
Meier and co-workers.25 
 In many cases non-covalent interactions are reversible and this can be useful, but 
also makes the system less robust. A non-covalent interaction that is almost as strong 
as a chemical bond is the interaction between biotin and streptavidin127. Hammer 
and co-workers128 used polymersomes of PBD-B-PEG end-functionalized with biotin 
(actually biocytin) to study the adhesiveness of these polymersomes to streptavidin, 
both surface immobilized and free in solution. They showed that when biotin was 
attached to a longer PEG chain than the non-functionalized membrane polymers 
there was a difference in adhesive properties. When biotin sticks out of the 
membrane the adhesion to immobilized streptavidin increased whereas in solution 
no difference was found. The group of Meier published a series of papers where they 
used biotin-functional polymers to adhere polymersomes to streptavidin129-130. In 
one example131 they used a double biotinylated triblock copolymer PMOXA-PDMS-
PMOXA to adhere biotinylated ligands to the surface. In this case streptavidin with 
four binding sites fulfilled the function of effectively connecting the polymersome 
and targeting ligand. The fact that streptavidin has four binding sites also puts some 
restrictions on its applicability. If the concentration of streptavidin becomes too high 
crosslinking of polymersomes will become dominant and bigger aggregates will form. 
The interaction of cyclodextrin and adamantane is another example of a host-guest 
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pair that strongly interacts and of which one of the binding partners can be easily 
immobilized on the surface of a polymeric membrane58,132  
 An interesting, strong, metal ion complexation that is often used in protein 
science to purify proteins from a cell lysate is the nickel–NTA interaction with 
histidine-tags. The group of Meier showed two133-134 examples where they 
immobilized the NTA ligand on the surface of PBD-B-PEG polymersomes. They 
demonstrated to be able to complex both green fluorescent protein (GFP) and bone 
morphogenetic protein (BMP) via their His-tags on the polymersome surface. 
 
 Functional moieties have also been attached covalently to premade 
polymersomes. However, there are some restrictions to the chemistry involved. In 
most cases polymersomes are formed and used in an aqueous environment, so the 
chemistry should be applicable in water and be selective. A recent report 135 on the 
immobilisation of polymersomes on a substrate exploited peripheral aldehydes to 
form an imine bond, which is in principle reversible. An irreversible bond that can be 
formed and is common in bio-conjugation techniques is the amide bond. Carboxylic 
acids present on the periphery of polymersomes were activated as NHS esters33 
which allowed the attachment of several proteins via available amine residues. 
Another coupling strategy adopted from bioconjugation is the use of the maleimide 
functionality. Maleimides readily react with thiols which can be made available in a 
controlled fashion in both peptides and proteins by the introduction of a cysteine 
residue. In this way Pang et al. 136 showed how they were able to couple mouse-anti-
rat monoclonal antibodies for brain delivery in rats to the surface of polymersomes.  
 As depicted in Figure 17 Opsteen et al.137 reported the use of the copper-
catalysed (2+3) Huisgen cycloaddition to immobilise fluorescent dansyl, GFP and 
biotin on the surface of azide end-functional PS-PAA vesicles. PS-PAA was easily 
synthesised via ATRP and the introduction of the azide moiety was achieved by 
substitution of the bromine end group present after ATRP. However, not all block 
copolymers allow for easy modification. Therefore, van Dongen et al. 138 adopted a 
strategy in which they mixed in up to ten percent of an acetylene-functional PS-PEG 
in their PS-PIAT polymersomes. These so-called anchors allowed for the 
immobilisation of enzymes on the vesicle surface. In order to steer away from the 
toxic Cu catalyst, in recent years also strain-promoted copper-free click reactions 
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have been developed139. Other click strategies have also been adopted. Very recently 
Petersen et al.140 introduced the vinyl sulfone moiety in polymersomes. This moiety 
also reacts fast and selective with thiols. They showed how via this method RGD 
peptides could be coupled on the periphery of their poly(methyl caprolactone)-b-PEG 
polymersomes.   
  
 
 
Figure 17. Surface functionalization of 
polymersomes assembled from PS-PAA-N3 
with molecular probes via click chemistry. 
The same methodology has been applied 
to immobilize proteins, e.g. green 
fluorescent protein137. Reprinted with 
permission (ref 137) 
 
 
 Besides the use of surface functionalization to improve drug delivery or in vivo 
imaging, it has been employed to improve on the cellular uptake of the polymersome 
nanoreactors as discussed in section 4.2. 
  A first report of such an artificial organelle inside a cell was provided by Ben-
Haim et al.141. They showed how PMOXA-PDMS-PMOXA polymersomes functionalized 
with oligonucleotide polyguanylic acid (polyG) are efficiently recognized by 
macrophages and engulfed. A selection of other cell types did not show significant 
cell uptake, underlining the specificity for macrophages. After assessing the fate and 
distribution of the polymersomes inside the macrophages they loaded the newly 
constructed organelle with trypsin, an intestinal protease, and delivered it to the cell. 
As a traceable substrate they chose the hydrophobic tripeptide serine protease 
specific substrate BZiPAR (bis-(CBZ-Ile-Pro-Arg)-R110), which can diffuse passively 
through both cell membranes and the polymeric membrane. First they blocked the 
cell’s own protease to prevent false positives. After the substrate reached the 
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polymersome loaded trypsin in the cell, the substrate was converted to release the 
coupled Rhodamine effectively making the cells fluorescent.  
 In a more recent example van Dongen, Verdurmen et al.139 used the inherently 
semi-permeable polymersome based on PS-PIAT to construct an artificial organelle. 
They ligated the cell penetrating peptide Tat to the surface of their polymersomes to 
induce cellular uptake by HeLa cells. The enzyme horseradish peroxidase (HRP), 
which was encapsulated in the polymersome, subsequently catalysed the oxidation of 
compound 3,3’,5,5’-tetramethylbenzidine (TMB) by hydrogen peroxide. The 
oxidation product of TMB was easily detected and showed good conversion inside 
the cell. This model reaction was used to demonstrate that the artificial organelle 
was capable of neutralizing oxidative species in a cellular environment.  
 
1.6 Conclusion 
Polymersomes are new versatile carriers that have high potential for in vivo imaging and 
nano therapeutics. Although quite different from liposomes general aspects known from 
liposomal science can be used to design polymersomes with specific functions. Control 
can be exerted over size, shape, surface function and topology, which will influence the 
in vivo circulation time and therefore the applicability of these nano-carriers. A large 
variety of examples can nowadays be found in literature that show how polymersome 
research has caught up with liposomal science in the past decade and in many cases 
adds extra dimensions to what is possible. 
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Functionalized Polymersomes Based on Poly-
butadiene-b-poly(ethylene glycol) 
 
 
 
 
 
 
 
 
In this chapter we describe the synthesis of block copolymers of polybutadiene-triazole-poly(ethylene glycol), 
which form the basis of Chapters 3, 4 and 5, via a copper catalyzed “click” approach. We introduce a variety 
of different end functionalities at the poly(ethylene glycol) block, while keeping the polybutadiene block 
constant. Secondly, we show in this chapter that polymersomes of polybutadiene-triazole-poly(ethylene 
glycol) are readily formed, and sized down, via either the solvent switch or rehydration method. The latter 
allows for straightforward loading of hydrophobic drugs in the membrane. 
Finally, polymersomes were formed and tagged with a fluorescent dye and the cell penetrating Tat-peptide to 
illustrate the self assembly of polymeric vesicles and the surface functionalization with peptides. Bare 
polymersomes hardly showed binding to a monolayer of hCMEC/D3 cells, whereas polymersomes conjugated 
with Tat to the periphery showed good association with this cell line. 
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2.1 Introduction 
Polymersomes, or polymeric vesicles, have large potential for use in biomedical 
applications1 as was discussed in depth in Chapter 1. The basic building blocks of 
polymersomes are amphiphilic block copolymers2. In order to form a bilayer vesicular 
structure the hydrophilic block should constitute approximately 25 percent of the block 
copolymer amphiphile. For imaging and targeting applications, it is obligatory to 
introduce functional handles in the polymeric vesicles to attach tracers or targeting 
moieties3. Therefore a set of amphiphilic block copolymers is required with a variety of 
functionalities.  
 Throughout this thesis we chose to work with the amphiphilic block copolymer of 
1,2-polybutadiene-block-poly(ethylene glycol) (PBd-b-PEG) to form polymeric vesicles. 
This choice was made mainly for three reasons. First of all, this block copolymer is 
generally considered to be biocompatible and has been reported to readily form 
polymersomes within a relatively large experimental window4. Secondly, the 
poly(ethylene glycol) block covering the periphery is known to introduce stealth 
characteristics and is therefore preventing all non-specific interactions with living cells 
and bio(macro)molecules5. Finally, 1,2-polybutadiene is a hydrophobic polymer with a 
glass transition temperature well below room temperature. Therefore the membrane 
forming the polymersome is relatively fluidic and dynamic in nature. This allows 
polymersomes to be resized to a desired average particle size by means of extrusion and 
ultrasound. A low glass transition temperature also allows polymersomes to be formed 
via rehydration in addition to the solvent switch method6. Formation of polymersomes 
via rehydration will yield relatively large polymersomes – which can be downsized - and 
is anticipated to allow the encapsulation of hydrophilic drugs in the lumen.  
 
Synthetic approach 
We chose to adopt a modular approach to synthesize block copolymers of PBd-b-PEG 
based on the copper catalyzed (2+3) cycloaddition7 of azides and alkynes as depicted in 
Scheme 1. Both polymer blocks are connected via a triazole moiety, resulting in 
polybutadiene-triazole-poly(ethylene glycol). The main advantage of this approach is the 
possibility to synthesize a set of block copolymers with different end groups, starting 
from a single batch of polybutadiene. Thus only the poly(ethylene glycol) (PEG) block 
has to be modified in order to access end-functional or higher molecular weight 
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analogues. As shown in Scheme 1 we aimed for the synthesis of PBd66-b-PEG22 in 
combination with a maleimide or amine functional PEG44 analogue. 
 
 
Scheme 1. Synthetic overview to amphiphilic block copolymers of PBd-b-PEG (1-3) with different end 
functionalities. Polymer 1 is inert and forms the basic building block for polymersome formation. Block 
copolymer 2 bears an amine end group to allow conjugation with isothiocyanate derivatives of e.g. 
fluorescein. Finally, polymer 3 is maleimide end-functionalized to allow for conjugation with cysteine 
containing peptides. 
In this chapter we describe the synthesis of the amphiphilic block copolymer PBd-b-PEG, 
as well as the amine and maleimide end-functional analogues. We show that this block 
copolymer easily forms resizable polymersomes, either via the solvent switch method or 
via rehydration. Furthermore, we demonstrate that conjugation of peptides to the 
surface can be achieved and that in the case of Tat-peptides cell adhesion is induced. The 
experimental procedures also serve as an experimental platform for the biofunctional 
systems described in Chapters 3-5. 
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2.2 Results and Discussion 
2.2.1 Block copolymer synthesis 
Polybutadiene is synthesized via anionic polymerization of 1,3-butadiene8. The choice of 
solvent in the polymerization has a large influence on the reactivity of the monomers. 
Propagation in THF will mainly yield 1,2-polybutadiene, while propagation in e.g. 
hexane will yield mainly 1,4-polybutadiene as reported by Kalnin’sh and Panarin9. Since 
we chose to adopt a modular approach, we need to introduce a functional end-group. 
Three methods exist for the introduction of functional groups in anionic polymerizations 
as was summarized by Hirao and Hayashi10. One can either (i) start with a protected 
functional group as the initiator, (ii) polymerize monomers with a protected functional 
group, or the strategy we adopted (iii) terminate the living polymer with a protected 
functional group.  
 The polymerizations of 1,3-butadiene were straightforward and could be easily 
followed by the colour of the reaction mixture. After addition of butyllithium at -78 °C 
the colour changed from yellow to dark orange, and turned to pale yellow after all 
monomer was consumed. At that point, the polymerization was terminated with 1-
(trimethylsilyl)propargyl bromide to obtain alkyne end-functional PBd. The product was 
analyzed by means of size exclusion chromatography (SEC) as depicted in Figure 1. The 
product showed a double molecular weight distribution which is a phenomenon 
previously observed and explained by Tohyama et al.11 During termination fast halogen-
metal exchange between the living polymer and terminating molecule occurs as a side 
reaction, after which the living polymer chain can react with the halogenated polymer 
chain via a SN2’ mechanism. The double molecular weight polymer therefore does not 
contain any functional group and is not reactive toward azides. Furthermore excess of 
PBd is easily removed via column chromatography after PBd-b-PEG is formed as shown 
in the SEC traces in Figures 1 and 2 for the formation of polymer 1a.  
 Poly(ethylene glycol) is a frequently used hydrophilic polymer and commercially 
available in a variety of different lengths. We purchased poly(ethylene glycol) (PEG) 
with a molecular weight of 1 kg/mol and poly(ethylene glycol) monomethyl ether 
(mPEG) with molecular weights of 1 and 2 kg/mol. The synthesis of the mono-azide 
functionalized polymers 7a-b proceeded straightforward using mesylation and 
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subsequent nucleophilic substitution by azides following previously reported 
procedures12.  
 
 
Figure 1. SEC traces for the synthesis of 1a starting from polybutadiene (5) and PEG derivative 7a. As can 
be seen polybutadiene shows a bimodal distribution after polymerization, which does however not 
interfere in the synthesis of 1a 
 
Figure 2. The non reactivity of the dimeric polybutadiene polymerization by-product was further 
illustrated by analyzing the silica column waste fraction (dashed line). It mainly contains the higher 
molecular weight polybutadiene, while the lower molecular weight polybutadiene in 5 (solid line) is 
consumed to form the desired block copolymers. 
Starting from PEG with a molecular weight of 1 kg/mol we synthesized the hetero 
bifunctional derivative 8, which formed the precursor for compounds 9 and 10. First, an 
azide and carboxylic acid were introduced to obtain a statistical mixture of the diacid 
(25%), diazide (25%) and desired compound 8 (50%). The three products were 
separated on a silica column to isolate α-azido ω-carboxy poly(ethylene glycol) (8). In 
the infrared spectrum of 8 (Figure 3), the presence of an azide is clearly visible as shown 
by the absorption around 2100 cm-1. The carbonyl stretch of the carboxylic acid residue 
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shows an absorption around 1650 cm-1. In addition, in the 1H-NMR spectrum the two 
protons next to the azide (triplet at 3.39 ppm) and the two protons next to the 
carboxylic acid (singlet at 3.98 ppm) are clearly visible and integrate in a 2:2 ratio. 
 The amine functionality of 10 was introduced in a two step procedure. First, the 
methyl ester derivative 19 was formed, after which 1,2 diaminoethane was coupled via a 
nucleophilic acyl substitution. These two conversions were quantitative and can be 
visualized by analyzing the 1H-NMR spectrum showing a clear shift of the singlet of the 
methylene group adjacent to the carbonyl.  
 
  
Figure 3. Left) Indicative infrared absorptions of 8 (dashed) compared to PEG (solid) PEG derivative 8 
contains both an azide (2100 cm-1) signal as well as the carbonyl stretch of the carboxylic acid (1650 cm-1). 
Right) Indicative proton NMR shifts (CDCl3) of 8 contains a triplet at 3.38 ppm originating from the 
methylene next to the azide moiety, a broad signal originating from the backbone and finally a singlet at 
3.98 ppm originating from the methylene next to the carboxylic acid function. 
The PBd and PEG blocks were coupled via the copper catalyzed azide/alkyne (3+2) 
cycloaddition, which is often referred to as “click reaction”7. The use of this click reaction 
to form block copolymers has been described in detail by Opsteen et al.12-13 The reaction 
was performed under argon with a twofold excess of polybutadiene to ensure that all 
PEG was coupled to PBd. After the coupling reaction, the excess of PBd – along with the 
double molecular weight by-product - was removed via silica gel column 
chromatography. Eluting with dichloromethane, polymers 1, 2 and 11 had an Rf value of 
0 compared to 1 for PBd (5). After the excess of PBd had been eluted, polymers 1, 2 and 
11 were eluted with 8% methanol in dichloromethane. The SEC traces associated with 
the standard block copolymer 1a are shown in Figures 1 and 2.  
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Via this methodology three types of block copolymers were obtained. One without a 
functional handle (1a-b), which served as a basic building block for polymersome 
formation, a second one with an amine end function (2) allowing for fast labelling with 
isothiocyanate probes to visualize polymersomes. Finally, a carboxylic acid end 
functional block copolymer (11) was synthesized. Next, polymer 11 was coupled to 
maleimide derivative 1214 via a carbodiimide mediated coupling to obtain the 
maleimide end functional block copolymer 3. This maleimide functional polymer served 
as scaffold to conjugate peptides, enzymes and antibodies to the polymersome 
periphery by means of thiol-maleimide coupling15. 
 
2.2.2 Polymersome formation and functionalization 
Polymersomes have been reported to form in a variety of ways. Of all reported methods, 
the solvent switch method (and variations thereof) and the rehydration method are 
most often applied6. In the solvent switch method the amphiphilic block copolymer is 
dissolved in a solvent suitable for both blocks, after which aggregation is induced by 
dilution of the polymer solution with a poor solvent for one of the blocks, in most cases 
an aqueous buffer. The rehydration method generally yields relatively large 
polymersomes of up to several micrometers. In this technique first a thin, thoroughly 
dried block copolymer film is formed by coating a block copolymer solution onto a glass 
or Teflon substrate. Polymeric vesicles are formed by rehydrating the film in aqueous 
buffer, which allows polymeric vesicles to bubble off the polymer film into the solution.  
 
First the rehydration method was used to form polymersomes of polymer 1a without 
any additional surface functionalities. To visualize the polymersome membrane, 0.01 
weight% of the hydrophobic and fluorescent dye Nile-Red was dissolved in 1 mL 
chloroform along with 1 mg of polymer 1a. While fast rotating the chloroform was 
removed under reduced pressure to obtain a thin polymer film on the inside of a glass 
vial, which was dried thoroughly for an additional hour under reduced pressure (5 
mbar). Polymeric vesicles were formed by the addition of 3 mL THF:MilliQ (1:3), while 
the sample was rotated at atmospheric pressure. After 15 minutes the THF was removed 
to obtain polymersomes in MilliQ. The membranes of the vesicles were visualized by 
means of confocal laser scanning microscopy (CLSM) as depicted in Figure 4. 
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Figure 4. Several CLSM pictures of giant polymersomes prepared via the rehydration method. The 
membrane was loaded with 1 w% of the hydrophobic fluorescent dye Nile-Red. 
 
Figure 5. Top left) DLS results of polymersomes formed via rehydration with the drug C1 encapsulated 
both before (solid) and after (dashed) the sample was resized by ultrasound treatment. Top right) DLS 
analysis of polymersomes formed via the solvent switch method (long dashed), which were downsized by 
means of extrusion; 200 nm (dash-dotted) and 100 nm (solid). Bottom left) molecular structure of 
hydrophobic model drug C1. Bottom right) TEM image of a dried polymersome sample formed via solvent 
switch of 1a and extruded through 200 nm membranes (bar is 200 nm).  
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Analogous to the encapsulation of Nile-Red, we also encapsulated 1 w% of the 
hydrophobic model drug C1 in the membrane (Figure 5). The polymersome size 
distribution was analyzed directly after rehydration by means of dynamic light 
scattering (DLS) as depicted in Figure 5. Since for most biomedical applications vesicles 
in the micrometer size regime are too large, we reduced the size of these drug loaded 
vesicles by treating them with ultrasound, prior to removal of THF. The resulting 
vesicles showed a particle size distribution around 90 nm. The encapsulation efficiency 
of C1 was 90 percent and stable for at least 5 days as was measured by means of HPLC 
analogous to the procedure reported by van Rooy et al.16 for this compound.  
 Intrinsically smaller polymeric vesicles were obtained upon forming polymersomes 
via the solvent switch method as was deduced from the DLS measurements depicted in 
Figure 5 (right panel). Polymersomes were formed by dissolving 10 mg of polymer 1a in 
1 mL THF, after which 3 mL of MilliQ was added slowly to form the polymersomes. The 
initial size was around 500 nm and was downsized to 200 and 100 nm by means of 
extrusion through membranes with predefined sizes as depicted in Figure 5. 
Transmission electron microscope (TEM) pictures were obtained from the 200 nm 
samples (Figure 5, bottom) and showed polymersomes characterized by a single 
membrane of approximately 12-18 nm17. 
 
2.2.3 Surface functionalization and cell adhesion  
In the preceding paragraphs, the synthesis of polymers and the methods to form 
polymersomes were described and illustrated. All polymersome samples described thus 
far, however, did not contain any functionalities coupled to the periphery. As noted in 
the first section, we chose PEG as the hydrophilic polymer since it is known to prevent 
all interactions with the environment. Therefore polymersomes consisting of polymers 
1a-b were not expected to show any interactions both in vitro and in vivo. In order to 
induce (specific) interactions of polymersomes the periphery should be functionalized 
with a suitable ligand.  
 To illustrate that interactions with living cells can be induced in vitro, we prepared a 
set of polymersomes according to the solvent switch procedure. This time, however, we 
partially labelled the amine end functional polymer 2 with fluorescein isothiocyanate 
(FITC) and mixed it in for 10 percent. The maleimide end functional polymer 3 was also 
mixed in for 10 percent, so that the standard polymer 1a made up 80 percent of the 
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polymer (10 mg polymer in total in 1 mL of THF). Polymersomes were formed by the 
addition of 3 mL phosphate buffered saline (1xPBS) and extruded through a 200 nm 
membrane to obtain polymersomes of 200 nm and a PDI of 0.12. The remainder of THF 
was removed by running the sample over a Sephadex G200 column after which the 
combined opaque polymersome fractions were diluted to 10 mL (1 mg polymer/mL 
PBS). 
 
 
Figure 6. CLSM images of a monolayer of hCMEC/D3 cells, incubated with fluorescent polymersomes (bar 
is 20 µm). Polymeric vesicles which are not functionalized with peptides only show limited association 
with the cell monolayer (left), whereas polymersomes with Tat-peptide on the surface show high 
association with these cells.  
Tat-peptide18 was synthesized by standard Fmoc chemistry19 with an additional 
cysteine added to the C-terminus to allow conjugation to the peripheral maleimide of 
polymersomes. To reduce possible Cys-Cys dimmers of the peptide, 1 mg of peptide 
(excess) was dissolved in 0.25 mL PBS together with 0.5 mg of (tris(2-
carboxyethyl)phosphine (TCEP). After 15 minutes the peptide solution was added to 1.5 
mL of the polymersome solution and allowed to couple for 1 hour. The excess of TCEP 
and Tat-peptide were removed by dialysis against PBS for 24 hours, after which both the 
polymersomes without and with Tat-peptide were separately added to the medium of a 
monolayer of hCMEC/D320 cells grown on a transwell filter (for details on this specific 
cell type and assay, see Chapter 4). The cells were fixed and visualized by CLSM, 
selectively exciting the fluorescein label on the polymersomes. Comparison of the 
fluorescent images (Figure 6) shows that the polymersomes without any targeting 
moiety do not interact with the cell layer, whereas the Tat-functionalized polymersomes 
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strongly interact with the cells. This experiment therefore clearly demonstrates that 
polymersomes of 1 indeed display stealth characteristics toward these cells and that the 
chemistry developed in this chapter allows for labelling of polymersomes with 
fluorescent markers and peptides. 
 
2.3 Conclusion 
In this chapter we have shown the modular synthesis of the amphipilic block copolymer 
of PBd-b-PEG (1a-b) along with its amine (2) and maleimide (3) analogues. These 
polymers readily formed polymersomes via rehydration techniques and allowed the 
encapsulation of the hydrophobic dye Nile-Red and the hydrophobic drug C1 in the 
membrane. The drug loaded polymersomes could be resized by ultrasound treatment to 
90 nm with a PDI of 0.15. Intrinsically smaller polymersomes were formed via the 
solvent switch method and sized down by extrusion. Upon mixing in 10 percent of 
fluorescently labelled polymer 2 and 10 percent of maleimide functional polymer 3 we 
were able to visualize polymersomes by CLSM and conjugate the cell penetrating Tat-
peptide to the periphery. Polymersomes without Tat-peptide showed limited association 
with a monolayer of hCMEC/D3 cells, while Tat-polymersomes showed a strong 
association with the cells. Thus, we showed that we gained access to PBd-b-PEG block 
copolymers and were able to form polymersomes with controlled size, membrane 
loading and surface functionalization forming an experimental platform for the 
polymersomes and experiments described in Chapters 3-5. 
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2.5 Experimental Procedures 
General Notes Compound 12 was synthesized according to the literature procedure published by 
van der Venken et al.14 
 
Materials Sec-butyllithium (ALDRICH 1.4M in hexane), tetrabutylammonium fluoride (TBAF) 
(ALDRICH, 1.0M in THF), sodium hydride (ALDRICH, 60% dispersion in mineral oil , Chelex resin 
(ALDRICH), were used as received. Tetrahydrofuran (THF) (ACROS ORGANICS, 99+% extra pure, 
stabilized with BHT) was distilled under argon from sodium/benzophenone, and triethyl amine 
(TEA) (BAKER) was distilled from calcium hydride under an argon atmosphere prior to use. 
Polymersome extrusions were performed using 200 nm filters (Acrodisc 13 mm Syringe Filter, 0.2 µm 
Nylon membrane) and 0.1 µm PC membrane (WHATMAN). Column chromatography was carried out 
using silica gel (Acros, 0.035-0.070 mm, pore diameter ca. 6 nm)) Note that silica gel from other 
suppliers gave less satisfactory results for α- azido ω- carboxy poly(ethylene glycol).  
 
Instrumentation Infrared (IR) spectra were obtained using a Thermo Matson IR 300 FTIR 
spectrometer. Data are presented as the frequency of absorption (cm-1). Proton nuclear magnetic 
resonance (1H NMR) spectra were recorded on a Varian Unity Inova 400 FTNMR spectrometer. 
Chemical shifts are expressed in parts per million (δ scale) relative to the internal standard 
tetramethylsilane (δ=0.00 ppm). Molecular weight distributions were measured using size exclusion 
chromatography (SEC) on a Shimadzu (CTO-20A) system equipped with a guard column and a PL gel 
5 μm mixed D column (Polymer Laboratories) with differential refractive index and UV (λ=254 nm 
and λ=345nm) detection, using tetrahydrofuran (SIGMA ALDRICH chromasolv 99.9%) as an eluent at 
1 mL/min and T = 35 °C. Particle size distributions were measured on a Malvern instruments 
Zetasizer Nano-S. 
 
Polybutadiene-block-poly(ethylene glycol) general procedure (1a/b, 2 and 11) Poly(ethylene 
glycol) 7a, 7b or 10 (7a, 10: 80 mg 0.08mmol, 7b: 160 mg 0.08 mmol) and 5 (800 mg, 2.6 equiv. 
0.21mmol) were dissolved in dry tetrahydrofuran (10 mL) under an argon atmosphere. The general 
procedure is further described for the coupling of 7a and 5. The temperature was raised to 55 °C and 
CuBr (30 mg, 0,2 mmol) and PMDETA (70 mg, 0,3 mmol) were added. The reaction was allowed to 
proceed for 12 hours after which all solvents were removed. The crude product was redissolved in 50 
mL dichloromethane and washed with 0.33 M EDTA (3 × 25 mL). The organic layer was dried over 
MgSO4 and poured on a short silica column, which was eluted with dichloromethane. After all non -
reacted polybutadiene (5) was flushed off, the product was eluted with 8 v% methanol in 
dichloromethane. After removal of all solvents the product was obtained (250 mg, 60%, 1a). The 
product was analyzed by size exclusion chromatography, showing a single size distribution (PDI = 
1.14) with a shift toward higher hydrodynamic volume compared to polybutadiene. 1HNMR: δ 1.16 
(m, 134H, CH2CH), 2.11 (m, 67H, CH2CH), 3.37 (s, 3H, CH3O), 3.64 (m, 90H, CH2CH2O), 4.94 (m, 134H, 
CHCH2), 5.45 (m, 67H, CHCH2). Mn was determined by NMR (1a. 4.7 kg/mol, 1b. 5.7 kg/mol, 3. 4.7 
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kg/mol and 11. 4.7 kg/mol) The SEC traces are shown in Figures 1 (1a) Figure 7 (1b). 
 
maleimide end functional polybutadiene-b-poly(ethylene glycol) (3) Polymer 11 (100 mg, 21 
µmol) was dissolved in 6 mL dichloromethane. Next, N,N’-diisopropylcarbodiimide (DIPCDI, 400 μL, 
1M in DMF) and N-hydroxybenzotriazole (HOBt, 450 μL, 1M in DMF) were added. After ten minutes, 
12 (20 mg, 0.14 mmol) was added and the solution was stirred overnight. All dichloromethane was 
removed and ice cold methanol (10 mL) was added at once. The precipitate was gently shaken to 
dissolve side products and excess of 12. After 1 hour the suspension was centrifuged at 5000 rpm for 
30 minutes. Methanol was decanted and a new aliquot was added to repeat the centrifuge step  (3x). 
The product was dried under vacuum to yield the product (60 mg, 60%). 1HNMR (CDCl3): δ 1.16 (m, 
134H, CH2CH), 2.11 (m, 67H, CH2CH), 3.65 (m, 90H, CH2CH2O), 4.08 (s, 2H, OCH2CON), 4.94 (m, 134H, 
CHCH2), 5.45 (m, 67H, CHCH2), 6.96 (s, 2H, maleimide); SEC (THF): Mw/Mn 1.17, Mn = 4.7 kg/mol. 
 
propyne- endcapped polybutadiene (5) A Schlenk tube was thoroughly cleaned, rinsed with 
butyllithium, flushed with MilliQ and oven dried over night. The Schlenk tube was evacuated and an 
argon atmosphere was applied, after which 1,3-butadiene (7.1 g, 131 mmol) was condensed at -78 °C. 
THF was distilled under argon over sodium/benzophenone and was added to the flask (10 mL). The 
polymerisation was initiated by the addition of sec-butyllithium (1,4 mL, 2 mmol, 1.4M in hexane). 
The mixture was allowed to heat up to -35 °C as the colour changed from pale yellow to orange. After 
the colour changed back to yellow the reaction was terminated by the addition of dry THF (10 mL) 
containing trimethylsilyl propargylbromide (400 mg, 2.1 mmol). After all colour had disappeared 
tetrabutyl ammonium fluoride (4 mL, 4 mmol,1M in THF) was added and the mixture was stirred for 
1 hour. All solvents were removed and the product was dissolved in dichloromethane, after which it 
was filtered over a slab of silica, eluting with dichloromethane. The final product was obtained by 
coevaporation with toluene (4x 50 mL) to remove any traces of propargyl bromide. The product 
contained two molecular weight distributions as determined by size exclusion chromatography 
(THF): 3.7 kg/mol (60%) and 7.4 kg/mol (40%). The higher molecular weight, a polymer dimer as 
reported and explained by Tohyama et al.21, is not reactive toward azides and was easily removed by 
silica column chromatography, after the block copolymers were formed as shown in Figures 4-6. 
1HNMR: δ 5.45 (m, 67H, CHCH2), 4.94 (m, 134H, CHCH2), 2.11 (m, 67H, CH2CH), 1.16 (m, 134H, 
CH2CH).  
 
α- azido ω-methoxy poly(ethylene glycol) (7a/b) Poly(ethylene glycol) monomethyl ether (5 
mmol, 1 or 2 kg/mol to obtain respectively 7a or 7b) was coevaporated with benzene (3x) and 
dissolved in dry and under argon distilled THF (250 mL). The general procedure is further described 
for the preparation of 7a. The flask was cooled on an ice bath and air was replaced by argon before 
freshly distilled triethyl amine was added (5 mL). The mixture was stirred for 3 hours, after which 
mesyl chloride (1.14 gram 2 equiv. 10mmol) in THF (10 mL) was added. The mixture was allowed to 
warm to room temperature and was stirred for 6 hours. All THF was removed and methanol  (100 mL) 
containing sodium azide (3.25 g, 10 equiv., 50mmol) was added. The mixture was refluxed overnight 
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after which methanol was removed and water (100 mL) was added. The product was extracted with 
dichloromethane (5x 100 mL). The combined organic layers were dried over magnesium sulfate and 
DCM was removed, yielding 4.5 gram (90%) product 7a. The SEC traces of both 7a and 7b are 
depicted in Figures 1 and 7 respectively. 1HNMR (7a): δ 3.37 (s, 3H, CH3O), 3.39 (t, 2H, CH2N3), 3.64 
(m, 90H, CH2CH2O). FTIR: 2098 cm-1 (azide). SEC (THF): Mn (7a) = 1 kg/mol, Mw/Mn = 1.19.  
 
α- azido ω- carboxy poly(ethylene glycol) (8) Poly(ethylene glycol) (5 g, 5 mmol, 1 kg/mol) was 
coevaporated with benzene (3x) and dissolved in dry and under argon distilled THF (250 mL). The 
flask was cooled on ice and air was replaced by argon, followed by the addition of distilled triethyl 
amine (5 mL). The mixture was stirred for 3 hours, after which mesyl chloride (0.6 gram, 1.1 equiv., 
5.1mmol) in THF (10 mL) was added over 1 hour. The reaction was allowed to warm to room 
temperature and stirred for 6 hours. THF was removed. Next, methanol (100 mL) and sodium azide 
(3.25 g, 10 equiv. 50 mmol) were added. The reaction was heated to reflux overnight, whereafter 
methanol was removed and water (100 mL) was added. The mixture of statistical products was 
extracted with dichloromethane (5x 100 mL). The combined organic layers were dried over MgSO4, 
and dichloromethane was removed.  
 The products were coevaporated with benzene (3x), dissolved in freshly distilled THF (250 mL) 
and cooled on an ice bath. An argon atmosphere was applied and sodium hydride (400 mg, 60% in oil, 
2 equiv.) was added. After three hours t-butyl bromoacetate (2.9 g, 3equiv. 14mmol) in THF (10 mL) 
was added and the temperature was raised to 50 °C. The reaction was allowed to proceed overnight, 
after which all solids were filtered off and THF was removed. The products were dissolved in 2M HCl 
(100 mL) and heated to reflux for 5 hours. The final product was extracted with dichloromethane  (5x 
100 mL). The combined organic layers were dried over MgSO4 and all solvents were removed. The 
product (Rf = 0.5) was purified using silica column chromatography (eluent MeOH:DCM:NH 3 
=15:85:5) yielding 1.5 gram (30%) of product. TLC: R f = 0.5, permanganate staining, eluent 
DCM:MeOH = 92:8. 1HNMR: δ 3.39 (t, 2H, CH2N3), 3.64 (m, 90H, CH2CH2O), 4.00 (s, 2H, OCH2COOH). 
FTIR: 2098 cm-1 (azide), 1570 (C=O of carboxylic acid salt). SEC (THF): Mn = 1 kg/mol, Mw/Mn = 1.19 
 
α- azido ω- amino poly(ethylene glycol) (10) α- azido ω- carboxy poly(ethylene glycol) (8, 1 g, 1 
mmol) was dissolved in methanol (50 mL) Next, concentrated sulphuric acid (5 drops) was added. 
The mixture was heated under reflux overnight, after which methanol was removed. The product was 
dissolved in water (50 mL) and extracted with dichloromethane (5x 50 mL). The organic layer was 
dried over MgSO4 and all solvents were removed. TLC: Rf = 0.65, permanganate staining, eluent 
DCM:MeOH = 92:8. Indicative 1HNMR shifts: δ 4.17 (s, 2H, OCH2COOMe), 3.75 (s, 3H, COOCH3) and IR: 
1748 cm-1 (carbonyl/ester) 
 The product was dissolved in methanol (50 mL) and 1,2-diamino ethane (0.5 mL, excess) was 
added. The mixture was heated under reflux for 48 hours, after which all methanol was removed. The 
product was dissolved in 1M hydrochloric acid (50 mL) and extracted with dichloromethane (5x 50 
mL). The combined organic layers were dried over MgSO4 and all solvents were removed to yield 800 
mg product (80%). TLC: Rf = 0.55, permanganate and nynhydrin staining, eluent DCM:MeOH = 92:8. 
Functionalized Polymersomes Based on Polybutadiene-b-poly(ethylene glycol) 
 
57 
1HNMR: δ 2.99 (t, 2H CH2CH2NH2), 3.39 (t, 2H, CH2N3), 3.64 (m, 90H, CH2CH2O), 4.01 (s, 2H, 
OCH2CONH). FTIR: 2098 cm-1 (azide), 1696 cm-1 (amide). SEC (THF): Mn = 1 kg/mol, Mw/Mn = 1.24. 
 
 
Figure 7. SEC (THF) traces of alkyne –endcapped polybutadiene after anionic polymerization (solid line, 
5), α-azido ω-methoxy poly(ethylene glycol) (short dashed line, 7b) and the block copolymer 
polybutadiene-b-poly(ethylene glycol) (long dashed line, 1b). 
Partial Fluorescein labelling of polymer 2 Polymer 2 (50 mg, 10 µmol) was dissolved in THF (10 mL) 
and Et3N (1 mL) was added. Next, fluorescein isothiocyanate (1 mg, 0.2 equiv.) was added and allowed to 
react for 48 hours. Solvents were removed and the labelled polymer was purified by preparative SEC 
(THF) to yield 25 mg product (50 %). The product was a single spot on TLC (8 percent methanol in DCM; 
UV and permanganate stain) which appeared brightly fluorescent and in contrast to the starting material 
showed good absorption @ 340 nm in the UV detector of SEC. 
 
Tat-peptide Tat-peptide was synthesized by means of standard Fmoc chemistry. The purity was 
more than 95 percent as analyzed by means of HPLC eluting in water/acetonitrile containing 0.1% 
v/v trifluoroacetic acid. The volume fraction of acetonitrile was increased from zero to hundre d 
percent over 30 minutes. Maldi-TOF (cyano-4-hydroxycinnamic acid): [M+H] calc: 1719.0 g/mol and 
[M+H] found: 1718.7 g/mol.  
 
Polymersome formation via rehydration Polymer 1 (1 mg) and the drug or dye (1w%, 0.1 mg) was 
dissolved in chloroform (1 mL) and added to a 5 mL glass vial. While fast rotating the chloroform was 
removed under reduced pressure to obtain a thin polymer film on the inside of the glass vial, which 
was dried thoroughly for an additional hour under reduced pressure (5 mbar). Polymeric vesicles 
were formed by the addition of 3 mL THF:MilliQ (1:4), while the sample was rotated at atmospheric 
pressure. After 15 minutes the polymersomes were reduced in size by treating them for 60 minutes 
with ultrasound (35 °C, 48 kHz, 200W). Finally THF was removed to obtain polymersomes in 3 mL 
MilliQ.  
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Determination of drug encapsulation Polymersomes were formed via the rehydration method as 
described above, containing 1 w% of C1. The free drug was spun down in an eppendorf tube to pellet 
the free drug and the top 1.00 mL of the polymersomes was freeze-dried. The drug was extracted into 
500 µL acetonitrile and analyzed on HPLC. The amount of encapsulated drug was back calculated. To 
validate this method we also added free drug to empty polymersomes and repeated the procedure to 
find no drug encapsulated (negative control). A calibration curve (0.01 – 0.1 mg C1/mL) was 
measured on a analytical HPLC, eluting over 30 minutes in a gradient of 0 to 100% aceto nitrile in 
water (both containing 0.1 v% TFA, 0.7 mL/min). C1 was dissolved in MeCN and the UV detector was 
set to measure absorbtion at 333 nm.   
 
Polymersome formation via solvent switch the desired ratio of block copolymer 1:2:3 (10 mg 
total) was dissolved in THF (1 mL) and slowly diluted with MilliQ or 1x PBS buffer (3 mL). The 
opaque solution was extruded subsequently trough 400 nm, 200 nm and 100 nm filters (WHATMAN, 
extrusion kit) and purified over a Sephadex G200 column. The opaque fractio ns were combined and 
diluted to 10 mL (1 mg polymer/mL) The average size and polydispersity was determined by DLS. 
 
Conjugation of peptides to polymersomes TCEP (0.5 mg) was dissolved in 300 µL PBS pH 7.4 and 
added to peptide (1 mg, excess to maleimides). The solution was allowed to stand for 15 minutes, after 
which it was added to the polymersomes (1.5 mL). The coupling was allowed to proceed for three hours, 
after which the solution was transferred into a dialysis bag (Spectrapore MWCO 12-14 kDa) and dialyzed 
against PBS buffer for 24 hours (replacing PBS every 5-10 hours). 
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Size Dependent Biodistribution and SPECT 
Imaging of 111In-labelled Polymersomes 
 
 
 
 
 
 
 
Polymersomes, self assembled from the block copolymer polybutadiene-block-poly(ethylene glycol), were 
prepared with well-defined diameters between 90 and 250 nm. The presence of ~1% of diethylene 
triamine penta acetic acid on the polymersome periphery allowed to chelate radioactive 111In onto the 
surface and determine the biodistribution in mice as a function of both the polymersome size and 
poly(ethylene glycol) corona thickness (i.e. PEG molecular weight). Doubling the PEG molecular weight 
from 1 kg/mol to 2 kg/mol did not change the blood circulation half-life significantly. However, the size 
of the different polymersome samples did have a drastic effect on the blood circulation times. It was 
found that polymersomes of 120 nm and larger become mostly cleared from the blood within 4 hours, 
presumably due to recognition by the reticuloendothelial system. In contrast, smaller polymersomes of 
around 90 nm circulated much longer. After 24 hours more than 30 percent of the injected dose was still 
present in the blood pool. This sharp transition in blood circulation kinetics due to size is much more 
abrupt than observed for liposomes and was additionally visualized by SPECT/CT imaging. These 
findings should be considered in the formulation and design of polymersomes for biomedical 
applications. Size, much more than for liposomes, will influence the pharmacokinetics and therefore 
long circulating preparations should be well below 100 nm. 
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3.1 Introduction 
Polymersomes, or polymer vesicles, are a relatively new class of nanocapsules that 
are formed by the self assembly of amphiphilic block copolymers in aqueous media 1. 
Polymersomes can be regarded as the polymeric analogues of liposomes with a 
thicker, more stable and less leaky membrane. These characteristics make 
polymersomes an interesting class of nanocarriers for the delivery of diagnostic and 
therapeutic agents. For these applications it is generally desired to have long 
circulating particles which are not readily cleared from the blood stream by the 
reticuloendothelial system (RES)2. From liposomal in vivo studies it is known that 
size, next to PEGylation and charge, is a major factor that influences the blood 
circulation kinetics and biodistribution. Liposomes of more than 200 nm have been 
shown to accumulate in the spleen and liver, whereas liposomes of less than 70 nm 
tend to accumulate predominantly in the liver3,4. Liposomes with a size between 90 
and 150 nm have the longest blood circulation times. The blood circulation times of 
liposomes can be further enhanced by the introduction of up to ten percent 
PEGylated phospholipids5,6. Polyethylene glycol (PEG) prevents the opsonisation by 
blood proteins and the subsequent recognition and degradation by macrophages of 
the reticuloendothelial system. PEGylated liposomes may exhibit blood circulation 
half-lives (t½) of more than 15 hours, depending on the PEG chain length, charge and 
size of liposomes3,4,7. Finally, the effect of surface charge in liposomal formulations8 
and nanocarriers9 has been studied. Both a slightly negative and positive surface 
charge was reported to have a positive effect on the blood circulation kinetics.  
 The number of reports on biodistribution of neutral polymersomes is limited and 
is basically restricted to the work of Discher10,11 who used fluorescently labelled 
polymersomes to determine the effect of longer PEG chains and surface charge on t½ 
values, the work of Lee et al.12 and the recent work by Kataoka et al. who studied the 
size dependence of fluorescently labelled polyelectrolyte vesicles (PICsomes) for the 
preferred accumulation in tumour tissue compared to healthy tissue13. Also near 
infrared dyes have been encapsulated in order to visualize tumours in mice14,15. 
Discher et al. reported that polymersomes exhibit blood circulation half-lives up to 
28 hours. These high t½ values are partly due to the fact that polymersomes are fully 
PEGylated upon choosing PEG as the hydrophilic part of the block copolymer that 
constitutes the polymersome bilayer. It was furthermore shown that neutral 
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polymersomes circulate with the highest t½ values. Finally Tsourkas et al.16 
encapsulated a Gd-based magnetic resonance imaging (MRI) contrast agent for 
enhanced MRI imaging. By measuring the concentration of Gd in blood, they were 
also able to determine a concentration time profile.  
 One of the most quantitative methods to determine the biodistribution of drug 
delivery vehicles in vivo is by radio isotope labelling. This technique is often used for 
liposomal formulations, but has until now been hardly explored for polymersomes. 
There is one report on the biodistribution and radiolabelling (14C/3H) of negatively 
charged polymersomes12 and one study that shows data on the encapsulation and 
biodistribution of a radio-labelled model drug encapsulated in polymersomes17. 
However, the effect of polymersome size on biodistribution has not been analysed 
before with this technique. If radiolabelling of polymersomes with a suitable isotope 
such as 111In would be developed, this would not only allow quantitative 
determination of organ distribution but also visualisation with SPECT/CT imaging, as 
has previously been demonstrated for 50 nm polymer micelles 18,19.  
 
 
Figure 1. Schematic presentation of polymersome formation, 111In labelling and in vivo SPECT/CT 
imaging. 
 In this chapter we present a systematic study into the effect of size on the 
biodistribution of polymersomes via the quantitative technique of 111In 
radiolabelling, in combination with SPECT/CT imaging as depicted schematically in 
Figure 1. It is shown that polymersomes of around 90 nm in diameter have long 
circulation times in male Balb/C mice. Upon increasing the diameter to 120 nm and 
above the long circulating properties are lost and polymersomes are cleared from the 
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blood stream within a few hours by mainly the liver and spleen. The effect on 
circulation time upon changing the size from 90 to 120 nm is also clearly visualized 
by SPECT/CT imaging.  
 
3.2 Results and Discussion 
The amphiphilic block copolymer used in this study was polybutadiene-block-
poly(ethylene glycol) (PBd-b-PEG) because of its well-known biocompatibility and 
glass transition temperature (Tg) well below room temperature. Because of this low 
Tg the membrane of polymersomes formed from PBd-b-PEG remains fluidic which 
allows good control over the size via standard sizing techniques such as extrusion.  
 The general synthetic route towards the three block copolymers used in this 
study is depicted in Scheme 1 (see also Chapter 2). As can be seen from this scheme 
we adopted a modular approach based on the copper-catalyzed (2+3) cycloaddition 
reaction20. One of the main advantages of this modular approach is the possibility  to 
vary the molecular weight of PEG between 1 and 2 kg/mol, while keeping the 
molecular weight (distribution) of PBd exactly constant at 3.7 kg/mol. Polybutadiene 
was synthesised by means of anionic polymerisation. The reaction was initiated with 
sec-butyllithium at -78 °C. After all monomer was consumed, the living polymer was 
endcapped with 3-bromo-1-(trimethylsilyl)-1-propyne21. Deprotection with 
tetrabutyl ammonium fluoride yielded the alkyne-functional polybutadiene 1. 
Poly(ethylene glycol) monomethyl ether was purchased with a molecular weight of 
either 1 or 2 kg/mol. The introduction of an azide was straight forward by 
mesylation and azidation as published elsewhere22. PBd and PEG were coupled in 
THF at 60 °C by the addition of copper bromide and PMDETA as ligand. This reaction 
yielded the non functional block copolymers PBd-b-PEG with a molecular weight of 
approximately 4.7 kg/mol (4a) and 5.7 kg/mol (4b) depending on the PEG molecular 
weight. These inert block copolymers served as the basic building blocks for 
polymersome formation.  
 To allow radiolabelling of polymersomes with 111In a third block copolymer was 
synthesised with diethylene triamine penta acetic acid (DTPA) as chelating end 
group. Polybutadiene was coupled to α-amino-ω-azido-poly(ethylene glycol) via the 
same click approach as described above to obtain amine end-functional PBd-b-PEG 
(5) with a molecular weight of 4.7 kg/mol (PEG molecular weight of 1 kg/mol). DTPA 
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is a metal chelating agent that coordinates well to bi- and tri-valent metals. Copper, 
as used in the coupling reaction of PBd and PEG, can also coordinate strongly to 
DTPA. To prevent undesired occupation of DTPA by copper, all traces of copper in 
the different PBd-b-PEG analogues were removed by treating the polymers with 
Chelex resin in THF (as confirmed by ICP-MS). Finally p-benzyl-isothiocyanate DTPA 
was introduced in block copolymer 5 by reacting the amine end group and 
isothiocyanate in THF with triethylamine as base to form polymer 6.  
 
 
Scheme 1. Overview of polymers and the reaction path towards these compounds. Exact details on 
the synthesis can be found in the experimental section at the end of this Chapter and in Chapter 2. i) 
anionic polymerisation of 1,3 butadiene followed by endcapping and deprotection ii) azidation with MsCl 
followed by NaN3 iii) coupling of polymers via copper catalysed (2+3) cycloaddition iv) NaH, t-butyl 
bromoacetate in THF, followed by deprotection in 1M HCl v) esterification in MeOH/H 2SO4 vi) 
nucleophilic acyl substitution by 1,2 diamino ethane in MeOH vii) amine coupling of p-SCN-Bn-DTPA. 
 Polymersomes were formed by slowly diluting a solution of 4a:6 or 4b:6 = 99:1 
(w:w) in THF with 2-(N-morpholino)ethanesulfonic acid (MES) buffer with a pH of 
5.5. After the addition of MES buffer the samples were extruded through 0.2 µm 
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syringe filters to yield polymersomes of around 250 nm diameter. To size the 
polymersomes even further down the samples were either extruded through 100 nm 
filters (to yield ~120 nm polymersomes) or treated with ultrasonic sound waves at 
35 °C (to yield ~90 nm polymersomes). After resizing, the samples were washed with 
MES buffer and concentrated. It should be noted that extrusion through 100 nm 
membranes yielded the narrowest particle size distribution, whereas ultrasound 
waves and extrusion through syringe filters gave broader distributions. All partic le 
polydispersities were found to be below 0.15, which is comparable to results often 
encountered for liposomal formulations (see Figures 4 and 5 for the full DLS curves). 
The characteristics of the polymersomes are summarized in Table 1, as is the 111In 
labelling efficiency and blood plasma stability of the different samples which will be 
discussed next. 
 
Table 1. Overview of polymersome characteristics.  
ID size 
(nm) 
PDI Mw PEG 
(kg/mol) 
ζ 
potentiala 
111In 
labelling  
efficiency 
specific 
activity 
(MBq/mg) 
4 h 
plasma 
24 h 
plasma 
1k90 94 0.15 1 -14.76 97% 10 85% 79% 
1k120 115 0.05 1 -13.11 95% 10 84% 78% 
1k250 259 0.14 1 -12.42 94% 10 87% 80% 
2k90 87 0.13 2 -9.96 60% 6 77% 73% 
a) Zeta potentials were measured on a NanoSight NS500 in tap-water with an applied potential of 
24V. Polymersomes (250 nm) formed from only polymer 4a, i.e no DTPA chelated to the surface, have 
a zeta potential of -6.32 mV. 
 
 111In labelling was performed by adding 15 MBq 111InCl3 to 30 µL of 
polymersome solution. Samples that labelled with an efficiency of more than 95 
percent were used without further purification, and were diluted with PBS to 1.25 
MBq per mL. The one sample that had a labelling efficiency of only 60 percent (2k90) 
was purified over a PD10 desalting column after which it was also diluted with PBS. 
The stability of the 111In-labelled preparations was tested by adding 20 µL of each 
sample to 500 µL human blood serum. After 24 hours about 80 percent of the 
Indium-111 radioactivity was still associated with the polymersomes as summarized 
in Table 1. These results show that these polymersomes of well-defined size allow for 
stable radio isotope labelling for in vivo applications. 
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 After establishing polymersome synthesis and evaluation of the radiolabelling 
stability we studied the biodistribution as function of size and peripheral PEG 
thickness. As might be expected from similar studies based on liposomes, larger 
particles will influence the circulation kinetics negatively. In order to study if a 
similar trend is also valid for polymersomes, we injected male Balb/c mice (6 weeks 
old, 20-23 g/animal) with 250 kBq (0.2 mL or 0.42 mg/kg) of 111In-labelled 
polymersome solution in the tail vein. Each group contained four animals which were 
sacrificed after 4 or 24 h. Tissues of interest were collected, weighed and counted for 
radioactivity as summarized in Figure 2.  
 Upon looking at the blood levels a clear effect of polymersome size can be 
recognized immediately. Vesicles of 90 nm circulate much longer than vesicles of 120 
nm and larger. After 4 hours more than 50 percent of the 90 nm polymersomes were 
still present in the blood pool, which after 24 hours was reduced to 25 percent 
(based on a blood volume assumption of 1.5 g per animal). This allows us to estimate 
the blood half live of these 90 nm polymersomes to be around 20 hours, a number 
comparable to blood circulation half lives as reported by Photos et al10. Upon 
increasing the particle size both the liver and spleen accumulation became higher, an 
effect that is more abrupt for the liver than for the spleen. The abundance of 90 nm 
polymersomes in lungs was relatively high, which most likely is caused by high blood 
levels in lung tissue. These data show that – similarly to liposomes – smaller 
polymersomes circulate longer. However there is a major difference in the 
correlation between size and blood circulation kinetics of these polymersomes and 
liposomes. For polymersomes the transition from long-circulating to short-
circulating , upon increasing the size, is much more abrupt than for liposomes. A 
possible explanation might be found in the more rigid1 structure of polymersomes 
which results in less flexibility. This feature could be of practical use since it could 
have a beneficial effect on tumour accumulation via the enhanced permeability and 
retention (EPR) effect13,23. 
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Figure 2. Biodistribution of differently sized 111In-labelled polymersomes in Balb/C mice 
(n=4/group). a) 4 hours post injection and b) 24 hours post injection. 
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 In order to investigate the effect of the PEG corona on biodistribution two 
polymersome samples were included in these experiments with an average diameter 
of ~90 nm, but with different PEG lengths of 1 and 2 kg/mol (Table 1 and Figure 2). 
Although the sample with the thicker PEG corona seemed to circulate longer in the 
blood stream and showed lower liver and spleen accumulation this effect is not 
significant, especially because there is also a small size difference between both 
samples. 
 
 A powerful method of imaging organs/tissue particle distributions in living 
animals (and humans) is by Single Photon Emission Computed Tomography (SPECT) 
imaging. SPECT/CT imaging is a tool often used in nuclear medicine to obtain three 
dimensional images in a non-invasive manner. The polymersomes as described in 
this chapter have a high enough specific activity to image them by this technique. 
Typically for imaging of mice 15 MBq of activity is needed, an amount easily 
accessible via the route described herein.  
 In order to illustrate by SPECT/CT the abrupt transition from long circulating to 
fast clearance upon increasing the polymersome size, we prepared samples of 90 nm 
polymersomes and 120 nm polymersomes with 15 MBq of 111In. The procedure was 
analogous as described above, only the dilution factor with PBS was adjusted to end 
up with a sample of 75 MBq per mL. Each animal was injected intravenously with 15 
MBq (0.2 mL, 25.2 mg/kg) 111In-polymersomes in the tail vein and was scanned after 
4 hours. The resulting images are depicted in Figure 3. The top panel of Figure 3  (a-c) 
shows the results for the long circulating polymersomes of 90 nm with a PEG 
molecular weight of 1 kg/mol. As visualized by radioactivity in the heart and lungs, 
the polymersomes are still present in the blood circulation. The lower panel of Figure 
3 (d-f) shows 4 h post-injection scans of the 120 nm polymersomes. All the 
radioactivity is present in liver and spleen. This is in agreement with the 
biodistribution data as discussed above. These scans again show the strong size 
dependence of polymersomes with regard to blood circulation kinetics.  
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Figure 3. SPECT/CT images (4 h p.i.) of polymersomes injected in male BalB/c mice. Top (a-c) long 
circulating 90 nm polymersomes clearly show circulation through the liver, lungs and carotid artery. 
Bottom (d-f), 120 nm polymersomes show fast accumulation in the liver and the spleen.  
3.3 Conclusion 
We have demonstrated that for polymersomes, size is an important factor in the 
blood circulation kinetics. Polymersomes of 120 nm and larger are readily cleared 
from the blood, whereas smaller polymersomes of approximately 90 nm are long 
circulating with an estimated blood half life of 20 hours. We have shown that 
polymersomes containing 1 percent of a DTPA end-functional amphiphilic block 
copolymer of polybutadiene-block-poly(ethylene glycol) can be prepared with a 
sufficient specific activity for SPECT/CT imaging. The effect of size on the 
biodistribution could therefore also be illustrated by this technique to confirm that 
90 nm polymersomes are long circulating whereas 120 nm polymersomes readily 
accumulate in the liver and spleen. The effect of increasing the PEG molecular weight 
from 1 to 2 kg/mol was not found to be significant in this case. These findings should 
be taken into account upon designing polymersome formulations for imaging or drug 
delivery purposes. Polymersome size, much more than for liposomes, will influence 
the circulation kinetics of polymersomes.  
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3.5 Experimental Procedures 
General note The synthesis of polymers 1-5 was described in detail in Chapter 2. Animal 
experiments were approved by the local animal welfare committee and carried out according to 
national regulations. 
 
Materials p-isothiocyanate-benzyl diethylenetriamine penta-acetic acid (MACROCYCLICS >94%), 
Chelex resin (ALDRICH), were used as received. Tetrahydrofuran (THF) (ACROS ORGANICS, 99+% 
extra pure, stabilized with BHT) was distilled under argon from sodium/benzophenone , and triethyl 
amine (TEA) (BAKER) was distilled from calcium hydride under an argon atmosphere prior to use. 
Polymersome extrusions were performed using 200 nm filters (Acrodisc 13 mm Syringe Filter, 0.2 µm 
Nylon membrane) and 0.1 µm PC membrane (WHATMAN). 111InCl3 was purchased from Covidien, 
Petten, The Netherlands. Instant Thin-Layer Chromatography Silica Gel impregnated glass fibre 
(ITLC-SG) strips were purchased from Varian.  
 
Instrumentation Infrared (IR) spectra were obtained using a Thermo Matson IR 300 FTIR 
spectrometer. Data are presented as the frequency of absorption (cm -1). Molecular weight 
distributions were measured using size exclusion chromatography (SEC) on a Shimadzu  (CTO-20A) 
system equipped with a guard column and a PL gel 5 μm mixed D column (Polymer Laboratories) 
with differential refractive index and UV (λ=254 nm and λ=345nm) detection, using tetrahydrofuran 
(SIGMA ALDRICH chromasolv 99.9%) as an eluent at 1 mL/min and T = 35 oC. Particle size 
distributions were measured on a Malvern instruments Zetasizer Nano-S and zeta potentials were 
measured on a NanoSight NS 500 instrument. 
 
Conjugation of Diethylene Triamine Penta Acetic acid (DTPA) (6)  amine end-functional 
polybutadiene-block-poly(ethylene glycol) (5, 110 mg, 23 µmol) was dissolved in THF (10 mL). To the 
solution, p-isothiocyanate-benzyl diethylene-triamine-penta-acetic-acid (14 mg, 0.95 equiv. 22 µmol) 
and triethylamine (5 mL) were added. The mixture was stirred at room temperature for 48 hours, 
after which all solvents were removed. The products were dissolved in THF (5 mL) and cooled on ice 
for 6 hours, after which the solution was filtered through a 200 nm syringe filter. The product was 
obtained by removing all THF. The DTPA end groups were not quantified, yet their presence was 
confirmed by FTIR and 111In test labelling. FTIR: 1730 cm-1 (carboxylic acid). SEC (THF): Mw/Mn = 
1.26, Mw (theoretical) = 5.3 kg/mol. 
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Polymersome formation (general) Polymer 4a (9.9 mg, 2.1 µmol) or 4b (9.9 mg, 1.7 µmol) and  
diethylene-triamine-penta-acetic-acid functional polybutadiene-block-poly(ethylene glycol) 6 (0.1 
mg, 0.02 µmol)were dissolved in THF (200 µL). Polymersomes were formed by the slow addition of 
0.1 M. 2-(N-morpholino)ethanesulfonic acid buffer of pH 5.5 (0.6 mL, MES). The samples were passed 
three times through a 200 nm syringe filter to yield polymersomes of ~250 nm. Polymersomes of 
~120 nm were obtained by multiple extrusion through 100 nm filters (one pass will yield ~160 nm 
polymersomes) and polymersomes of less than 100 nm were obtained by treating the sample with 
ultrasonic sound waves (48 kHz, 200W) for 30 minutes at 35 °C. Samples were washed and 
concentrated to 200 µL by means of a spin column (100 kDa MWCO, 3000 rpm). Note that for the 
biodistribution samples a stock solution containing 9.9 mg 4a and 0.1 mg 6 per 200 µL THF was 
prepared to prevent variation in concentration and ratio of polymers. The DLS results of all samples 
are depicted in Figures 4 and 5. 
 
111In labelling To 30 µL polymersomes, 150 µL 0.1 M. 2-(N-morpholino)ethanesulfonic acid (MES) 
buffer (pH 5.5) and 15 MBq 111InCl3 were added. The labelling mixture was incubated at room 
temperature for 30 minutes. Labelling efficiency was analyzed by Instant Thin-Layer 
Chromatography Silica Gel impregnated glass fibre (ITLC-SG), developed in 0.1 M NH4Ac (pH 5.5)/0.1 
M EDTA (1:1, v/v). Samples with a labelling efficiency of more than 95 percent were used without 
purification and diluted with PBS buffer prior injection. Samples with a coupling efficiency of less 
than 95 percent were purified over a PD10 desalting column and diluted with PBS.  
 
Blood Plasma stability To study the stability of polymersome preparations, 20 µL of radio-labelled 
polymersomes was incubated in 500 µL blood serum for 4 and 24 hours at 37 °C. Association of 111In 
with the polymersomes was analyzed by ITLC-SG, developed in 0.1 M NH4Ac (pH 5.5)/0.1 M EDTA 
(1:1, v/v). 
 
Biodistribution studies Biodistribution was analyzed in male BALB/c mice (6 weeks of age, 20-23 g 
per animal). The animals were divided in 8 groups of 4 animals and injected in their tail vein with 
250 kBq (0.2 mL or 0.42 mg/kg) of 111In-labelled polymersome preparation. Mice were sacrificed by 
CO2 inhalation 4 or 24 h postinjection (p.i.), a blood sample was drawn, and tissues of interest were 
dissected, weighed, and counted in a gamma-counter along with a standard of the injected activity to 
allow calculation of the injected dose per gram tissue (% ID/g).  
 
SPECT/CT imaging Two animals were selected for SPECT/CT imaging and injected with 15 MBq (0.2 
mL, 25.2 mg/kg) 111In-polymersomes in the tail vein. The animals were sacrificed by CO 2 inhalation 
and scanned with the U-SPECT-II (MILabs) 4 hours postinjection. 
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Figure 4. DLS intensity size distributions of sample 2k90nm (top) and 1k 90nm (bottom) as measured on 
a Malvern Nano S machine. Both samples were resized by treatment with ultrasound (48 kHz, 200 W, 35 
degrees Celsius ). 
 
Figure 5. DLS intensity size distributions of sample 1k120nm (top) and 1k 250nm (bottom) as measured 
on a Malvern Nano S machine. Both samples were resized by means of extrusion through respectively 200 
and 100 nm membranes. 
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Peptide-Mediated Blood-Brain Barrier Transport of 
Polymersomes 
 
 
 
 
 
 
 
 
In this chapter we report the design of polymersomes tagged with a dodecamer peptide, G23, that are able to 
cross the blood-brain barrier both in vitro and in vivo. Transport over the blood-brain barrier was induced by 
recognition of G23 to the gangliosides GM1 and GT1b to accommodate transcytosis of 220 nm polymersomes 
in an in vitro model and 166 nm polymersomes in vivo. These findings open new opportunities for the 
development and formulation of medicines against brain related diseases. 
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4.1 Introduction 
The effective treatment of brain-related diseases is severely hampered by the presence 
of the blood-brain barrier (BBB), a polarized layer of endothelial cells that physically 
separate blood from brain tissue1. Besides being able to cross the BBB, drugs must 
display sufficient stability and bioavailability2. Once drugs have reached the brain side, 
they are exposed to multidrug receptors on the endothelial cell surface to rapidly clear 
them from the brain3. Of these challenges, both bioavailability and crossing the BBB may 
be overcome by the application of nanocarriers that effectively target the endothelial 
cell layer and induce transcytosis across the BBB.  
The best studied nanocarriers for drug delivery over the BBB are liposomes. To 
target them over the BBB, liposomes have been decorated4-7 with antibodies, proteins8 
or peptide9-10 parts of protein binding domains11. However, most targeted liposomes 
showed only a limited association with the BBB in vivo as was recently shown by van 
Rooy et al. in a comparative study8. Only liposomes conjugated to transferrin antibody 
RI7217 – having a molecular weight of 90 kg/mol – were able to significantly enhance 
brain uptake. 
A relatively new class of nanocarriers consist of polymeric vesicles, or 
polymersomes12-13, which spontaneously self-assemble in aqueous media from 
amphiphilic block copolymers. They resemble liposomes in their basic morphology, but 
have as a clear difference a thicker bilayer membrane. This renders them considerably 
more stable than liposomes, and improves the blood circulation ability14. Furthermore, 
the large apolar compartment allows a more efficient transport of hydrophobic drugs. 
Since the majority of CNS drugs are hydrophobic, there is a large added value in 
preparing polymeric carriers for efficient transport over the BBB into the brain 
parenchyma. Until now, only one group has reported the conjugation of transferrin15 or 
transferrin antibody RI721716 to polymersomes, for targeted transport over the BBB. 
Clearly, to develop an efficient nanocarrier system, a broader choice in selective 
targeting units is required. Moreover these targeting units should still be active when 
conjugated to the polymersome surface and preferential have a low molecular weight 
for easy synthesis and conjugation.  
In this chapter we report the design and synthesis of a polymersome nanocarrier, 
tagged with a dodecamer peptide of only 1645 g/mol, that is able to efficiently cross the 
BBB, both in vitro and in vivo. The peptide G23 was identified by means of phage display 
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with ganglioside GM1 as target. Although the G23 peptide has previously been reported 
for binding to gangliosides17, it has now been employed for the first time to 
accommodate transport of nanocarriers over the BBB.  
 
 
Figure 1. Cartoon of polymeric vesicles tagged with a small GM1 binding peptide. The polymersome 
formulations are able to efficiently cross the BBB into the brain parenchyma, opening new routes toward 
effective treatment of brain-related diseases. 
4.2 Results and Discussion 
The block copolymers for the formation of polymersomes are depicted in Scheme 1. 
Details on the synthetic procedures can be found in Section 4.5 and Chapter 2. We chose 
to work with amphiphilic block copolymers (1) consisting of polybutadiene and 
poly(ethylene glycol) (PEG) mainly for two reasons. First of all, this block copolymer is 
generally considered to be biocompatible, and secondly the low glass transition 
temperature of polybutadiene allows for extrusion – and therefore resizing – of the 
resulting polymersomes. This has been shown to be of great importance for long in vivo 
circulation18-19. Furthermore, PEG induces stealth behaviour of the vesicles and 
therefore prevents cell adhesion as well as opsonisation and thereby recognition by the 
reticulo endothelial system (RES). To functionalize the polymersomes with targeting 
peptides, maleimide end groups were introduced (2). As a tracing moiety, either 
Chapter 4 
 
78 
fluorescein (4), rhodamine (5) or diethylenetriamine pentaacetate (6) (DTPA, for radio-
isotope labelling) was introduced in 3 via isothiocyanate derivatives of the tracer.  
 
 
Scheme 1. Left) Amphiphilic block copolymers used in this study. Polymer 1 is the main building block of 
the polymersomes. Polymer 2 is a maleimide-functionalized analogue to couple peptides. Starting from 
polymer 3, fluorescein, rhodamine and DTPA end-functionalized analogues were obtained. Right) TEM 
picture of polymersomes formed from 1, 2 and 4 in a ratio of 8:1:1. The black bar represents 200 nm. 
The peptides that were known before this study to target the BBB were limited to Tat-
peptide9-10, opioid-derived peptides20 and the bigger RVG-9R peptide11, which all 
showed limited in vivo delivery into the brain parenchyma. In order to identify more 
potent peptides, we recognized that caveolae, which are present on the luminal surface 
of endothelial cells, are well known as cellular entry portals for transcytotic transport21. 
Since caveolae are enriched in GM1, we reasoned that this could be an appropriate 
target to mediate transport into the brain. A phage library selection was performed, 
using the Ph.D-12 library from BioLabs with immobilized GM1 as target22. After three 
panning rounds 20 plaques were selected of which 10 shared a known carbon nanotube 
binding sequence23. Three plaques shared the sequence defined as G23. The other seven 
plaques showed unique sequences. We selected the peptides defined as G23 and G88 
based on their efficient binding and homogeneous patterning upon interaction of the 
phages with human Cerebral Microvascular Endothelial Cells (hCMEC/D3)24 as shown in 
Figure 9. The selected peptides were synthesized via standard Fmoc chemistry with an 
additional C-terminal cysteine as a functional handle.  
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Polymersomes were prepared by mixing block copolymers 1, 2 and 4 in a ratio of 8:1:1 
for all in vitro studies (Table 1). The polymeric vesicles were formed via the solvent 
switch method, after which they were extruded to an average size of 220 nm with a 
polydispersity index (PDI) of 0.11. The selected peptides were coupled via 
cysteine/maleimide chemistry, starting from the same batch of maleimide-
functionalized polymersomes. To check whether the peptide coupling was successful, 
zeta potentials were measured. The zeta potentials showed in all cases a clear change in 
surface charge after coupling of the peptides (table 1). For in vivo experiments 
polymersomes were prepared with rhodamine as tracer, thus combining polymers 1, 2 
and 5 in a ratio of 8:1:1. The polymersomes were reduced in size to 160 nm, to allow 
sufficiently long blood circulation to pass the brain endothelial cells, yet short enough to 
prevent false comparison of targeted and non-targeted particles due to a big difference 
in blood clearance19.  
 
Table 1. Characteristics of polymersome samples used for in vivo and in vitro studies. 
ID/Peptide[a] Sequence[b] Size (PDI) Charge[c] Zeta[d]  
Nonfluor – 220 (0.11) – –6.32 
G88fluor  NPAGPSPAHIISC 220 (0.11) 0 –14.59 
G23fluor HLNILSTLWKYRC 220 (0.11) +2 –1.70 
Scrfluor KISHLLNYRTWLC 228 (0.10) +2 –2.83 
G23(5%)fluor HLNILSTLWKYRC 227 (0.12) +2 –3.21 
Nonrhod – 164 (0.10) – –2.64 
G23rhod HLNILSTLWKYRC 165 (0.12) +2 –8.42 
[a] Samples contain 10 mol% fluorescently labelled polymer (fluor = fluorescein, rhod = rhodamine), 10% 
of the surface is covered with peptides. [b] Peptide sequences with C-terminal cysteine for coupling to the 
polymersome surface. [c] Formal charge at pH 7. [d] Measured in water with an applied potential of 24 V.  
First the transcytosis capacity of targeted and non-targeted polymersomes was 
determined in hCMEC/D3 cells, cultured on transwell filters. The hCMEC/D3 cell line is a 
good model for the human blood-brain barrier, as developed and verified by Weksler et 
al.24-25. Recently this assay was used and validated by Ragnaill et al.26 to study the 
transcytosis of SiO2 nanoparticles. An overview of the experimental setup is provided in 
Figure 2c. The polymersomes were added to the apical side of the model and incubated 
for 18 hours at 37 °C, after which the percentages of applied dose in the apical chamber 
(AP), basolateral chamber (BA) and cell monolayer (FIL) were determined by means of 
fluorescence spectroscopy.  
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Figure 2. a) In vitro transcytosis capacity of polymersomes functionalized with the selected peptides. b) 
Scrambling of the G23 sequence and lowering the surface functionalization with G23 both resulted in 
reduced in vitro transcytosis. c) Schematic overview of the in vitro hCMEC/D3 cell transwell assay. d) 
Kinetic plot of in vitro G23/mediated transcytosis of polymersomes.  
As evident from Figure 2a, the G23-polymersomes showed the most prominent 
transcytotic capacity. Specifically, 30.8 ± 1.4% of the G23-polymersomes were recovered 
at the basolateral side. This implies on average a more than four-fold increase in 
transcytotic capacity, compared to the basolateral recovery of non-targeted 
polymersomes (5.7 ± 0.8%), or polymersomes tagged with G88 (6.8 ± 1.9%). In addition 
to a highly efficient appearance in the basolateral medium, the G23-polymersomes 
showed an enhanced association with the cells (Figure 2a; G23; FIL). Thus, 5.5 ± 2.3% of 
the added dose remained cell-associated, representing 2-3 times as much as the cellular 
association of the other polymersome preparations tested, i.e. non-targeted (1.5% ± 
0.8%) and those tagged with G88 (1.5 ± 0.4%). These data thus emphasize the specific 
role of G23 in mediating the observed enhancement in transcytotic transport, and 
exclude potential leakiness of the cell monolayer, as this should have resulted in a non-
specific appearance of polymersomes in the basolateral medium. The specificity of G23-
mediated transport was further supported by determining the kinetics of transcytosis of 
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the G23-polymersomes across hCMEC/D3 cells. As shown in Figure 2d, typical 
saturation kinetics were obtained, supporting the involvement of an active, receptor-
mediated transport pathway, possibly reflecting differences in the kinetics of 
transcytosis and recycling of the receptor(s).  
To investigate a potential correlation between physicochemical properties (e.g. 
charge, hydrophobicity) and transcytotic capacity of the peptide, a scrambled version of 
the G23-peptide (Scr) was prepared and its ability in transport of polymersomes was 
compared to that of ‘native’ G23 and non-targeted polymersomes. As illustrated in 
Figure 2b a twofold reduction in transcytosis across the in vitro BBB model was 
observed between Scr-polymersomes and G23-targeted polymersomes. Secondly the 
peptide density was reduced to 5 mol%. Lowering the incorporation of G23 in 
polymersomes also led to a two-fold reduction in transcytosis (Figure 2b). Together, 
these data strongly support the view that the G23-peptide, when coated on the surface 
of polymersomes, displays a specific capacity in mediating their transport across 
polarized hCMEC/D3 cells. 
 
Although in a different context, peptide G23 was reported to bind to a structurally 
similar ganglioside GT1b17. Furthermore the removal of tetanus toxin C from its 
ganglioside receptor GT1b by peptide G23 has been reported27, together with this study 
clearly indicating that G23 recognizes at least two gangliosides. In nature additional 
gangliosides are encountered which are structural equivalents of GM1. We therefore 
investigated whether these gangliosides are present on the BBB model and secondly for 
which gangliosides G23 tagged polymersomes have affinity.  
Using a set of specific antibodies against individual ganglosides, immuno analysis 
revealed the presence of GD1a and GT1b, but not GD1b at the cell surface of hCMEC/D3 
cells as shown in Figure 3. Subsequently, we investigated whether the G23-
polymersomes display binding capacity towards GD1a and GT1b, using related and 
unrelated gangliosides as controls. The gangliosides – spotted on a dot blot – were 
incubated with radioactively labelled G23-polymersomes, after which binding only 
occurred to GM1 and GT1b. Accordingly, we determined whether the binding of G23-
polymersomes to GT1b also occurs in a cellular context by establishing the extent of 
colocalization between GT1b and fluorescently labelled G23-polymersomes. The 
colocalization of G23-polymersomes with GT1b was 16.2 ± 6.4%, while colocalization 
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with GD1a was less than 3% (Figure 4). Hence, these data support that both GM1 and 
GT1b may function as target sites for G23-polymersomes. 
 
 
Figure 3. Distribution of gangliosides, GD1a, GD1b and GT1b in a monolayer of hCMEC/D3 cells. The 
nuclei are stained blue by DAPI and the gangliosides are stained red via the corresponding antibody.  
 
 
Figure 4. Colocalisation of G23 tagged polymersomes (green) with ganglioside GD1a (left, stained in red), 
ganglioside GT1b (middle, stained red) and the evaluation of the amount of colocalisation (right). 
To reveal the potential of G23 to also mediate BBB passage in vivo, rhodamine-labelled 
G23-polymersomes and non-targeted polymersomes were administered by intracarotid 
artery injection in BALB/c mice. The brain distribution of both rhodamine-labelled 
polymersomes was then analyzed 24 h after injection by preparing thin brain slices as 
described in detail in the Section 4.5. The nuclei were stained green (CD31), the vessels 
were stained blue (DAPI) and polymersomes red (rhodamine). As demonstrated in 
Figure 5, next to their localization within the endothelial cells of the BBB (Figures 5a, b – 
upper panel), substantial amounts of the G23-polymersomes reached the brain 
parenchyma (Figures 5a, b – lower panel, c), indicating that they crossed the BBB and 
penetrated into the brain tissue. In marked contrast, non-targeted polymersomes were 
found mainly in the leaky vessels of the forth ventricle (Figure 5d) and ependymal cells 
of the aqueduct (Figures 5e, f – lower panel), and only occasionally in brain parenchyma 
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(Figures 5e, f – upper panel), further emphasizing the potency of G23 to mediate 
effective transfer of polymersomes across the BBB.  
 
 
Figure 5. In vivo brain distribution of polymersomes after intracarotid artery injection in mice. BALB/c 
mice were injected with G23- and non-targeted polymersomes. 24 h after injection brains were isolated 
and processed as specified in methods. (a, magnification in (b) upper panel) G23-polymersomes are found 
in microvessels, visualized with CD31 (PECAM), and in (a, magnification in (b) lower panel, and c) brain 
parenchyma. (d) Non-targeted polymersomes are found in the leaky vessels of the forth ventricle, and in 
(e, magnification in (f) upper panel) in parenchyma, and (e, magnification in (f) lower panel) ependymal 
cells of the aqueduct. Polymersomes are pseudocolored in red, CD31 in blue, and nuclei in green. Scale 
bars, 50 μm. 
4.3 Conclusion 
In conclusion, we have identified the low molecular weight peptide, G23, which when 
coupled to polymeric vesicles, binds to cell surface localized gangliosides GM1 and GT1b. 
By doing so it is able to mediate the transport of nanocarriers over the blood brain 
barrier both in vitro and in vivo. The combination of the low molecular weight targeting 
peptide, GM1/GT1b as targeting receptor, the robust polymeric carrier and the efficient 
in vitro and in vivo transcytosis is unprecedented and therefore adds new possibilities 
to the development of efficient drug nanocarriers for the treatment of brain and central 
nervous system-related diseases  
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4.5 Experimental procedures 
 
4.5.1 Synthesis and characterisation 
Notes The synthesis of compounds 1-3 and 7-14 were performed as discussed in Chapter 2. 
 
Materials Chelex resin (ALDRICH), was used as received. Tetrahydrofuran (THF) (ACROS ORGANICS, 
99+% extra pure, stabilized with BHT) was distilled under argon from sodium/benzophenone, and 
triethylamine (TEA) (BAKER) was distilled from calcium hydride under an argo n atmosphere prior to 
use. 111InCl3 was purchased from Covidien, Petten, The Netherlands. Instant Thin-Layer 
Chromatography Silica Gel impregnated glass fibre (ITLC-SG) strips were purchased from Varian. 
Thin layer chromatography (TLC) was performed on Merck precoated silica gel 60 F-254 plates (layer 
thickness 0.25 mm). Compounds were visualized by UV, ninhydrin and/or permanganate reagents. 
Column chromatography (CC) was carried out using silica gel, Acros (0.035-0.070 mm, pore diameter 
ca. 6 nm). Polymersome extrusions were performed using 200 nm filters (Acrodisc 13 mm Syringe 
Filter, 0.2 µm Nylon membrane) and 0.1 µm PC membrane (WHATMAN).  
 
Instrumentation Infrared (IR) spectra were obtained using a Thermo Matson IR 300 FTIR spectrometer. 
Data are presented as the frequency of absorption (cm-1). Molecular weight distributions were measured 
using size exclusion chromatography (SEC) on a Shimadzu (CTO-20A) system equipped with a guard 
column and a PL gel 5 μm mixed D column (Polymer Laboratories) with differential refractive index and 
UV (λ = 254 nm and λ = 340nm) detection, using tetrahydrofuran (SIGMA ALDRICH chromasolv 99.9%) as 
an eluent at 1 mL/min and T = 30 °C. Particle size distributions were measured on a Malvern instruments 
Zetasizer Nano-S. and zeta potentials were measured on a NanoSight NS500 system in water with an 
applied potential of 24 V. MilliQ water was obtained from a Labconco water pro PS system. 
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Scheme 2. Synthetic route to amphiphilic block copolymers of PBd-b-PEG (1-3) with different end 
functionalities as developed in Chapter 2. Polymer 1 is inert and forms the basic building block for 
polymersome formation. Block copolymer 2 bears an amine end group to allow conjugation with 
isothiocyanate derivatives of e.g. fluorescein. Finally, polymer 3 is maleimide end functionalized to allow 
for conjugation with cysteine bearing peptides. Prior to use, all polymers were extensively washed with 
Chelex 100 resin in THF to remove any traces of copper. The amount of residual copper was in all cases 
determined by ICP-MS and found to be equal or less than MilliQ references. 
Fluorescent labelled polybutadiene-b-poly(ethylene glycol) (4 and 5) Compound 3 (50 mg, 10 µmol) 
was dissolved in THF (10 mL) and Et3N (1 mL) was added. Rhodamine B isothiocyanate (7.5 mg, ca. 1.5 
equiv.) or fluorescein isothiocyanate (7.5 mg, ca. 1.5 equiv.) was added and allowed to react for 48 hours. 
Solvents were removed and product 4 or 5 was purified by preparative SEC (THF) to yield 25 mg product. 
The product was a single spot on TLC (8 v% methanol in DCM; UV and permanganate stain) which 
appeared brightly fluorescent. Note that the isothiocyanate coupling of rhodamine B proceeded slowly as 
can be seen from the SEC traces (absorption @ 340 nm) in Figure 6. The elution volume that was collected 
in preparative SEC (THF) is depicted in the box (6.7 to 8.1 mL) 
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Figure 6. SEC (THF) analysis of block copolymer 
3, which does not absorb at 340 nm before the 
addition of rhodamine B isothiocyanate. After 2 
hours the labelled polymer (top~7.5 mL) does 
absorb at 340 nm, which increases over the next 
46 hours. The dashed box indicates the volume, 
containing product 5 (or 4 case of FITC), which 
was collected by preparative SEC in THF. 
 
PBd-b-PEG-DTPA (6) This reaction was performed as described in Chapter 3. In short, the amine end 
functional polybutadiene-b-poly(ethylene glycol) 3 (110 mg, 23 µmol) was dissolved in THF (10 mL). To 
the solution, p-isothiocyanate-benzyl diethylene-triamine-penta-acetic-acid (14 mg , 0.95 equiv. 22 µmol) 
and triethylamine (5 mL) were added. The mixture was stirred at room temperature for 48 hours, after 
which all solvents were removed. The products were dissolved in THF (5 mL) and cooled on ice for 6 
hours, after which the solution was filtered through a 200 nm syringe filter. The product was obtained by 
removing all THF. The DTPA end groups were not quantified, yet their presence was confirmed by FTIR 
and 111In test labelling. FTIR: 1730 cm-1 (carboxylic acid). SEC (THF): Mw/Mn = 1.26, Mw (theoretical) = 
5.3 kg/mol. 
 
Peptide Synthesis All peptides were synthesised by means of standard Fmoc chemistry. To the C-
terminus of all native peptide sequences (as determined in phage display) was an additional cysteine 
added to allow bioconjugation. All peptides were more than 90 percent pure as analyzed by means of 
HPLC (water/acetonitrile with 0.1% TFA; gradient acetonitrile from 0 to 100% in 30 minutes). 
Additionally in all cases the right mass was found by means of Maldi-TOF (Maldi-TOF (cyano-4-
hydroxycinnamic acid), analyzed with moverz software:  
 
G23: [M+H] calc: 1645.88 g/mol and [M+H] found:1645.6 g/mol.  
SCR:  [M+H] calc: 1645.88 g/mol and [M+H] found: 1645.6 g/mol.  
G88: [M+H] calc: 1262.6 g/mol and [M+H] found: 1262.1 g/mol.  
 
4.5.2 Polymersome formation and peptide conjugation 
Fluorescent, maleimide displaying polymersomes Compounds 1 (8 mg, 1.7 µmol), 3 or 4 (1 mg, 
0.2 µmol) and 2 (1 mg, 0.2 µmol) were dissolved in THF (200 µL). Polymersomes were formed by the 
slow addition of 0.8 mL of PBS buffer of pH 7.4. The samples were passed six times through a 200 nm 
syringe filter (Aerodisc) to yield polymersomes of approximately 220 nm. To obtain polymersomes of 
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around 160 nm the solution was extruded six times over a 100 nm filter (Lipex high pressure 
extruder, Northern Lipids). The resulting opaque suspension was purified over a Sephadex G200 
column (1.5 x 8 cm). The opaque fractions were combined and PBS was added to a total volume of 10 
mL, i.e. a polymersome suspension containing 1 mg polymer per mL. The final polymersome solution 
was analyzed by DLS to determine the mean size and polydispersity index.  
 
 
Figure 7. TEM image of polymersomes formed 
from block copolymer 1. The black bar 
represents 200 nm. 
 
 
Radio-labelled, maleimide displaying polymersomes Compounds 1 (9 mg, 1.9 µmol), 5 (0.1 mg, 
0.02 µmol) and 2 (1 mg, 0.2 µmol) were dissolved in THF (200 µL). Polymersomes were formed by 
the slow addition of 0.6 mL of 0.1 M. 2-(N-morpholino)ethanesulfonic acid (MES) buffer of pH 5.5. 
The samples were passed three times through a 200 nm syringe filter to yield polymersomes of  
approximately 220 nm. The solution was extruded six times over a 100 nm filter (extrusion kit) to 
obtain polymersomes of around 160 nm. The resulting opaque suspension was purified over a 
Sephadex G200 column (1.5 x 8 cm), eluting with MES buffer. The opaque fractions were combined 
and the mean particle size was determined by DLS. 
 To 0.2 mL of polymersomes, 25 MBq of 111InCl was added and allowed to chelate for 20 minutes, 
after which the coupling efficiency was analyzed by Instant Thin-Layer Chromatography Silica Gel 
impregnated glass fibre (ITLC-SG) strips, developed in 0.1 M NH4Ac (pH 5.5)/0.1 M EDTA (1:1, v/v). 
The sample was purified over a PD10 desalting column, eluting with PBS buffer pH 7.4, and diluted 
with PBS to a total volume of 10 mL, i.e. a polymersome suspension containing 1 mg polymer per mL. 
 
Conjugation of peptides to polymersomes Tris(2-carboxyethyl)phosphine (0.5 mg, TCEP) was 
dissolved in PBS of pH 7.4 (300 µL) and added to the peptide (1 mg). The solution was allowed to 
stand for 15 minutes, after which it was added to 1.5 mL of polymersomes . The coupling was allowed 
to proceed for three hours, after which the solution was transferred into a dialysis bag (Spectrapore 
MWCO 12-14 kD) and dialysed against PBS buffer for 24 hours (replacing PBS every 5-10 hours). The 
zeta potential of the polymersomes was determined by means of DLS (Table 1) and all preparations 
were tested for hCMEC/D3 cell binding as shown in Figure 8. 
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Figure 8. CLSM images revealing association of polymersomes (green fluorescent dots) with a 
monolayer of hCMEC/D3 cells. Left) Untargeted fluorescein labelled polymersomes. Middle) 
Polymersomes tagged with 10% G88 and labelled with fluorescein. Right) Polymersomes tagged with 
10% G23 and labelled with fluorescein for visualization. 
4.5.3 Phage display for selection of GM1-binding peptides 
To perform a phage library selection on monosialotetrahexosylganglioside (GM1), GM1 -C11-N3 was 
covalently coupled to a 96-wells plate via the Cu-catalyzed azide-alkyne cycloaddition, which assures 
a proper physiological orientation of the oligosaccharide chains22. A maleimide-functionalized plate 
(Thermo Scientific, Waltham, MA) was washed with phosphate buffered saline (3x, PBS (0.1 M 
Na2HPO4, 0.15 M NaCl pH 7.2) and incubated for 2 h at room temperature with 0.5 M propargylamine 
diluted in immobilization buffer (0.2 M NaHCO3, 0.5 M NaCl, pH 8.0), with refreshing the solution 
after the first hour. Next, the plate was washed two times with ultrapure sterile water and GM1 -C11-
N3 (0.2 μg/well), sodium ascorbate (0.28 μg/well) and CuSO4 (0.3 μg/well), all diluted in water, were 
sequentially added to the plate. After an overnight incubation at room temperature the plate was 
washed two times with ultrapure sterile water, followed by adding a small volume of PBS to cover th e 
bottom of the plate, and stored at 4 °C. The coupling reaction was verified with Alexa Fluor 488 
labelled cholera toxin B (CTxB-AF488). 0.43 nM CTxB-AF488 was added to the plate, followed by an 
incubation for 90 min at 37 °C Subsequently, the plate was washed 10 times with PBS and the 
fluorescence intensity was measured on a Perkin-Elmer LS 500 luminescence spectrometer. The 
fluorescence signal showed a 1.42-fold increase compared to a 5 mg/mL BSA-treated plate.  
Three panning rounds with a premade phage library (Ph.D.-12, BioLabs) encoding peptide 12-mers, 
were performed according to the manufacturer’s protocol. Briefly, each well was incubated with blocking 
buffer (5 mg/mL BSA in 0.1 M NaHCO3 pH 8.6) for 1 h at 4 °C. After six times washing with Tris-Buffered 
Saline Tween-20 (TBST, 50 mM Tris-HCl pH=7.5, 0.1% [v/v] Tween-20), 10 μl of a 100-fold dilution of the 
original library in TBST (2 x 109 phage clones) was added to the wells and incubated for 1 h at room 
temperature with gentle shaking. The plate was washed 10 times with TBST, with an increase in the 
Tween-20 concentration to 0.5% [v/v] in the second and third panning round, to remove non-bound 
phages. Phages that were bound to the GM1-coated plate were eluted with 0.2 M Glycine-HCl containing 1 
mg/mL BSA (pH 2.2) for 15 min at room temperature. Eluted phages were amplified in ER2738 E.coli, 
purified, precipitated in PEG/NaCl (20% [w/v] polyethylene glycol-8000, 2.5 M NaCl) or titered on 
IPTG/Xgal LB plates. After the third panning round, 20 out of the approximately 100 plaques present were 
randomly chosen and the DNA was isolated. The DNA was precipitated with ethanol from suspensions of 
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phage pellets in iodide buffer (10 mM Tris-HCl (pH 8.0), 1 mM EDTA, 4 M NaI), according to the 
manufacturer’s protocol for single-stranded phage DNA isolation. The DNA samples were sequenced by 
BaseClear BV, Leiden, The Netherlands. 
 
4.5.4 In vitro evaluation 
hCMEC/D3 cell line maintenance and differentiation A human brain microvessel endothelial cell line, 
hCMEC/D3, was obtained from Dr. P.O. Couraud (Institut Cochin, Paris, France). Cells were maintained in 
25 cm2 flasks precoated with 100 μg/mL rat tail collagen type I (Cultrex, R&D Systems, Trevigen) in EBM-
2 basal medium (Lonza Group, Basel, Switzerland), supplemented with EGM-2-MV bullet kit (Lonza Group, 
Basel, Switzerland) containing VEGF, R3-IGF-1, hEGF, hFGF-B, hydrocortisone, and 2.5% FBS and 100 
μg/mL penicillin/streptomycin. For differentiation of the cells EBM-2 basal medium was supplemented 
with 1 μM dexamethasone (Sigma, St. Louis, MO) and 1 ng/mL bFGF (Invitrogen, Carlsbad, CA). Cells were 
maintained at 37 °C under an atmosphere of 5% CO2. 
 
Incubation of hCMEC/D3 cells with fluorescently labelled phage particles Individual phage clones 
were amplified according to manufacturer’s protocol. Briefly, an overnight culture of ER2738 E. coli was 
diluted 1:100 and 10 μl of phage stock in glycerol was added to 1 mL of the diluted bacterial culture. The 
suspension was incubated for 4.5 h under shaking and subsequently centrifuged for 30 sec at 14 000 rpm., 
the supernatant transferred to a fresh tube and re-centrifuged. In a fresh tube, 1/6 volume of 20% 
PEG/2.5 M NaCl was added to the upper 80% of the supernatant. Phages were allowed to precipitate at 
4°C for 2 hours. The PEG precipitate was spun down at 12,000 g for 15 minutes at 4°C, supernatant 
decanted, re-spun and residual supernatant removed with a pipette. The phage pellet was re-suspended in 
100 μl 0.25 mg/mL FITC (Sigma, St. Louis, MO) in 0.3 M NaHCO3 (pH 8.6). After 1 h of incubation under 
gentle shaking conditions, 20% PEG/2.5 M NaCl (1/5 of the original volume) was added. The resulting 
phage suspensions were kept for 30 min on ice and subsequently centrifuged for 10 min at 14 000 rpm at 
4 °C. The supernatant, containing unbound FITC, was discarded and the pellet was resuspended in TBS. 
The precipitation and re-suspension of the phage particles was repeated twice more. The protein content 
in the final suspension was determined with a NanoDrop 1000 spectrometer (Thermo Scientific, Waltham, 
MA). Equal amounts of protein (phages) were added to hCMEC/D3 cells, grown on coverslips, and 
incubated for 2 h at 37°C. Cells were washed with prewarmed hank’s buffered salt solution (HBSS) and 
fixed. Samples were analysed and representative images were acquired, using a Provis AX70 
epifluorescence microscope (Olympus corporation, Center Valley, PA).  
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Figure 9. CLSM images of cell binding of fluorescein labelled plagues displaying the peptide sequences as 
selected in phage display. G88 and G23 were selected for further research based on their cell adhesion and 
homogeneous patterning. 
 
Transcytosis assay 2 x 105 cells/cm2 were seeded onto Transwell filters with a pore size of 0.4 μm 
(Corning Life Sciences B.V., Amsterdam, The Netherlands), precoated with collagen type I. Differentiation 
media was changed twice a week and the transendothelial electrical resistance (TEER) values were 
measured using a Millicell-ERS (Millipore, Billerica, MA). Experiments were performed in hCMEC/D3 
monolayers, cultured for 14 days with TEER values of ~ 30 Ω/cm2. For further details see reference25.  
Fluorescein-labelled polymersomes (40 μg/mL) diluted in EBM-2 medium, were added to the apical 
compartment and incubated for 16-18 h at 37 °C. The media in the apical and basal compartments were 
collected and the filter membrane with the cells was separated from the support. Subsequently, the filter 
was soaked in water to osmotically rupture the cells, resulting in release of the polymersomes. The 
fluorescence intensity in the three compartments, i.e., apical, basal and filter with cells, was measured 
with a Perkin-Elmer spectrofluorometer LS500 at the corresponding wavelengths 495 nm (excitation) and 
520 nm (emission).  
 
Immunofluorescence detection of cell surface gangliosides in hCMEC/D3 cells, and their 
colocalization with G23-polymersomes hCMEC/D3 cells were seeded onto glass coverslips, precoated 
with 100 μg/mL collagen type I, and maintained in differentiation medium. The medium was refreshed 
when cells reached confluency and the experiments were performed the next day. To detect cell surface 
exposed glycosphingolipids, live cells were incubated with primary antibodies anti-GD1a 5 μg/mL, anti- 
GD1b 5 μg/mL, anti-GT1b 20 μg/mL (Seikagaku Corp., Japan) in 1% BSA (PBS) for 30 min, at 10 °C. Cells 
were fixed with 2.4% paraformaldehyde and incubated with secondary antibodies in the presence of DAPI 
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and mounted, or alternatively, the medium was aspirated and 40 μg/mL of G23-polymersomes were 
added for an additional 30 min at 10 °C prior to fixation. The coverslips were mounted onto microscopic 
slides with Faramount aqueous mounting medium (Dako). Images were acquired with a confocal 
microscope (Leica TCS SP2 (AOBS), 63x oil objective, NA = 1.4), and processed using ImageJ software (NIH, 
http://rsb.info.nih.gov/ij). After background correction, the colocalization analysis was performed 
according to the auto-threshold method. The extent of colocalization is presented as colocalizing pixels 
between particles and the lipid/protein of interest, divided by the total number of particles’ pixels, i.e., 
percentage of colocalizing pixels.  
 
Dot blot analysis of G23-polymersome binding to isolated gangliosides The binding of G23-
polymersomes to isolated gangliosides was determined in a dot blot assay as described in reference28 with 
minor modifications. Briefly, 10 μl of a 0.5 μM solution of GM1, and 5 μl of a 1 μM solution of GM2, GM3, 
GD3, GD1a, GD1b and GT1b gangliosides (Alexis Corporation, Läufelfingen, Switzerland) were spotted 
onto an immobulon-FL (PVDF) membrane (Millipore Corporation, Billerica, MA). The membrane was 
incubated with radio-labelled G23-polymersomes (5 μg/mL) in PBS containing 1% BSA for 3h. Upon 
extensive washing the membrane was air dried, covered with a multipurpose Cyclone phosphor imaging 
screen (Perkin-Elmer, Downers Grove, IL, USA), and placed in an X-ray film cassette overnight at room 
temperature. The screen was subsequently analyzed using a Perkin-Elmer Cyclone Storage Phosphor 
System (Downers Grove, IL, USA). The positions of gangliosides were visualized on the screen by spraying 
with Ehrlich’s reagent (20 mL of 37% hydrochloric acid with 0.6 g of 4-(dimethylamino)-benzaldehyde 
(Sigma-Aldrich, Steinheim, Germany) solubilised in 80 mL ethanol), and heating at 120 °C for 10 min. 
 
4.5.5 In vivo evaluation 
Intracarotid artery injection of G23-polymersomes in mice Male 20–25 g BALB/c mice were obtained 
from Harlan (Horst, The Netherlands). The mice were kept in standard macrolon cages (26.2 x 42 x 15 cm) 
under controlled conditions (23 ± 1°C, 12-h light, 12-h dark cycle, pellets (Arie Blok, Woerden, The 
Netherlands) and water ad libidum). The experiments were approved by the Animal Ethics Committee of 
the University of Groningen, The Netherlands and performed by licensed investigators in accordance with 
the Law on Animal Experiments of The Netherlands. Mice were anaesthetized by isoflurane/oxygen. The 
neck was shaved and the mice were placed under a dissecting microscope. The neck was prepared for 
surgery with chlorhexidine and the skin was cut by a mediolateral incision. The muscles were separated to 
expose the right common carotid artery, which was then separated from the vagal nerve. The proximal 
end of the common carotid artery was clamped with a micro clamp. The tip of a 29 G needle connected to a 
0.3 mL syringe was inserted into the carotid artery. The polymersomes were injected over 15 - 20 s (< 
0.01 mL/s) in order not to open the blood brain barrier29. Following polymersomes administration the 
needle was retracted, the puncture hole was closed by suture and covered with collagen to prevent any 
leakage. The micro clamp was removed to establish the blood flow. The skin was closed with ~5 sutures. 
At the end of the procedure, 0.1 mg/kg buprenorfine (Temgesic) was injected subcutaneously for 
postoperative pain relief. The animal was kept warm during recovery. The surgical procedure took 15 
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min/animal. Rhodamine-labelled G23- polymersomes and non-targeted polymersomes were injected in 3 
animals each. 24 h after polymersomes administration the mice were sacrificed by carbon dioxide 
asphyxiation, the brains were isolated, snap frozen in liquid nitrogen and stored at -80 oC until further 
processing. 8 and 10 μm brain sections were made on a Leica CM 3050 cryostat microtome and mounted 
onto polylysine microscopic slides (ThermoScientific, Waltham, MA). The sections were air dried for 1 h at 
room temperature and fixed for 15 min at -20 °C in acetone. After blocking with 10% goat serum in PBS 
for 1 h at room temperature, the sections were incubated with an antibody against PECAM- 1 (CD31) 
(MEC 13.3, BD Biosciences) overnight at 4 °C. Alexa Fluor 633 conjugated secondary antibody (Invitrogen 
Carlsbad, CA) was applied for 2 h at room temperature, together with DAPI. Samples were analyzed with a 
confocal microscope (BMBME Leica SP2) and a TissueFaxs fluorescence microscope (TissueGnostics, 
Vienna, Austria). 
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Brain and Organ Distribution of G23, Scrambled 
G23 and RI7217 Tagged Polymersomes 
 
 
 
 
 
 
 
 
In the previous chapter we developed a small peptide (G23) tagged polymersome that is able to efficiently 
cross the blood brain barrier in an in vitro model by recognition of ganglioside GM1 and GT1b. Furthermore 
we showed that these polymersomes are able to cross the blood brain barrier into brain parenchyma in vivo. 
In vivo and in vitro transport was either analyzed by means of fluorescence spectroscopy or confocal laser 
scanning microscopy of fluorescently labelled polymersomes. A more quantitative method to analyze 
biodistributions proceeds by means of radiolabelling as employed in Chapter 3. In this chapter, we compare 
the biodistribution of G23, scrambled G23 and RI7217 tagged polymersomes in the most relevant organs and 
different regions of the brain via the method of radioisotope labelling. We demonstrate that G23 
polymersomes indeed show enhanced accumulation in the brain, albeit that also in the lungs a 15 fold 
increase in accumulation was observed. These findings underline that G23 tagged polymersomes might be 
promising carriers for brain targeting, but also suggest that application in lung tissue targeting is feasible. 
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5.1 Introduction 
One of the major challenges in medicinal chemistry is the development of drugs or drug-
formulations that are able to cross the blood-brain barrier (BBB)1. The effective 
treatment of many brain-related diseases is hampered by the presence of this polarized 
layer of endothelial cells that physically separates blood from brain tissue2. Furthermore 
most conventional drug candidates lack stability and/or bioavailability3, or once having 
reached the brain side are cleared by multidrug receptors on the endothelial cell 
surface1. The field of nanomedicine may offer solutions to overcome these obstacles by 
making devices available such as nanocarriers providing options for tissue-targeted 
delivery of therapeutics and local release of drugs. 
 Various targeting moieties and targeting sites have been employed to induce 
transport of liposomes over the BBB4. However, in a recent comparative study van Rooy 
et al.5 showed that most peptides and proteins are rather ineffective in inducing this 
transport. The most widely applied targeting moiety in literature is transferrin antibody 
RI7217, which in combination with transferrin and insulin have also been employed to 
target polymersomes over the BBB6-7.  
 In Chapter 4 we described the development of a dodecamer peptide tagged 
polymersome that is able to cross the blood brain barrier both in vitro and in vivo. This 
report was the first to describe transport of polymersomes over the BBB by a small, 
1645 g/mol, peptide which recognizes ganglioside GM1 and GT1b as targeting site. The 
polymersomes were visualized either by fluorescence spectroscopy or by confocal laser 
scanning microscopy. Although this analysis method provides a good impression of the 
efficiency with which polymersomes can cross the BBB into the brain parenchyma, it 
does not allow for a quantitative determination. A method that does so for 
biodistribution is radioisotope labelling, as we showed in Chapter 3 for differently sized 
polymersomes.  
 
 In this chapter we analyze in vivo biodistributions of polymersomes conjugated with 
G23 peptide, scrambled G23 peptide (Scr) and RI7217 by means of 111In radioisotope 
labelling. After 24 hours, G23 tagged polymersomes showed increased brain 
accumulation by a factor of 5.8 compared to polymersomes bearing the scrambled G23 
sequence. Polymersomes tagged with the 90 kg/mol RI7217 antibody showed a 10.3 
fold increase in brain accumulation. The most striking result was found in the 
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biodistribution over the organs. G23 polymersomes gave a 15 fold increase in lung 
accumulation compared to polymersomes tagged with the scrambled G23 sequence. 
These data underline that G23-functionalized polymersomes are promising for targeted 
delivery over the BBB, although application in lung tissue targeting might be another 
viable option. 
 
 
Figure 1. Polymersomes were self assembled from 89 w% (1), 1 w% (2) and 10 w% (3). After self 
assembly the polymersomes were labelled with radioactive 111In and conjugated with peptide G23, Scr or 
transferrin antibody RI7217. Next, biodistributions were determined in male Balb/c mice. 
5.2 Results and Discussion 
The block copolymers used in this study are depicted in Figure 1 and are equal to the 
polymers described in Chapters 2 and 3. This Figure shows that polymersomes were 
formed from a mixture of polymers 1, 2 and 3 in a ratio of 89:1:10 followed by 111In 
labelling and finally peptide conjugation. It should be noted that switching the order of 
events led to a poor 111In labelling efficiency.  
 Peptides G23 and Scr were synthesized via Fmoc chemistry8 with a C-terminal 
cysteine for conjugation, only the monoclonal antibody RI7217 did not contain a free 
accessible cysteine. Therefore on average 3.1 thiols - as determined via Ellman’s reagent 
- were introduced by means of a standard SATA modification9. The formation of 
polymersomes was accomplished via the solvent switch method, starting from a solution 
of 10 mg polymer in 0.2 mL THF. After the addition of 0.6 mL 2-(N-
morpholino)ethanesulfonic acid MES buffer (0.1 M, pH 5.5, metal free) polymersomes 
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were formed as indicated by the opaque colour. The sample was extruded subsequently 
over 200 and 100 nm membranes to obtain polymersomes of 166 nm with a 
polydispersity index of 0.12 as determined by dynamic light scattering (DLS) before 
radiolabelling and conjugation of the targeting moieties. The polymersomes were 
purified over a Sephadex G200 column, labelled with 25 MBq 111In and subsequently the 
MES buffer was switched for phosphate buffered saline (PBS, 20 mM, pH 7.4) over a 
PD10 desalting column. After switching buffers, the peptides or the antibody were 
coupled to the peripheral maleimide groups via the C-terminal cysteine or SATA 
moieties, respectively. Finally the samples were dialyzed over night to remove excess of 
peptide. The 111In labelling efficiency was tested by means of IC-TLC after the initial 
indium labelling and subsequent dialysis. The radioisotope labelling efficiency was 
virtually quantitative and appeared stable towards dialysis. The polymersomes were 
diluted with PBS to 1 mg of polymer per mL (0.2 µmol polymer per mL, 2.5 MBq per mL) 
 After the successful formation of labelled polymersomes, the biodistribution in male 
Balb/c mice was evaluated by injecting 200 µL of polymersomes in the tail vain. The 
biodistribution over the main organs was determined as well as the distribution of 
polymersomes over different parts of the central nervous system (CNS). In Chapter 3 
was shown that polymersomes of 120 nm and larger are readily cleared from the blood 
stream. The current research was performed using polymersomes with an average 
diameter of 166 nm, which are expected to circulate in the blood stream for less than 4 
hours, excluding significant contributions of blood associated polymersomes in different 
organs to the counts (Table 1).  
 The observed distribution of polymersomes over the central nervous system is 
depicted in Figure 2. It shows that the G23 peptide is able to increase the transport of 
polymersomes into the total brain with a factor of 6.5 (4 hours) and 5.8 (24 hours) as 
compared to the scrambled sequence of G23. In the cerebellum, cortex and brain rest a 
similar increase as compared to scrambled G23 was observed, which in all cases was 
statistically relevant. This underlines the specificity of the native G23 sequence to 
enhance blood brain barrier transport. We also included RI7217 tagged polymersomes 
in this study, since RI7217 is the most widely employed targeting moiety in literature. 
Compared to the scrambled G23 sequence, polymersomes tagged with this antibody 
showed a 10 fold increase in total brain accumulation after 24 hours. Furthermore, 
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0.096 % ID/g was found to be associated with the total brain, a number that is in 
agreement with previous reports on polymersomes in male Balb/c mice6.  
Upon comparing G23 and RI7217 targeted polymersomes a clear trend becomes 
apparent from Figure 2. In all CNS domains, the RI7217 tagged polymersomes seem to 
perform better than the G23 tagged polymersomes. However, the difference in brain 
distribution is not statistically significant after 4 hours, while after 24 hours the 
accumulation in the cortex and brain rest is significantly lower for G23 polymersomes, 
but not for the total brain and cerebellum.  
 
Figure 2. Biodistribution at 4 and 24 hours post injection (p.i.) of RI7217, G23 and Scr tagged 
polymersomes over different parts of the central nervous system in male Balb/c mice (n = 4, 9 weeks of 
age, 20-23 gram). †) Statistically significant difference as compared to Scr as calculated for G23, and *) 
statistically significant difference compared to RI7217 as calculated for G23. 
 
Table 1. Biodistribution of polymersomes 
tagged with G23, Scr and RI7217 after blood 
volume correction as described in the 
experimental section. 
 
Comparison of in vivo transport over the blood brain barrier with other targeted 
nanocarriers reported in literature is not straightforward, since the animal model, 
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method of administration and type/size of nanocarrier will influence the experimental 
outcome. However, in a recent literature study by van Rooy et al.4, it was summarized 
that most targeted carriers show a 2 to 3 fold increase in BBB transport. Among the 
small peptides, Tat-peptide coupled to poly(lactic-co-glycolic acid) nanoparticles 
showed a most prominent (6.5 fold) increase in brain uptake in mice10, followed by a 4.9 
fold for the nine amino acid bradykinin agonist peptide RMP-7 targeted liposomes in 
rat11. This suggests that G23 targeted polymersomes are among the most efficient 
peptide targeted nanocarriers reported to date.  
 
 We also analyzed the biodistribution of targeted polymersomes over all main organs 
and corrected them for blood values12 (Table 1). As anticipated – since we applied 
polymersomes of 166 nm – after 4 and 24 hours almost all polymersomes were cleared 
from the blood stream and accumulated in the liver and spleen. However, as depicted in 
Figure 3, the G23 tagged polymersomes revealed an interesting deviation from the 
expected distribution in the lung tissue. Compared to the scrambled sequence of G23, 
polymersomes tagged with native G23 showed a statistically significant 15 fold increase 
in lung association. This data again underlines the specificity of the sequence of G23 
peptide in targeting, since the scrambled sequence did not show deviation from the 
expected biodistibution (Chapter 3). Interestingly, this finding opens up new 
opportunities for the application of G23 targeted polymersomes in lung tissue targeting. 
 
 
Figure 3. Biodistribution at 4 and 24 hours post 
injection (p.i.) of RI7217, G23 and Scr tagged 
polymersomes over lung tissue in male Balb/c 
mice (n = 4, 9 weeks of age, 20-23 gram). †) 
Statistically significant difference compared to 
Scr as calculated for G23, and *) statistically 
significant difference compared to RI7217 as 
calculated for G23. 
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The biodistribution of polymersomes tagged with RI7217 did not reveal any significant 
deviations. This is in agreement with considerations in literature behind the choice for 
RI7217 in BBB targeting research. Although other transferrin antibodies have been 
reported to cross the BBB more efficiently, RI7217 has the highest specificity,5 i.e. does 
not target other tissues. 
 
5.3 Conclusion and Perspective 
G23 tagged and radio-labelled polymersomes were designed for GM1 (and GT1b) 
mediated brain targeting and indeed show a significant increase in brain accumulation. 
Compared to RI7217 tagged polymersomes, G23 labelled polymersomes accumulate to a 
slightly lower extent in the brain than RI7217 tagged polymersomes. Although no direct 
comparison could be made, G23 tagged polymersomes can cross the BBB rather 
efficiently compared to other small peptide targeted nanocarriers reported in literature. 
In addition, the lung association of G23 tagged polymersomes appeared substantial with 
a 15 fold increase compared to the scrambled sequence of G23. Hence, polymersomes 
tagged with G23 peptide may also have potential for targeted drug delivery to the lungs. 
 
 With respect to future experiments, it may be worthwhile to reconsider the size of 
the polymersomes applied. If the nanocarrier is circulating longer in the blood, the 
chances of transport either over the blood brain barrier or to the lungs might be higher. 
Furthermore it would be interesting to look beyond the design of G23 targeted 
polymersomes into the method of administration. Perhaps, it is possible to favour BBB 
transport over lung accumulation by injecting G23 targeted polymersomes into the 
intracarotid artery as was performed in Chapter 4. 
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5.5 Experimental Procedures 
Radiolabelled, maleimide displaying polymersomes Polymers 1 (9 mg, 1.9 µmol), 2 (0.1 mg, 0.02 
µmol) and 3 (1 mg, 0.2 µmol) were dissolved in THF (200 mL). Polymersomes were formed by slow 
addition of 0.6 mL 0.1 M 2-(N-morpholino)ethanesulfonic acid (MES) buffer of pH 5.5. The samples 
were passed three times through a 200 nm syringe filter to yield polymersomes of approximately 250 
nm. The solution was extruded six times over a 100 nm filter (extrusion kit) to obtain po lymersomes 
of around 160 nm. The resulting opaque suspension was purified over a Sephadex G200 column (1.5 
x 8 cm), eluting with MES buffer. The opaque fractions were combined and the mean particle size was 
determined by DLS. 
 25 MBq of 111InCl was added to the polymersomes and allowed to chelate for 20 minutes, after 
which the coupling efficiency was analyzed by Instant Thin-Layer Chromatography Silica Gel 
impregnated glass fibre (ITLC-SG) strips, developed in 0.1 M NH4Ac (pH 5.5)/0.1 M EDTA (1:1, v/v). 
The sample was purified over a PD10 desalting column, eluted with PBS buffer pH 7.4, and diluted 
with PBS to a total volume of 10 mL, i.e. a polymersome suspension containing 1 mg of polymer per 
mL (2.5 MBq per mL). 
 
Conjugation of peptides to polymersomes A solution of tris(2-carboxyethyl)phosphine (TCEP, 0.5 
mg) was dissolved in PBS (300 µL) of pH 7.4 and added to the peptide (1 mg, excess  to maleimides). 
The solution was allowed to stand for 15 minutes, after which it was added to 1.5 mL of the 
polymersomes. The coupling was allowed to proceed for three hours, after which the solution was 
transferred into a dialysis bag (Spectrapore MWCO 12-14 kDa) and dialysed against PBS buffer for 12 
hours. 
 
Conjugation of RI7217 to polymersomes RI7217 antibody was coupled to maleimide 
polymersomes by a sulfhydryl-maleimide coupling technique as described previously9 with minor 
modifications. Free sulfhydryl groups were introduced into the antibody using N-succinimidyl-S-
acetylthioacetate, (SATA. Free SATA was separated from the antibody by centrifugation over a filter 
with a 30 kDa cut-off (MWCO). SATA groups were deacetylated for 90 min at room temperature by 
addition of 100 μl of deacetylation solution (0.1M PBS, 0.5M hydroxylamine and 0.02 mM TCEP, pH 
7.4) per millilitre of antibody to generate sulfhydryl groups. This resulted in an SH/protein 
(mol/mol) ratio of 3.1 as determined by Ellman’s reagent assay. After deacetylation, the RI7217 
antibody was allowed to react with 111In-labelled maleimide polymersomes overnight at 4°C. 
 
Radio TLC Quality control of the coupling of 111In to the polymersomes was performed by spotting 5 
μL of the polymersome preparation on an ITLC-SG strip. TLC strips were developed with 0.1 M 
ammonium acetate (pH 5.5)/0.1 M EDTA (1:1, v/v) as the eluent. After development, the strips were 
air-dried and read in a VCS-103 radiochromatograph scanner (AmRay Medical, Drogheda, Co.Louth, 
Ireland). Regions of interest were drawn for 111In-labelled polymersomes (Rf value: 0) and unbound 
111In (Rf value: 0.8-0.9), and the relative amounts of these compounds for each sample were 
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measured. Efficiency of 111In-labelling of polymersomes was >95% and 111In-labelled polymerisomes 
were stable at room temperature for more than 10 days. Nevertheless, 111In-labelled polymersomes 
were freshly prepared for each set of in vivo experiments. 
 
Tissue biodistribution of functionalized polymersomes Male Balb/c mice were obtained from 
Harlan (Horst, The Netherland). The mice were kept in standard macrolon cages under controlled 
conditions (23 ± 1°C, 12-h light, 12-h dark cycle, chow (Arie Blok, Woerden, The Netherlands) and 
water ad libidum). All experiments were approved by the Animal Ethics Committee of the University 
of Groningen, The Netherlands and performed by licensed investigators in accordance with the Law 
on Animal Experiments of The Netherlands. Mice (n = 4) were injected with 200 μl of radio -labelled 
polymersomes (ca. 180 ug polymer per mouse = 38 nmol polymer / mouse; ca. 0.5 MBq) in PBS by 
penile vein injection using a 3 / 10 cc Terumo Insulin Syringe U-100 attached to a 29 G needle. At 4 
and 24 h after injection, the mice were sacrificed by cervical dislocation. At each time point the 
kidney, brain, liver, lung, muscle, spleen, and femur (containing bone marrow) were collected, and a 
blood sample was drawn. The brain was divided into the cerebrum and cerebellum. The cerebrum 
was subdivided into cerebral cortex and brain rest. The samples were weighed and the radioactivity 
was measured using a Compugamma CS 1282 gamma counter (LKB-Wallac, Turku, Finland). The 
radioactivity levels in the injected polymersome solutions served as internal standards. The results 
were expressed as percentage injected dose per gram of tissue (%ID/g). Where indicated, tissue 
levels were corrected for capillary blood content12 using the formula: corrected tissue concentration 
= [organ concentration – (capillary blood content x blood concentration)] / ( 1 – capillary blood 
content), where the tissue capillary blood content is expressed as a fraction of the organ volume, 
which approximates for bone, brain, kidney, liver, lung, muscle and spleen to 0.11, 0.03, 0.24, 0.31, 
0.50, 0.04 and 0.17, respectively)13. 
 
Statistical analysis Results are presented as mean + standard deviation. The statistical analysis was 
conducted using SPSS 16.0 for Windows. Due to inhomogeneity of variance the biodistribution data 
were analyzed by the nonparametric Kruskal-Wallis test, followed by the Mann-Whitney U test to 
compare the groups for which the Kruskall-Wallis test was significant. P values < 0.05 were 
considered statistically significant. 
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Shedding the Hydrophilic Mantle of Polymersomes 
 
 
 
 
 
 
 
 
 
 
Block copolymers of polybutadiene-b-poly(ethylene glycol) were prepared in which both segments were 
coupled via an acid sensitive hydrazone moiety. Polymersomes that were subsequently formed showed 
a strong pH-dependent colloidal stability as a result of the pH sensitive removal of the PEG block. By 
mixing this stimulus responsive block polymer with an inert analogue it was possible to systematically 
remove percentages of PEG from the polymersome mantle. The minimum amount of surface PEGylation 
needed to retain stable polymersomes was found to be as low as five percent.  
 
 
 
 
 
 
 
 
 
 
 
 
 
René P. Brinkhuis, Taco R. Visser, Floris P.J.T. Rutjes and Jan C. M. van Hest, Polymer Chemistry, 2011, 2, 
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6.1 Introduction 
Polymeric vesicles, or polymersomes, can be regarded as the polymeric analogues of 
liposomes. They are formed by the self-assembly of amphiphilic block copolymers in 
aqueous media1-2. Compared to liposomes, polymersomes are characterized by an 
increased membrane stability and the ability to enclose larger quantities of 
hydrophobic compounds2. This makes them highly interesting for usage as 
nanocarriers in biomedical applications such as drug delivery and in vivo imaging3. 
Nowadays researchers have gained a high degree of control over polymersome 
composition, size and peripheral functionalities which are all important elements in 
the design of drug delivery vehicles4. An important challenge however remains the 
triggered release of compounds from the interior of the polymersomes, which 
requires a controlled destabilization of the membrane.  
 Destabilization of the particles is often realized by degradation or a triggered 
change in solubility of one of the blocks5, but it can in principle also be realized by 
removal of the stabilizing hydrophilic segment of the amphiphilic block copolymer. 
This hydrophilic block is in most cases the biocompatible polymer poly(ethylene 
glycol) (PEG) which introduces stealth-like properties to the nanocarriers when they 
circulate through the body. Basically it is the shielding of the hydrophobic domain by 
highly stretched peripheral PEG chains6 which gives rise to the stability of 
polymersomes in water. Until now it is however unclear how much PEG is required 
to maintain a stable colloidal polymeric capsule. To investigate this, a systematic 
removal of different percentages of PEG from the polymersome surface should be 
accomplished. This requires the introduction of a triggerable cleavage site between 
the hydrophobic and hydrophilic parts of the block copolymer that constitutes the 
polymersome membrane. 
 Different block copolymer cleavage methods have already been reported, based on 
UV light7-8, reduction9-14 or oxidative and enzymatic pathways15. Site selective acidic 
cleavable block copolymers reported today make use of a triphenyl ether linker16, a 
cyclic ortho ester17 or cis aconitic acid18. All other acid labile systems are based on 
random hydrolysis19-22. An interesting pH cleavable moiety for block copolymer 
cleavage is the hydrazone linkage. This functionality is well known for its strong acid 
dependent stability in the physiological pH range23-25. Hydrazones have been used in 
the field of liposomal delivery systems as cleavable linkers between PEG chains and 
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surface peptides in order to hide the peptides up to the moment of cellular uptake26. 
In another example Kataoka et al. showed the efficient release of drugs, conjugated 
via hydrazone bonds, from polymeric micelles upon lowering the pH to endosomal 
levels27. Amphiphilic block copolymers of which the hydrophobic and hydrophilic 
parts are connected by the pH sensitive hydrazone linkage have very recently been 
reported to form pH responsive aggregates in aqueous solution28.  
 
 
Figure 1. Formation of an inert and an acid labile amphiphilic block copolymer via hydrazone formation 
(1, 2) and click chemistry (3, 4), respectively. These polymers readily form polymersomes. Lowering the 
pH will hydrolyse the hydrazones, shedding the poly(ethylene glycol) shell. This will either result in fully 
disrupting the vesicle or reducing the degree of polymersome PEGylation. 
In this chapter the controlled colloidal destabilization of polymersomes formed by 
the self assembly of amphiphilic block copolymers of polybutadiene-b-poly(ethylene 
glycol) (PBd-b-PEG) is investigated. By using different combinations of an inert 
amphiphilic block copolymer and PBd-b-PEG of which both parts are connected by a 
hydrazone linker, the minimum amount of PEG needed for stabilization is 
determined. We show that it is possible to take away 95 percent of peripheral PEG 
chains by lowering the pH, without disrupting the colloidal stability of 
polymersomes. Furthermore, we can tune the speed of polymersome degradation by 
adjusting the PEG chain length. This research therefore adds a new element to the 
methods available to control polymersome stability and gives new insights in the 
stabilizing power of PEG chains on the polymersome surface. An overview of the 
procedure followed is depicted schematically in Figure 1.  
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6.2 Results and Discussion 
Hydrazone coupled block copolymers 1 and 2 were synthesized as depicted in 
Scheme 1. Polybutadiene was synthesized by means of anionic polymerisation and 
terminated with a protected aldehyde, diethyl chloroacetal29. PEG with a molecular 
weight of 1 and 2 kg/mol was modified into a hydrazide to obtain 8 and coupled to 
aldehyde end-capped polybutadiene 6 by hydrazone formation. Stable block 
copolymers 3 and 4 were prepared as described in Chapter 2. In figure 2 the size 
exclusion chromatograpy (SEC) results of the coupling via hydrazone formation are 
depicted as analyzed for polymer 1. This reaction proceeded readily in 
dichloromethane without the addition of a catalyst. The desired block copolymers 
were in all cases obtained with a polydispersity index well below 1.2 as determined 
by SEC. 
 
 
Scheme 1. Synthetic route to hydrazone coupled block copolymers 1 and 2. i) anionic polymerisation 
of 1,3 butadiene and endcapping ii) deprotection of aldehyde. iii) PEG methyl ester formation and iv) 
PEG hydrazine formation v) coupling of polybutadiene and poly(ethylene glycol) by hydrazone 
formation.  
 To determine the pH sensitivity it was investigated whether the obtained 
hydrazone-functional polymers could be fully cleaved at low pH, or whether an 
equilibrium between polymer 1/2 and their cleaved products was obtained. For this 
purpose polymers 1 and 2 were assembled into polymersomes, after which the pH 
was lowered to 4.4. Subsequent TLC analysis showed no traces of the block 
copolymer, only the free PEG and polybutadiene blocks were observed. These results 
were confirmed by SEC analysis. As can be observed from Figure 2 no significant 
amount of block copolymer was present after one hour incubation at pH 4.4.  
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Figure 2. SEC traces of a) Coupling of polybutadiene and PEG via hydrazone formation. b) After 
incubation of 2 at pH 4.4 the original polybutadiene chain is obtained back. 
 The pH dependent stability of polymersomes, assembled fully from cleavable 
polymers 1 or 2, was evaluated next. A standard solution of extruded polymersomes 
with an average diameter of around 200 nm was prepared. The pH of this solution was 
7.5, so no significant hydrolysis could take place in the time frame of sample preparation 
(see Figure 3a). After injection of a polymersome sample in buffers ranging in pH, the 
size distribution was monitored over time by dynamic light scattering (DLS). This 
method was useful to study destabilization of the polymersomes, since we envisioned 
that whenever enough PEG was cleaved off, the bare polybutadiene would start to 
aggregate and form larger, more polydisperse aggregates which eventually would phase 
separate with water. The DLS results as depicted in Figure 3 show two trends. First of all 
Figure 3a shows how below pH 5.4 polymersomes assembled from 1 lost their stability 
within one hour and started to aggregate, whereas at physiological pH (7.4) the vesicles 
were stable in solution for more than three days. Secondly, the DLS curves plotted in 
Figure 3b show a marked difference in destabilization rate between PBd-b-PEG 1 and 2 
while incubating in the same buffer, pH 6.4. Whereas polymersomes composed of 1, 
with the shorter PEG block of 1 kg/mol, started to aggregate after three hours, the time 
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needed to induce aggregation of polymersomes composed of 2, with a PEG length of 2 
kg/mol was more than doubled. These results suggest that the time dependent stability 
of these polymeric vesicles can be tuned by adjusting the block copolymer composition. 
Furthermore, these polymersomes are stable at physiological pH but readily aggregate 
under slightly acidic conditions. What is not clear from these results is whether the gain 
in stability is a result of slower hydrolysis or better shielding, if longer peripheral PEG 
chains are applied.  
 
 
Figure 3. a) Relative size distribution of polymersomes composed of 1 as a function of time in hours upon 
incubation in buffers of different pH. b) Relative size distribution of polymersomes composed of 1 and 2 at 
pH6.4 as a function of time in hours. 
 Via this experiment it is also not possible to determine the composition of the 
vesicles at the point where aggregation starts to occur. It is actually the bending 
point in the graph which is interesting because this reflects the composition in which 
there is just enough PEGylation left to stabilize the polybutadiene sphere. To 
estimate the polymersome composition at the bending points we decided to prepare 
mixed polymersomes composed of an inert amphiphilic block copolymer (3 or 4) and 
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a pH sensitive one (1 and 2). Furthermore, in the previous section we showed that at 
pH 4.4 block copolymers 1 and 2 are fully cleaved and there is no sign of an 
equilibrium. 
 We therefore exposed the mixed polymersomes to a medium with a pH of 4.4. At 
this point all cleavable PEG chains were removed, leaving a polybutadiene bilayer 
displaying only the non cleavable PEG chains as drawn in Figure 1. After three days 
all samples were re-measured with DLS to check whether the particle size remained 
the same or aggregation had occurred. These measurements were performed for 
both the 1 kg/mol PEG and 2 kg/mol PEG analogues for which the results are 
depicted in Table 2. All samples were stable even after cleaving off 90 percent of the 
PEG chains. The first sample to become unstable consisted of polymersomes that had 
a ratio of 95 percent 1 to 5 percent of 3. This actually means that a little more than 5 
percent PEGylation with PEG of 1 kg/mol is enough to stabilize the polybutadiene 
sphere. Upon doubling the chain length to PEG of 2 kg/mol we were able to remove 
more than 95 percent of the periphery without disrupting the system. This means 
that when longer PEG chains are employed even less than 5 percent PEGylation will 
efficiently stabilize these polymersomes. 
 
Table 2. Average size of mixed vesicles 1 with 3 and 2 with 4. In all cases the DLS revealed a 
polydispersity well below 0.1 and a derived count rate of ±6000 kcps, except for the unstable ones 
printed in bold, for which the polydispersity becomes large (>0.6) and the derived count -rate small 
(<500 kcps). 
 Time(h) 0% 85% 90% 95% 100% 
PEGylation 
1kg/mol 
0 227  230  239 226 208 
 72 234  220  247 2000+ 2000+ 
PEGylation 
2kg/mol 
0 208  212  251 223 201 
 72 208  215  244 242 2000+ 
 
Although this low amount of PEGylation needed to stabilize polymersomes surprised 
us at first, it can easily be rationalized by considering generally known systems. In 
liposomal formulation it is common to introduce five to ten percent PEGylation to 
induce longer blood circulation times by blocking all interactions with the 
environment. Furthermore it has been shown for cationic lipid vesicles that ten  
percent of PEGylation is enough to block all cell interactions, basically shielding a 
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positively charged bilayer from its surrounding30. Finally a theoretical study by 
Smart et al showed how only a very limited amount PEG chains can cover a surface 
by either adopting a mushroom or a fully stretched shape depending on the PEG 
density6. 
 
6.3 Conclusion 
We have constructed polymersomes composed of a mixture of stable and pH 
sensitive, cleavable PBd-b-PEG amphiphilic block copolymers. With these mixed 
polymersomes we were able to determine the minimum amount of poly(ethylene 
glycol) needed for stabilization. At physiological pH these polymersomes retained 
their colloidal stability for at least three days. Under slightly acidic conditions 
polymersome stability was only lost when the degree of PEGylation was lowered to 
5%. This percentage could be even further decreased by doubling the poly(ethylene 
glycol) molecular weight.  
 
6.4 Acknowledgement  
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6.5 Experimental Procedures 
General note All reactions are described for the lower molecular weight analogue, polyethylene glycol 
with a molecular weight of 1 kg/mol. The procedures for the poly(ethylene glycol) with a molecular 
weight of 2 kg/mol were identical and performed with equimolar amounts. The synthesis of polymers 3 
and 4 is described in Chapter 2.  
 
Materials Sec-butyllithium (ALDRICH 1.4M in hexane), 1,3 butadiene (SIGMA ALDRICH, 99+%), 
polyethylene glycol 1000 monomethyl ether (FLUKA), polyethylene glycol 2000 monomethyl ether 
(FLUKA), sodium hydride (ALDRICH, 60% dispersion in mineral oil), hydrazine (ALDRICH, 1M in THF) 
were used as received. Tetrahydrofuran (THF) (ACROS ORGANICS, 99+% extra pure, stabilized with BHT) 
was distilled under argon from sodium/benzophenone and triethyl amine (TEA) (BAKER) was distilled 
from calcium hydride under an argon atmosphere prior to use. Polymersome extrusions were performed 
using 200 nm filters (Acrodisc 13 mm Syringe Filter, 0.2 µm Nylon membrane) and dialysis was 
performed using Spectra/Por molecular porous membrane tubing (Spectrum Laboratories, Inc, 12-14.000 
MWCO) 
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Instrumentation MilliQ water was obtained from a Labconco water pro PS system. Thin layer 
chromatography (TLC) was performed on Merck precoated silica gel 60 F-254 plates (layer thickness 0.25 
mm). Compounds were visualized by UV, ninhydrin or permanganate reagent. Column chromatography 
(CC) was carried out using silica gel, Acros (0.035-0.070 mm, pore diameter ca. 6 nm). Infrared (IR) 
spectra were obtained using a Thermo Matson IR 300 FTIR spectrometer. Data are presented as the 
frequency of absorption (cm-1). Proton nuclear magnetic resonance (1H NMR) spectra were recorded on a 
Varian Unity Inova 400 FTNMR spectrometer. Chemical shifts are expressed in parts per million (δ scale) 
relative to the internal standard tetramethylsilane (δ=0.00 ppm). Molecular weight distributions were 
measured using size exclusion chromatography (SEC) on a Shimadzu (CTO-20A) system equipped with a 
guard column and a PL gel 5 μm mixed D column (Polymer Laboratories) with differential refractive index 
and UV (λ=254 nm and λ=345nm) detection, using tetrahydrofuran (SIGMA ALDRICH chromasolv 99.9%) 
as an eluent at 1 mL/min and T = 30 °C. Particle size distributions were measured on a Malvern 
instruments Zetasizer Nano-S . 
 
Polybutadiene-hydrazone-poly(ethylene glycol) (1) Polymers 8 (80 mg) and 6 (800 mg , 2 equiv.) 
were dissolved in dry dichloromethane (2 mL). The mixture was allowed to react for 24 hours while 
gently stirring after which the mixture was poured on a short silica column, which was eluted with 
dichloromethane. After all non reacted 6 was flushed off the product was eluted with 8 percent methanol 
in dichloromethane. After removal of all solvents 300 mg of the product was obtained in 60 percent yield. 
1HNMR (CDCl3): δ 5.45 (m, 67H, CHCH2), 4.94 (m, 134H, CHCH2), 3.65 (m, 90H, CH2CH2O), 3.38 (s, 3H, 
CH3O), 2.11 (m, 67H, CH2CH), 1.16 (m, 134H, CH2CH). SEC (THF): Mw/Mn = 1.14, see Figure 4. Mn: 4.7 
kg/mol. 
 
Polybutadiene-hydrazone-poly(ethylene glycol) (2) 1HNMR (CDCl3): δ 5.45 (m, 67H, CHCH2), 4.94 (m, 
134H, CHCH2), 3.65 (m, 180H, CH2CH2O), 3.38 (s, 3H, CH3O), 2.11 (m, 67H, CH2CH), 1.16 (m, 134H, CH2CH). 
SEC (THF): Mw/Mn = 1.17, Mn: 5.7 kg/mol. 
 
Aldehyde endcapped Polybutadiene (6) All glassware was extensively cleaned, flushed with 1.6 M 
butyllithium, rinsed again and flame dried. Then 1,3 butadiene (10.6 gram, 0.19 mol) was condensed into 
a Schlenk tube and freshly distilled THF (10 mL) was added. The solution was stirred and cooled to -78 °C 
after which sec-butyllithium (2 mL, 1.4M in hexane, 2.8 mmol) was added at once. The deep orange 
reaction mixture was allowed to warm to -35 °C and stirred until the colour changed to pale yellow. 
Another aliquot of THF (10 mL) was added and the temperature was fixed at -35 °C. The reaction was 
terminated by the addition of 3-chloroacetaldehyde diethyl acetal (2 equiv.) via a syringe and the reaction 
was allowed to warm to room temperature. After the yellow colour had disappeared MilliQ (10 mL) and 
TFA (5 mL) were added. The mixture was heated to reflux overnight, after which all THF was removed. 
Then NaOH solution (65 mL, 1M) was added and the product was extracted with DCM (3x 50 mL). DCM 
was removed and the product was purified over a silica column (1:1 hexane:DCM, Rf = 0.9) to remove the 
excess of acetaldehyde. The product was obtained quantitatively as a colourless viscous oil. 1HNMR 
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(CDCl3): δ 9.72 (d, 1H, CH2CHO), 5.45 (m, 67H, CHCH2), 4.94 (m, 134H, CHCH2), 2.11 (m, 67H, CH2CH), 1.16 
(m, 134H, CH2CH). SEC (THF): Mw/Mn = 1.14, see Figure 4, Mn: 3.7 kg/mol 
 
α- methoxy ω-methyl ester poly(ethylene glycol) (7) Poly(ethylene glycol) monomethyl ether, (5 g, 
1kg/mol, 5 mmol), was coevaporated with benzene three times and dissolved in freshly distilled THF (250 
mL). Next, sodium hydride (350 mg, 60% on mineral oil, 1.75 equiv.) was added while an argon 
atmosphere was applied. While stirring, hydrogen gas was allowed to escape for three hours. The 
temperature was raised to 60 °C and methyl bromoacetate (3 g, 3.8 equiv.) was added via a syringe. The 
reaction was allowed to proceed for 12 hours after which all THF was removed and the products were 
dissolved in 25 mL dichloromethane. The solution was poured on a slab of silica gel and flushed with 
dichloromethane (250 mL). The product was eluted with 10 percent methanol in dichloromethane, 
yielding 4.5 gram (90%) product. TLC was run in 14 % MeOH in DCM. Staining was performed with 
KMNO4, and with ninhydrin as a control (no staining); Rf = 0,60. 1HNMR (CDCl3): δ 3.38 (s, 3H, CH3O), 3.65 
(m, 90H, CH2CH2O), 3.75 (s, 3H, COOCH3), 4.17 (s, 2H, OCH2COO). FT- IR: 2876 cm-1 (C-H sat.), 1748 cm-1 
(C=O). SEC (THF): Mw/Mn = 1.22 
 
α- methoxy ω-hydrazide poly(ethylene glycol) (8) 1.5 gram of 7 (1.5 mmol) was coevaporated with 
benzene three times and dissolved in 50 mL methanol under an argon atmosphere. While stirring, 
1hydrazine solution (5 mL, 1M in THF, 10 equiv.) was added at once. The reaction was refluxed overnight 
after which the mixture was concentrated. The crude product was dissolved in dichloromethane (50 mL) 
and washed with 1M HCl solution (50 mL). The organic layer was dried over MgSO4 and all solvents were 
removed, yielding 1.2 gram (80%) of product. TLC was performed with 14 % MeOH in DCM as eluent; 
ninhydrin was used as staining agent ; Rf = 0,55. 1HNMR (CDCl3) : δ 3.38 (s, 3H, CH3O), 3.65 (m, 90H, 
CH2CH2O), δ 4.14 (s, 2H, OCH2CON). FT-IR: 3400 cm-1 (NH), 1683 cm-1 (C=O). SEC (THF): Mw/Mn = 1.22, see 
Figure 4  
 
Figure 4. SEC traces of PBd-b-PEG (1) and its constituents PBd (6) and PEG 1000 derivative (8). 
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Full hydrolysis experiments Vesicles were prepared by dissolving polymer 1 or 2 (40 mg) in THF (0.5 
mL). While gently stirring, milliQ (2 mL) was added drop wise. The opaque solution was extruded twice 
through a 200 nm syringe filter and purified over a Sephadex G200 column. To 900 µL of this vesicle 
solution, 88 µL of a 2 M Na2HPO4 solution and 12 µL of a 1M citric acid solution was added (10x 
concentrated McIlvain buffer)31. After three hours THF (3 mL) was added and the solutions were spotted 
on TLC eluting with 10% methanol in dichloromethane, as were their constituents and the untreated 
polymers 1 and 2. staining was performed with MNO4. The acid treated samples showed no trace of 
polymer 1 or 2 but instead showed spot on the position of PEG and PBd. The untreated samples showed a 
single spot in between PEG and PBd. Finally under these conditions none of the buffering components 
were eluted on TLC. The remainder of the solution was analyzed by GPC as depicted in Figure 2b. Because 
of the addition of the buffering components, eluting right after PEG, it was not possible to obtain an 
undisturbed signal of the free PEG.  
 
Polymersome preparation In general polymeric vesicles were prepared by dissolving 10 mg block 
copolymer (1, 2, 3, 4 or the desired combination) in THF (0.5 mL). While gently stirring, MilliQ (2 mL) was 
added drop wise. The opaque solution was extruded twice through a 200 nm syringe filter and purified 
over a Sephadex G200 column and all vesicle containing fractions were combined (DLS). The combined 
vesicle size distribution was measured by DLS.  
 
Stability studies All buffers were prepared according the method of McIlvaine31 which combines a 0.2 M 
Na2HPO4 and 0.1 citric acid solution to the desired pH in milliQ water. Vesicles were prepared as described 
above in MilliQ. For each measurement, 200 µL of vesicle solution was added to 800 µL of buffer. The pH 
was checked and the size distribution was monitored in time by dynamic light scattering. 
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Dynamically Functionalized Polymersomes via 
Hydrazone Exchange 
 
 
 
 
 
 
 
 
 
 
Polymersomes composed of block copolymers that are coupled via a hydrazone moiety (Chapter 6) are shown 
to exchange surface PEG chains with the environment via an aniline catalyzed transiminiation under 
equilibrium conditions. We show that the transimination equilibrium can be used to functionalize 
polymersomes with a different inner and outer moiety in a dynamic covalent way. Secondly, we show that 
addition of aniline as catalyst allows to exchange surface properties between polymersomes. These results 
therefore open new routes to the design of complex vesicular surfaces. 
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7.1 Introduction 
Polymersomes, or polymeric vesicles, can be regarded as the polymeric analogue of 
liposomes. Due to the higher molecular weight of the building blocks, polymersomes are 
considerably tougher and less permeable than their low molecular weight counterparts1. 
As a result, polymersomes have an interesting potential for a range of applications such 
as drug delivery2-3 and in vivo imaging4-5. For in vivo applications excellent control over 
stability and release properties is required, as well as the possibility to functionalize the 
carrier with specific targeting moieties, e.g. ligands. An appreciable amount of research 
has focused on the functionalization of polymersome surfaces6 with enzymes, peptides7 
and antibodies2,8. However, all these reported functionalization strategies are 
irreversible or make use of non-covalent interactions6,9. In contrast, one can also imagine 
that polymeric vesicles can be functionalized via covalent bonds that are reversible in 
nature.  
 Reversible covalent bonds are (or can be brought) in an equilibrium state, meaning 
that the bond is reversibly formed and broken as exploited in dynamic combinatorial 
chemistry10. In a recent example, Minkenberg et al.11 used reversible chemistry to 
spontaneously form amphiphiles that evolved to the thermodynamically most favourable 
supramolecular composition. If this chemistry is also applicable to preformed polymeric 
vesicles, it would allow the functionalization of polymersomes in a dynamic and modular 
way, in which one sample can be (re)-functionalized with a variety of different 
compounds, while keeping control over vesicle size and stability. Covalent bonds that 
have the potential to be brought into equilibrium have also been built in polymersomes. 
However, the reversibility has only been used for (triggered) disruption12-14, 
unidirectional surface functionalization15 or drug release16-17. 
 In Chapter 6 we showed that the colloidal stability of polymersomes can be 
controlled by the introduction of a hydrazone bond. Block copolymers of which both 
blocks are coupled via a hydrazone moiety can form polymeric vesicles which are stable 
at physiological pH. However, upon lowering the pH they lose their colloidal stability due 
to hydrolysis of the hydrazone18. Simultaneously, a similar system was independently 
reported by He et al.19 In both studies, lowering of the pH was used as a trigger to fully 
hydrolyze the hydrazone bond in the block copolymer, thus removing the PEG periphery.  
 At neutral pH, hydrazone bonds are equilibrium structures which favour bond 
formation as depicted in Figure 1a. However, bond formation and dissociation are very 
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slow. A method to induce faster dynamics in this equilibrium, without shifting the 
position, proceeds by the addition of a catalyst, aniline20. Following this methodology, 
Dirksen et al.21-23 showed that aniline-catalyzed hydrazone exchange between peptide 
fragments is 70 fold faster than the non-catalyzed reaction.  
 In this chapter, we report the use of the aniline catalyzed hydrazone equilibrium in 
the design of polymersomes with dynamic covalent surfaces. We form polymersomes of 
a hydrazone coupled amphiphilic block copolymer and make use of the aniline catalyzed 
hydrazone equilibrium to exchange surface functionalities with the surrounding solution 
as illustrated in Figures 1b-c. In this way, polymeric vesicles with a different inner and 
outer functionality can be formed. Finally, we show that exchange of surface properties 
between polymersomes is possible, following the same approach. This methodology 
therefore opens new routes in the design of complex polymeric membranes, starting 
from simple polymersome scaffolds. 
 
 
Figure 1. a) Equilibrium between hydrazide, aldehyde and hydrazone. The rate constant can be enhanced 
by the addition of aniline. b) After removing a PEG chain from the polymersome surface, either a PEG 
chain from solution or the original PEG chain can attack. c) Presentation of the exchange on the block 
copolymer level, expressing the role of aniline.  
7.2 Results and Discussion 
In Scheme 1 the basic building blocks for the self-assembly of polymersomes and the 
exchange reactions are depicted. Details on the synthetic procedures can be found in 
Section 7.5. We chose to work with the amphiphilic block copolymer polybutadiene-
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block-poly(ethylene glycol) for two reasons. First of all, this block copolymer is generally 
considered to be biocompatible and secondly the low glass transition temperature of 
polybutadiene allows for extrusion and therefore resizing of the polymersomes. This 
allowed us to prepare well-defined monodisperse samples making comparison of their 
properties relatively straightforward. PEG derivatives 1 and 2 contained a hydrazide 
moiety and were partially labelled with fluorescent dansyl and fluorescein (DY495) 
markers, respectively. Amphiphilic block copolymer 3 contained a hydrazone bond 
between both blocks and no functional end group. Block copolymer 4 was partially 
functionalized with rhodamine (DY549) and 5 was functionalized with a maleimide end-
group. Finally, as a negative control the stable amphiphilic block copolymers 6 and 7 
were employed. These polymers are direct analogues of 3 and 4, differing only in the 
connection between both blocks.  
 
 
Scheme 1. Overview of polymers used in this study. Polymers 1 and 2 are PEG derivatives, both containing 
a hydrazide moiety and labelled with dansyl or fluorescein (DY495), respectively. Polymers 3, 4 and 5 are 
amphiphilic block copolymers of polybutadiene-b-poly(ethylene glycol), containing a hydrazone linker 
between both blocks. Polymers 4 and 5 are functionalized with a rhodamine dye (DY549) and a maleimide 
end group, respectively. Finally, block copolymers 6 and 7 do not contain a hydrazone moiety. Polymer 6 
contains no functional end group and 7 is partially labelled with rhodamine B. Both are included as 
negative controls.  
We prepared polymersomes derived from 3 and 6 with a diameter of 220 nm. Thus, 
polymersomes from 3 contained a hydrazone moiety, while polymersomes from 6 did 
not and therefore served as a negative control. After the polymersomes were formed, the 
fluorescent PEG derivative 1 was added to all samples. To initiate the exchange of surface 
PEG for the dansyl-functionalized PEG (1) in solution, aniline (12 equiv) was added as 
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catalyst to the polymersomes formed from 6 and half of the polymersomes formed from 
3. To the other half of this sample no catalyst was added to serve as second negative 
control. For each time point a fraction of the samples was withdrawn and purified by 
size exclusion chromatography (SEC) to separate aniline and unbound PEG from the 
polymersomes. Next, the fluorescence intensity of the polymersome fraction was 
measured in a plate reader as plotted in Figure 2a (340 nm (excitation), 560 nm 
(emission)).  
 
 
Figure 2. Dynamic functionalization of polymeric vesicles. a) Aniline-catalyzed hydrazone surface 
exchange on polymeric vesicles (black) is faster than non-catalyzed exchange (blue). If no hydrazone is 
present in the block copolymer, surface exchange is not possible (red). Vesicles were stable and did not 
change in size during the exchange experiment: 0 hours b) and 30 hours c) as determined by DLS. 
 In principle, both samples prepared from polymer 3 should be able to exchange PEG 
chains with the environment by breaking and forming the hydrazone bonds. However, in 
the presence of aniline this equilibrium was set much faster, as is clearly visible from 
Figure 2a. The aniline containing sample reached its maximum fluorescence after 4.5 
hours, while the non catalyzed sample had not yet reached its equilibrium position after 
30 hours. The negative control, prepared from polymer 6, does not contain a hydrazone 
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bond and therefore was unable to exchange surface chains with its surroundings, 
therefore no increase in fluorescence was observed.  
 As these experiments were performed at neutral pH, it was expected that these 
polymeric vesicles kept their colloidal stability18-19. To confirm this, we analyzed the size 
distribution of the polymeric vesicles at each time interval by dynamic light scattering 
(DLS). As shown in Figures 2b-c no significant change in particle distribution was 
observed between 0 and 30 hours and moreover the derived count rate at a fixed 
measurement position appeared nearly equal for all data points, indicating identical 
concentration and size. This led us to conclude that indeed the surface of these 
polymersomes was in a dynamic equilibrium with its environment. 
 
 
To take this concept one step further, we prepared polymeric vesicles of a combination of 
3 and 4 in a ratio of 95:5. These polymeric vesicles thus exhibited hydrazone bonds and 
were partially fluorescently labelled at both the inner and outer surface. As can be 
derived from the absence of fluorescence in the negative control in Figure 2a (6 with 
aniline), free PEG is not able to cross the membrane of these polymeric vesicles on this 
timescale. Therefore PEG exchange is expected only to proceed on the polymersome 
outer surface, creating a vesicle with a different inner and outer functionalization. We 
repeated the aniline-catalyzed experiment with the abovementioned rhodamine 
prefunctionalized vesicles. Again at each time point any free PEG chains and aniline were 
separated from the polymersomes by size exclusion chromatography. The size and 
concentration of all samples was checked by DLS and found to be equal. Next we 
analyzed the fluorescence intensity of both fluorophores separately in a 96 well plate 
reader (dansyl excitation 340 nm, emission 540 nm; rhodamine excitation 540 nm, 
emission 592 nm). Within five hours, the rhodamine intensity decreased to 0.5 (Figure 
3a), which is consistent with our hypothesis that only the outer membrane is susceptible 
to dynamic exchange. Furthermore, the emission of dansyl reached its maximum 
following an opposite trend compared to the decrease of rhodamine (Figure 3b).  
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Figure 3. a-b) Starting from rhodamine-functionalized polymersomes the outer rhodamine is replaced by 
a dansyl-functionalized surface. c) Emission spectra of polymersomes before and after surface exchange of 
rhodamine-functionalized PEG chains by their fluorescein analogue. d) CLSM visualization of rhodamine 
and e) CLSM visualization of fluorescein on the same polymersomes and f) CLSM overlay image of d and e. 
The white bar represents 20 µm. 
To visualize the double functionalization of vesicles, we applied confocal laser scanning 
microscopy (CLSM). For this purpose, we replaced dansyl-PEG for a fluorescein-PEG 
derivative (2) and repeated the experiment. As depicted in Figure 3c (red) at time zero, 
after mixing and purification by SEC, the emission spectrum of the polymersomes only 
contained rhodamine emission (480 nm, for excitation of both fluorophores). However, 
when after 24 hours a sample was purified by size exclusion chromatography, the 
emission spectrum contained both rhodamine and fluorescein emission. Furthermore, 
Figure 3d-f show CLSM pictures obtained after 24 hours. Both fluorophores were excited 
at the same time (476 nm) and selectively captured as described in Section 7.5. As can be 
seen from Figures 3d-f, a good overlay between both fluorophores exists, indicating that 
both moieties are present on the same polymeric vesicle. The full and unfiltered pictures 
are shown in Section 7.5. 
 In the described experiments, it is not possible to visualize separately the 
functionalization of the in inner and outer surface. This might be possible on giant 
unilamellar vesicles24 in combination with high resolution CLMS. However, together 
these experiments clearly indicate that a different inner and outer membrane 
functionalization is obtained. The first experiment proved that free PEG chains in 
solution cannot cross the polymersome membrane on this time scale. The double 
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functionalization experiment clearly shows a decrease of 0.5 in rhodamine intensity and 
finally CLSM shows the colocalization of both fluorophores. Therefore we can conclude 
that the method as described herein allows for the substitution of the outer PEG surface 
of polymersomes for a new PEG surface containing a different functionality.  
 
 
Figure 4. a) Dynamic hydrazone exchange between vesicles functionalized with rhodamine and vesicles 
functionalized with cell penetrating Tat-peptides will result in a single set of doubly functionalized 
vesicles. b) After exchange polymersomes are both visible by CLSM (coloured in red) and associated with 
Hela cells c) Exchange in absence of Tat-vesicles will not yield vesicles that are both fluorescent and cell 
adhering. d) If rhodamine labelled vesicles are prepared from block copolymers lacking the hydrazone 
moiety (6 and 7), the experiment will not yield vesicles that are both fluorescent and cell adhering. The 
top images of b, c and d show CLSM and bright field overlay images and the bottom CLSM images of 45 x 
45 µm selections. The full unfiltered images are shown in Section 7.5. 
In the preceding experiments we have shown that hydrazone-functionalized polymeric 
vesicles are able to exchange moieties with the surrounding solution. We next 
investigated whether this exchange would also take place between polymeric vesicles. 
For this purpose we synthesized a block copolymer analogue with a maleimide end 
group and a hydrazone unit between both blocks (5). We formed polymersomes of a 
combination of 3 and 5 in a ratio of 8:2. The maleimide functionalities were reacted with 
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a cysteine residue connected to the cell penetrating Tat-peptide25-26, resulting in Tat-
functional polymersomes.  
 Rhodamine-functional polymersomes of 3 and 4 (9:1) were also formed as used in 
the previous experiments. Both types of polymersomes thus contained the hydrazone 
moiety between both blocks. Rhodamine polymersomes can be visualized by CLSM, but 
will not adhere to Hela cells, whereas Tat-polymersomes can adhere to cells7, but are 
invisible in CLSM. If dynamic exchange between these vesicles should take place, the 
resulting set of polymersomes should be both fluorescent and have cell-adhesion 
capacity as depicted schematically in Figure 4a.  
 After both the rhodamine and the Tat-polymersomes were formed, they were mixed 
in a 1:1 ratio and aniline was added. The exchange was allowed to proceed overnight, 
after which aniline and possible free PEG chains were removed by SEC. The sample was 
added to a Hela cell culture and after washing the cells, CLSM indeed confirmed the 
presence of cell adhering, fluorescent polymersomes as shown in Figure 4b. This clearly 
shows that both the cell adhesion and fluorescent properties are contained in a single 
polymersome. To exclude false positive results we included two negative controls in this 
study. When rhodamine polymersomes were reacted with aniline without the presence 
of Tat-polymersomes, no polymersomes were visibly associated with Hela cells (Figure 
4c). Secondly, if rhodamine polymersomes were formed lacking the hydrazone moiety (6 
and 7) and were reacted overnight in the presence of both aniline and Tat-
polymersomes, also no vesicles were visible in the Hela cells culture (Figure 4d). 
 
7.3 Conclusion  
 In conclusion, we have introduced a new concept to functionalize polymeric vesicles 
in a dynamic fashion. We have shown that polymersomes formed from a hydrazone-
coupled block copolymer exchange their surface functionality both with dissolved 
species and with other vesicles via the hydrazone equilibrium. Via this method 
polymeric vesicles can be conveniently formed with different inner and outer 
functionalities. Furthermore, multiple functional surfaces can be obtained via one single 
exchange experiment by mixing the appropriate sets of polymersomes.  
  
Chapter 7 
 
126 
7.4 Acknowledgement  
Prof. Dr. K.T Kim is thanked for pointing me to the aniline catalyzed hydrazone 
equilibrium. Taco R. Visser is acknowledged for his help in the synthesis and Frank de 
Graaf is acknowledged for his help in the exchange experiments and analysis. 
 
7.5 Experimental Procedures 
General notes The full synthetic route, including reaction steps and compounds reported in 
previous chapters is depicted in Scheme 1. Details of the synthesis of compounds 6, 7, 8, 10 and 
12 can be found in Section 2.5. Details of the synthesis of compounds 3 and 11 can be found in 
Section 6.5. Details of the synthesis of compound 15 were reported by Karlèn et al.27 Details of 
the synthesis of compound 16 were reported by Deiters et al.28 
Materials BCN dyes SX-1030 and SX-1031 were purchased from Synaffix and copper bromide was 
washed in ethyl acetate and dried under vacuum prior to use. All other reagents were at least 98% pure 
and used without further purification. Tetrahydrofuran (THF) (ACROS ORGANICS, 99+% extra pure, 
stabilized with BHT) was distilled under argon from sodium/benzophenone and triethylamine (TEA) 
(BAKER) was distilled from calcium hydride under an argon atmosphere prior to use. Polymersome 
extrusions were performed using 200 nm filters (Acrodisc 13 mm Syringe Filter, 0.2 µm Nylon membrane). 
 
Instrumentation MilliQ water was obtained from a Labconco water pro PS system. Thin layer 
chromatography (TLC) was performed on Merck precoated silica gel 60 F-254 plates (layer thickness 0.25 
mm). Compounds were visualized by UV, ninhydrin and/or permanganate reagents. Column 
chromatography (CC) was carried out using silica gel, Acros (0.035-0.070 mm, pore diameter ca. 6 nm). 
Infrared (IR) spectra were obtained using a Thermo Matson IR 300 FTIR spectrometer. Data are presented 
as the frequency of absorption (cm-1). Proton nuclear magnetic resonance (1HNMR) spectra were 
recorded on a Varian Unity Inova 400 FTNMR spectrometer. Chemical shifts are expressed in parts per 
million (δ scale) relative to the internal standard tetramethylsilane (δ=0.00 ppm). Molecular weight 
distributions were measured using size exclusion chromatography (SEC) on a Shimadzu (CTO-20A) 
system equipped with a guard column and a PL gel 5 μm mixed D column (Polymer Laboratories) with 
differential refractive index and UV (λ=254 nm and λ=340nm) detection, using tetrahydrofuran (SIGMA 
ALDRICH chromasolv 99.9%) as an eluent at 1 mL/min and T = 30 oC. Particle size distributions were 
measured on a Malvern instruments Zetasizer Nano-S. A TECAN Infinite 200 PRO plate reader was used to 
perform fluorescence intensity measurements. Confocal Laser Scanning Microscopy (CLSM) images were 
recorded on a Leica DM IRE2 TCS SP2 AOBS inverted microscope. An Argon laser and a Vioflame diode 
laser were used to excite the different fluorophores.  
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Scheme 1. Overview of the synthetic route to all structures employed in this chapter. Details on the 
synthetic procedures are described below. 
α-Dansyl ω-hydrazine poly(ethylene glycol) (1) Compound 10 (100 mg, 0.1 mmol) was dissolved in 
THF (10 mL) under an argon atmosphere. CuBr (5 mg), PMDETA (1 drop) and dansyl probe 16 (26 mg, 
0.95 equiv.) were added and heated to reflux overnight. Probe 16 was consumed as determined by TLC, 
after which all solvents were removed and the products were dissolved in DCM (1 mL). The product was 
purified on a silica column, eluting with DCM to remove any traces of 16. The product (70 mg, 60%) was 
obtained by eluting with 8% methanol in dichloromethane (Rf = 0.55 as a bright single fluorescent spot). 
1H-NMR (CDCl3): δ 9.33 (s, 1H, CONHNH2), 8.55 (d, 1H), 8.27 (t, 2H), 7.62 (s, 1H, CCH2N), 7.54 (q, 2H), 7.19 
(d, 1H), 4.42 (t, 1H, SNHCH2), 4.06 (s, 2H, OCH2CO), 3.79 (m, 2H, CH2N), 3.64 (m, 90H, CH2CH2O), 2.89 (s, 
6H, N(CH3)2), 1.70 (s, 2H, NHNH2). SEC (THF): Mn = 1.1 kg/mol, Mw/Mn = 1.26 (detection at 340 nm, 
while the starting material 10 does not absorb at 340 nm). 
 
Partial fluorescein labelling of α-azido ω-hydrazine poly(ethylene glycol) (2) Polymer 10 (100 mg, 
0.1 mmol) was dissolved in methanol (10 mL) and fluorescein probe SX-A1030 (5 mg, 0.06 equiv.) was 
added. The reaction was allowed to proceed overnight, after which all solvents were removed. TLC, eluting 
with acetonitrile:MilliQ (9:1) showed full consumption of dye SX-A1030 (RF = 0.75) and a new bright 
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fluorescent product (RF = 0.05) at the same height as 10 was formed (note that mixing of PEG and SX-
A1030 results in a clear separation under these conditions). The product was dissolved in ice-cold 
dichloromethane (1mL) and filtered over a 0.1 µm syringe filter. The product (85 mg, 80%) was obtained 
by removing all dichloromethane. SEC (THF): Mn = 1.4 kg/mol, Mw/Mn = 1.31 (detection at 340 nm, 
whereas the starting material, 10, does not absorb at 340 nm). 1HNMR (CDCl3): no significant deviation 
from 10, due to labelling with only 0.06 equiv. of dye. 
 
Partial Rhodamine labelled Polybutadiene-hydrazone-poly(ethylene glycol) (4) Compound 14 (100 
mg, 0.021 mmol) was dissolved in THF (10 mL) and Rhodamine probe SX-A1031 (5 mg, 0.02 equiv.) was 
added. The reaction was allowed to proceed overnight. Solvents were removed and product 4 was 
purified by preparative GPC (THF) to yield 70 mg product. The product was highly fluorescent and in 
contrast to 14 showed absorption in the GPC detector at 340 nm (see Figure 5). Mw/Mn = 1.22, Mn: 4.7 
kg/mol. 1HNMR (CDCl3) no significant deviation from 14, due to the low concentration of dye. 
 
 
Figure 5. Using equal polymer concentrations 
for SEC (THF) analysis. UV absorption at 340 nm 
can be detected for polymer 4, due to the 
presence of SX-1031, whereas only limited 
absorption is observed before the coupling (14).  
 
 
Maleimide end-functional Polybutadiene-hydrazone-poly(ethylene glycol) (5) Compound 14 (100 
mg, 21 µmol) was dissolved in THF (10 mL) under an argon atmosphere. Next, CuBr (5 mg, 34 µmol), 1 
drop of PMDETA (ca 50 mg, 0.28 mmol) and maleimide 15 (5 mg, 1.6 equiv.) were added and heated to 
reflux overnight. All solvents were removed and the products were dissolved in dichloromethane (1mL). 
The product was purified on a silica column, eluting with a gradient of 0 % to 8% methanol in 
dichloromethane to obtain 55 mg product (Rf in 8% methanol/DCM = 0.65). The product showed, in 
contrast to 14, good UV (254 nm) absorption in SEC analysis. SEC (THF): Mw/Mn = 1.26, Mn: 4.7 kg/mol 
(see Figure 6). 1HNMR (CDCl3): δ 6.96 (s, 2H, maleimide), 5.45 (m, 67H, CHCH2), 4.94 (m, 134H, CHCH2), 
3.65 (m, 90H, CH2CH2O), 2.11 (m, 67H, CH2CH), 1.16 (m, 134H, CH2CH).  
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Figure 6. Using equal polymer concentrations 
for SEC (THF) analysis. UV absorption at 254 nm 
can be detected for polymer 5, due to the 
presence of triazoles and a maleimide, whereas 
only limited absorption is observed before the 
introduction of a maleimide (14). 
  
 
Rhodamine labelled Polybutadiene-triazole-poly(ethylene glycol) (7) 50 mg 12 (10 µmol) was 
dissolved in THF (10 mL) and Et3N (1 mL) was added. Next. Rhodamine B isothiocyanate (7.5 mg, 1.5 
equiv) was added and allowed to react for 48 hours. Solvents were removed and product 7 was purified 
by preparative SEC (THF) to yield the product product (25 mg, 45%). The product was a single spot on 
TLC (8 percent methanol in DCM; UV and permanganate stain) which appeared brightly fluorescent. Note 
that the isothiocyanate coupling of rhodamine B proceeded slowly and the reaction did not go to 
completion as can be seen from the SEC traces (absorption @ 340 nm) in Figure 7. The elution volume 
that was collected in preparative SEC (THF) is depicted in the box (6.7 to 8.1 mL) 
 
 
Figure 7. SEC (THF) analysis of block copolymer 
12, which does not absorb at 340 nm before the 
addition of rhodamine B isothiocyanate. After 2 
hours the labelled polymer (top~7.5 mL) does 
absorb at 340 nm, which increases over the next 
46 hours. The dashed box indicates the volume, 
containing product 7, that was collected by 
preparative SEC in THF.  
 
 
α-azido ω-hydrazine poly(ethylene glycol) (10) Compound 8 (1g, 1 mmol ) was dissolved in methanol 
(50 mL) and 5 drops of concentrated sulfuric acid were added. The mixture was heated under reflux 
overnight, after which methanol was removed. The product was dissolved in water (50 mL) and extracted 
with dichloromethane (5x 50 mL). The organic layer was dried over MgSO4 and all solvents were removed. 
TLC: Rf = 0.65, permanganate staining, running in DCM:MeOH = 92:8. Indicative 1H-NMR (CDCl3) shifts: δ 
4.17 (s, 2H, OCH2COOMe), 3.75 (s, 3H, COOCH3) and IR: 1748 cm-1 (carbonyl/ester) 
 The product was dissolved in methanol (50 mL) and hydrazine (15 mL, 1M in THF) was added. The 
mixture was heated under reflux for 48 hours, after which almost all solvents were removed. The product 
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was dissolved in dichloromethane (50 mL) and washed with 1M hydrochloric acid (50 mL). The aqueous 
layer was extracted with dichloromethane (5x 50 mL). The combined organic layers were dried over 
MgSO4 and all solvents were removed to yield 800 mg product (80%). TLC: Rf = 0.55, permanganate and 
ninhydrin staining, eluent DCM:MeOH = 92:8. 1HNMR (CDCL3): 3.39 (t, 2H, CH2N3), 3.64 (m, 90H, 
CH2CH2O), 4.01 (s, 2H, OCH2CONH). FTIR: 2098 cm-1 (azide), 1696 cm-1 (C=O). SEC (THF): Mn = 1 kg/mol, 
Mw/Mn = 1.22. 
 
ω-azido-Polybutadiene-hydrazone-poly(ethylene glycol) (14) Polymer 10 (80 mg) and 13 (800 mg , 
2.5 equiv. 3.7 kg/mol) were dissolved in dry dichloromethane (2 mL). The mixture was allowed to react 
for 24 hours while gently stirring after which the mixture was poured on a short silica column, which was 
eluted with dichloromethane. After all non-reacted 13 was flushed off the product was eluted with 8 
percent methanol in dichloromethane. After removal of all solvents 240 mg of the product was obtained in 
65 percent yield. 1HNMR (CDCl3): δ 5.45 (m, 67H, CHCH2), 4.94 (m, 134H, CHCH2), 3.65 (m, 90H, CH2CH2O), 
2.11 (m, 67H, CH2CH), 1.16 (m, 134H, CH2CH). SEC (THF): Mw/Mn = 1.18, Mn: 4.7 kg/mol (see Figure 8). 
 
 
Figure 8. Synthesis of ω-azido-polybutadiene-
hydrazone-poly(ethylene glycol) (14) from 
polymers 10 and 13. Due to an increase in 
molecular weight the GPC trace shifts to shorter 
elution time. 
 
 
Tat-peptide Tat-peptide was synthesized by means of standard Fmoc chemistry. The purity was more 
than 95 percent as analyzed by means of HPLC eluting in water/acetonitrile both containing 0.1% v/v 
trifluoroacetic acid. The volume fraction of acetonitrile was increased from zero to hundred percent over 
30 minutes. Maldi-TOF (cyano-4-hydroxycinnamic acid): [M+H] calc: 1719.0 g/mol and [M+H] found: 
1718.7 g/mol.  
 
Polymersome formation (general procedure) 20 mg of the desired (ratio) of block copolymer(s) was 
dissolved in THF (2 mL) and slowly diluted with MilliQ water (6 mL) to obtain an opaque solution. The 
solution was extruded three times through a 200 nm syringe filter. THF was removed by purification over 
a Sephadex G200 column, eluting with demineralised water, after which the polymersome fractions were 
combined. If needed the pH was adjusted to neutral (NaOH) and the total volume was adjusted to 10 mL 
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(2 mg/mL, 0.4 mM). The average size was determined by dynamic light scattering and was in all cases 
around 200 nm with a PDI below 0.2. 
 
Dansyl-PEG solution exchange Three sample solutions were prepared containing: A) 3 mL 
polymersomes formed from 3 (0.4 mM), 0.8 mg of 1 (0.26 mM) and 1.7 mg aniline (6 mM) B) 3 mL 
polymersomes formed from 3 (0.4 mM) and 0.8 mg of 1 (0.26 mM) and C) 3 mL polymersomes formed 
from 6 (0.4 mM), 0.8 mg of 1 (0.26 mM) and 1.7 mg aniline (6 mM) At different time points a 600 µL 
sample of A, B and C was withdrawn and purified over a Sephadex G200 column, eluting with milliQ. The 
average size at a fixed attenuator and measurement position was determined by DLS and if necessary the 
samples were diluted to equally derived count rates. No significant change in size and polydispersity in 
time was observed. samples were prepared in a 96 well plate (200 µL/well) and measured in a plate 
reader, 340 nm excitation and 560 nm emission.  
 
Dansyl-PEG/Rhodamine-PEG solution exchange Polymersomes were formed of 3 and 4 in a ratio of 95:5 
as described above. The experiment was started by mixing 3 mL of polymersomes (0.4 mM), 3 mg of 1 (1.0 
mM) and 1.7 mg aniline (6.0 mM). At different time points a 600 µL sample was withdrawn and purified 
over a Sephadex G200 column, eluting with MilliQ. The average size at a fixed attenuator and 
measurement position was determined by DLS and if necessary the samples were diluted. No significant 
changes in size and polydispersity in time were observed. samples were prepared in a 96 well plate (200 
µL/well) and measured in a plate reader. Only the dansyl probe was observed upon excitation at 355 nm 
and the emission was measured at 540 nm. The rhodamine probe was selectively analyzed with an 
excitation of 540 nm and emission at 592 nm. Note that these excitations and emissions are not the 
spectral maxima of the probes, but allow the selective determination of both fluorophores. 
 
Fluorescein-PEG/Rhodamine-PEG solution exchange This experiment was performed to visualize the co 
localization of two fluorophores at polymersomes. As dansyl was not a suitable probe for CLSM due to fast 
quenching, it was replaced by fluorescein (compound 2). Polymersomes were formed of 3 and 4 in a ratio 
of 95:5 as described above. The experiment was started by mixing 600 µL of polymersomes (0.4 mM), 0.5 
mg 2 (0.56 mM) and 3 mg aniline (50 mM). After 24 hours a sample was purified over a Sephadex G200 
column eluting with MilliQ water. The average size at a fixed attenuator and measurement position was 
determined by DLS and no significant change in size and polydispersity was observed. The emission 
spectrum of both fluorophores was determined simultaneously in the plate reader by excitation at 480 nm. 
For the CLSM experiment the sample was excited with a 476 nm laser. Rhodamine was selectively 
visualized by recording emission between 580-610 nm and fluorescein was recorded between 500-530 
nm (Figure 9). 
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Figure 9. Left, selective detection of rhodamine emission after 24 hours of catalyzed exchange. Middle, 
selective detection of fluorescein emission and right, the overlay of both images showing the presence of 
both fluorophores at the same polymeric vesicles after 24 hours of equilibration.  
Tat-PEG/Rhodamine-PEG surface exchange Three sets (P1, P2 and P3) of polymersomes were formed as 
described above. P1 was formed from 3 and 4 in a ratio of 9:1 (rhodamine-labelled) (10 mL, 0.4 mM), P2 
was formed from 6 and 7 in a ratio of 9:1 (same as P1 but no hydrazone bonds) (10 mL, 0.4 mM) and P3 
was formed from 3 and 5 in a ratio of 8:2 (Maleimide, but no fluorescent label) (10 mL, 0.4 mM) 
 
P3 polymersomes were functionalized with Tat-peptide: 1.1 mg Tat (~0.5 equiv towards maleimides) was 
dissolved in 1 mL MilliQ and 5 mg tris(2-carboxyethyl)phosphine(TCEP) gel (Piercenet) was added. The 
mixture was incubated for 30 minutes after which the solution was filtered and added to the full 10 mL of 
maleimide-functional polymersomes P3. Possible residual Tat-peptide was removed by spin column 
(4000 rpm, 0.1 nm pores) until the eluate showed negative on Kaiser test (ninhydrin for free amines). The 
total volume was adjusted to 10 mL to have equal concentrations compared to P1 and P2 (0.4 mM). 
Three samples to test polymersome-polymersome surface exchange were prepared as follows: A) 600 µL 
P1 + 600 µL P3 + 1 mg aniline (1.2 mL sample; 0.4 mM in polymer and 9 mM in aniline); B) 600 µL P2 + 
600 µL P3 + 1 mg aniline (negative control, 1.2 mL sample; 0.4 mM in polymer and 9 mM in aniline) and C) 
600 µL P1 and 0.5 mg aniline (negative control, 0.6 mL sample; 0.4 mM in polymer and 9 mM in aniline) 
After 16 hours all samples were purified over a Sephadex G200 column eluting with milliQ water. 
 
Hela Cell Studies The cellular adhesion experiments were performed with HeLa cells, which were seeded 
one day before the experiment in 8-well microscopy chambers (Nunc, Wiesbaden, Germany) at a density 
of 40,000 cells/well. At the time of the experiment, cells had grown to approximately 50% confluence. The 
polymersome samples (20 μL) were diluted with Dulbecco’s Modified Eagle Medium DMEM (380 μL) and 
added to the cells, which were incubated for 1.5 h at 37 °C. The cells were washed with DMEM (3 × 400 
μL) and imaged immediately. Confocal laser scanning microscopy was performed using a Leica 
Microsystems TCS SP2 AOBS system (Mannheim, Germany). Excitation of rhodamine was achieved with 
an argon laser [488 nm (47%), 514 nm (39%) and 561 nm (36%)] and the resulting emission was 
acquired between 575 and 725 nm as an average of four scans. The full images are depicted in Figures 10-
12 
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Figure 10. Aniline catalyzed dynamic exchange between a set of Tat-functional polymersomes and a set of 
rhodamine functional polymersomes results in a new set of polymersomes that are both cell penetrating 
(Tat, Hela cells) and visible under CLSM. Top) Confocal fluorescent image, polymersomes are coloured as 
red dots; bottom) corresponding bright field image of the Hela cells. 
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Figure 11. Negative control: Aniline-catalyzed dynamic exchange between a set of Tat-functional 
polymersomes and a set of irreversibly functionalized (no hydrazone bond) rhodamine-polymersomes 
does not result in polymersomes that are both cell penetrating (Tat, Hela cells) and visible under CLSM. 
Top) Confocal fluorescent image, fluorescent-cell penetrating polymersomes would appear as red 
coloured dots. The absence of polymersomes indicated that indeed no polymersomes adhered or 
penetrate the Hela cells. Bottom) corresponding bright field image. 
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Figure S10. Negative control: Aniline-catalyzed dynamic exchange involving rhodamine-functionalized 
polymersomes in absence of Tat-polymersomes does not result in a new set of polymersomes that are 
both cell penetrating (Hela cells) and visible under CLSM. Top) Confocal fluorescent image, polymersomes 
would appear as red coloured dots. The absence of polymersomes indicated that indeed no polymersomes 
adhered or penetrate the Hela cells. Bottom) corresponding bright field image. 
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Summary & Perspective 
 
 
 
 
 
 
 
 
 
 
Manny potent drugs are hampered by a low bioavailability and never reach the desired tissue, which 
therefore renders them useless in a clinical environment. Additionally, organisms are equipped with 
impermeable physiological barriers, among them the blood-brain barrier. One strategy to overcome these 
obstacles is by chemical modification of the drugs to increase their bioavailability. However, this strategy 
involves alteration of the chemical structure which in many cases reduces the potency of the drug. 
Nanotechnology might overcome these obstacles by providing carriers that transport the unmodified drug to 
the desired place in the body. This thesis describes the design of such a polymeric nanocarrier system based 
on the block copolymer polybutadiene-block-poly(ethylene glycol) which has the ability to target and cross 
the blood-brain barrier and allows for in vivo SPECT imaging.  
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8.1 Summary 
In the first chapter an overview of the recent literature on polymeric vesicles, also 
known as polymersomes, in biomedical applications is given. From this chapter it 
becomes clear that the possibilities to tailor and optimize polymeric vesicles for a given 
application are only limited by the creativity of the researchers. The design flexibility 
makes polymersomes interesting candidates for nanomedicine, but also introduces a 
high degree of complexity. The rational design of a vesicle starts on the level of the 
choice of monomers to form amphiphilic block copolymers of predefined molecular 
weight, and reaches all the way up to the supramolecular level where shape, size, 
porosity and surface functionality become important.  
 To tackle this complexity, while retaining the flexibility in design, we have developed 
in chapter 2 a chemical platform based on the amphiphilic block copolymer 
polybutadiene-block-poly(ethylene glycol) which has the property to self assemble into 
polymersomes.  This platform allows to construct vesicles functionalized with multiple   
proteins, peptides and imaging probes; furthermore, control over the polymersome size 
is easily obtained. This chemical platform forms the basis of the research as described in 
chapters 3-7. 
 
 In chapter 3, size was demonstrated to be an important factor influencing the blood 
circulation of polymersomes. Vesicles of the amphiphilic block copolymer 
polybutadiene-block-poly(ethylene glycol) with an average size of 250, 120 and 90 nm 
were formed and labelled with a radioisotope, 111In. The biodistribution in mice over all 
main organs was analyzed and showed a similar trend as found for liposomes. However, 
for polymersomes the transition from long blood circulation to fast clearance by the 
liver and spleen was more abrupt, leading to the conclusion that long circulating 
polymersomes should be formulated well below a size of 100 nm. This sharp transition 
from long blood circulation (90 nm) to fast liver and spleen accumulation (≥ 120 nm) 
was also visualized by the non invasive technique of SPECT/CT imaging. 
 In chapters 4 and 5 we designed a G23-peptide functionalized polymeric vesicle that 
is able to efficiently cross the blood brain barrier by recognition of the gangliosides GM1 
and GT1b. These chapters also nicely illustrate that the design of polymersomes for 
biomedical (and other) applications is not only dependent on a good control over the 
chemistry and supramolecular assembly. To identify potent targets and ligands and test 
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them both in vitro and in vivo an in dept knowledge over the function and physiology of 
(in this case) the blood-brain barrier is needed. These kinds of potential drug delivery 
systems therefore can only be developed by a tight interplay between groups of 
different expertise such as (polymer) chemistry, nuclear medicine and cell membrane 
biology.  
 The resulting G23- tagged polymeric vesicles were additionally labelled with 
fluorescent or radioisotope labels for in vitro and in vivo analysis. In vitro studies 
showed a high and selective transcytosis potential for the G23-polymersomes which was 
confirmed by in vivo experiments in mice. An in dept in vivo analysis (chapter 5) 
revealed that G23-polymersomes were able to cross the blood-brain barrier with an 
efficiency comparable with antitransferrin-tagged polymersomes, which can be 
regarded as a golden standard. However, an unexpected result was the high 
accumulation of G23-polymersomes in lung tissue, which might either be circumvented 
by smart drug administration or be used to its advantage for targeted drug delivery to 
lung tissue (e.g. tuberculosis). 
 
 The final two experimental chapters (6 and 7) describe a more fundamental line of 
investigation into the design and functionalization of polymersomes. Again, a block 
copolymer based on polybutadiene-block-poly(ethylene glycol) was designed. However, 
this time both blocks were coupled via a hydrazone moiety, which is a dynamic bond 
and pH sensitive within the physiological relevant window.  
 In chapter six we explore the pH dependent stability of polymersomes assembled 
from hydrazone-coupled block copolymers. It was shown that these polymersomes of 
predefined size lost their colloidal stability upon lowering the pH from 7.4 to 6.4 and 
less. When a pH stable block copolymer, as developed in chapter 2, was mixed in  
structural control was regained.  It was demonstrated  that the presence of less than 5% 
of surface PEGylation was sufficient to maintain colloidal stability. 
 Finally, chapter 7 explores the (catalyzed) dynamic nature of polymersomes 
assembled from hydrazone-coupled block copolymers. It was shown that the 
introduction of a hydrazone moiety in polymersomes allows for the construction of 
more complex, asymmetrical and multifunctional polymeric vesicles. The dynamic 
nature of the hydrazone bond allowed the exchange of surface functionality both with 
polymers which were molecularly dissolved and between polymersomes. This opens up 
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new routes toward more complex multi-functionalized polymeric vesicles with control 
over size and colloidal stability. 
 
8.2 Perspective 
In this thesis a line of research is described, which  involves the successful design of a 
polymersome drug delivery system that can cross the blood-brain barrier in vivo. 
Although several research questions have been appropriately answered, such as 
targetability, and optimal size for biodistribution, in order to move toward actual 
applications of these polymeric vesicles in the clinic, important challenges still have to 
be dealt with in a future line of research.  
 
Throughout this thesis the amphiphilic block copolymer polybutadiene-block-
poly(ethylene glycol) was used because of its low glass transition temperature and 
biocompatibility. Although this polymer is not biodegradable on a timescale of days this 
polymer was chosen since it allowed us to control the overall polymersome structure in 
a relatively “simple” model. The lack of biodegradability rules out the complicating 
factor of decomposition, but seriously hampers the applicability in a clinical setting and 
therefore the biodegradability needs to be addressed in the future research. 
 In many cases there can be important, and sometimes unpredictable discrepancies 
between model systems and the actual drug delivery vehicles. For example, in chapter 3 
size was subject to research with respect to biodistribution in mice. Although studies 
with the empty polybutadiene-block-poly(ethylene glycol) polymersomes give 
important insights, they may not reflect the full complexity of a targeted drug delivery 
vesicle. In chapter 2 it was briefly mentioned that 1 weight percent of a drug could be 
encapsulated in the vesicle membrane. At this moment it is under investigation whether 
membrane stiffening, due to drug encapsulation, will influence the blood circulation of 
90 nm polymersomes. The effect of size and membrane stiffness are only two 
parameters that have to be simultaneously considered to understand blood circulation. 
 The results as discussed chapter 4 and 5 are highly promising for the development of 
a real biomedical application. In fact, both the in vitro and in vivo efficiency of transport 
for G23-tagged polymersomes over the BBB is high compared to most other delivery 
systems. Moreover, the design of this G23-vesicle, along with the identification of 
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G23/GM1 as tag and target, was accomplished within four years. However, also in this 
case many questions still have to be answered. Would a differently sized polymersome 
perform better, how much of a certain drug can be maximally encapsulated, how can a  
release mechanism be effectively introduced when the carrier reaches the brain 
parenchyma and is there an enhanced therapeutic effect? Furthermore, it should be 
noted that although the brain delivery of G23-polymersomes is high compared to other 
delivery systems, it is still less than one percent of the injected dose that reaches the 
brain.   
 
In 1999 Discher et al. published the first in dept study into polymeric vesicles which he 
coined polymersomes. One feature that was immediately noted is the resemblance with 
liposomes. Upon extending this comparison, it should be noted that liposomes have been 
studied for more than 50 years and are nowadays found in approved drug formulations. 
In this perspective liposomes have a head-start of more than 40 years. However, after a 
decade of research into polymeric vesicles one can say that basically anything which can 
be done with liposomes has been published with polymeric vesicles. Furthermore, in 
many (but not all) cases polymeric vesicles outperform liposomes, making biomedical 
applications feasible and just a matter of time. 
 In the near future, a gain in therapeutic effect by replacing existing therapeutics 
based on e.g. liposomes may be foreseen. But  probably the biggest potential for 
polymersomes lies in the huge diversity of polymers that can and have been used to 
meet specific criteria for a given application. Chemists can use their full creativity to 
adjust polymeric vesicles after receiving new input from different fields of science. And 
it is this adjustability and flexibility in design which elevates polymeric therapeutics 
above conventional approaches. Polymer therapeutics will continue to solve biomedical 
problems, where the possibilities for conventional medicine end. 
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Samenvatting & Visie 
 
 
 
 
 
 
 
 
 
 
Veel potentiële medicijnen zijn kansloos in een klinische toepassing, omdat ze leiden onder een te lage 
biologische beschikbaarheid en dus nooit in het juiste weefsel aankomen. Daarnaast kent het lichaam een 
aantal vrijwel onneembare barrières, waaronder de bloed-hersenbarrière. Een manier om de biologische 
beschikbaarheid van medicijnen te verbeteren is door ze chemisch aan te passen, maar dit resulteert vaak in 
een verminderde werking. Een relatief nieuwe manier om dit opstakel te nemen wordt gevonden  in de 
nanotechnologie. Nanotechnologie maakt het mogelijk om deeltjes ter grootte van 1/1000 tot 1/50 
haardikte te vormen waar een medicijn ingesloten wordt. Door vervolgens specifieke liganden op deze 
deeltjes te zetten kan het naar de juiste plek gebracht worden om het medicijn af geven. In dit proefschrift 
wordt de ontwikkeling van zo’n polymeer nanodeeltje beschreven dat in staat is de bloed-hersenbarrière over 
te steken en door middel van SPECT/CT scan gevisualiseerd kan worden. 
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8.1 Samenvatting 
 
In het eerste hoofdstuk wordt een overzicht gegeven van de meest recente literatuur op 
het gebied van polymeer nanodeeltjes (polymersomen) in biomedische toepassingen. 
Uit deze literatuurstudie komt naar voren dat de enige beperkende factor in de 
optimalisatie en toepassing 
van polymersomen de 
creativiteit van de onderzoeker 
is. De flexibiliteit in het design 
maakt van polymersomen een 
interessante klasse van 
deeltjes voor medicijn afgifte, 
maar maakt ook dat het 
formuleren erg complex wordt. 
Rationeel design begint 
daarom bij de keuze van monomeren om polymeren te maken van een goed gekozen 
lengte en gaat door tot de supramoleculaire chemie, waar keuzes als vorm, deeltjes 
grootte en oppervlakte chemie centraal komen te staan.  
 Om een weg te vinden in deze complexe chemische ruimte hebben wij in hoofdstuk 2 
een chemisch platform ontwikkeld gebaseerd op het amfifiele blok copolymeer 
polybutadiene-poly(ethylene oxide). Dit polymeer is in staat om zichzelf te assembleren 
in een dubbel membraan dat de buitenkant van een sferisch deeltje vormt, een 
polymersoom. Tevens wordt een methode beschreven om deze deeltjes in grootte te 
variëren van 1/1000 tot 1/50 van een haardikte en ze te functionaliseren met eiwitten, 
peptiden en fluorescente/radioactieve labels. Dit chemische platform vormt dan ook het 
uitgangspunt voor het onderzoek als beschreven in hoofdstukken 3-7.  
 
In hoofdstuk 3 wordt aangetoond dat deeltjes grootte een belangrijke factor is als het 
gaat om bloedcirculatie. Polymersomen met een gemiddelde grootte van 250, 120 en 90 
nm zijn gelabeld met een radioactief isotoop van indium (111In). De biodistributie na 4 
en 24 uur over de belangrijkste organen en het bloed is vervolgens bepaald in muizen. 
De algemene trend was gelijk aan die van liposomen (de fosfolipiden analoog van 
polymersomen). Echter, de overgang van lange bloed circulatie naar snelle lever- en 
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mildopname was veel abrupter. Dit leidt tot de conclusie dat voor lange bloedcirculatie 
de polymersomen kleiner dan 100 nm moeten zijn. Daarnaast is het effect van lange 
bloedcirculatie voor 90 nm deeltjes en snelle lever- en mildopname voor deeltjes van 
120 nm gevisualiseerd d.m.v. SPECT/CT scans, een veel gebruikte techniek in de 
nucleaire geneeskunde. 
 In hoofdstukken 4 en 5 wordt de ontwikkeling van een peptide (G23) 
gefunctionaliseerde polymersome dat de bloed-hersenbarrière kan oversteken 
beschreven. Dit gebeurd door herkenning van de gangliosiden GM1 en GT1b. Deze 
hoofdstukken illustreren tevens dat de ontwikkeling van polymersomen voor 
biomedische (en andere) toepassingen een multidisciplinair onderzoek is, waarvoor 
onderzoekers uit verschillende velden intensief met elkaar samen moeten werken. In dit 
geval was naast chemische kennis ook gedegen kennis over de fysiologie van de bloed-
hersenbarrière en nucleaire geneeskunde nodig om liganden te identificeren en die 
zowel in vitro als in vivo te testen.  
 Deze samenwerking resulteerde in de ontwikkeling van G23-gefunctionaliseerde 
polymersomen met een fluorescente en/of radioactieve (111In) label voor in vitro en in 
vivo studies.  In vitro cel studies laten zien dat G23-gefunctionaliseerde polymersomen 
in staat zijn om selectief over een bloed-hersenbarrière model transporteren 
(hCMEC/D3, transcytose). Dit wordt ook bevestigd door een eerste kleinschalige muis 
studie. 
 In hoofdstuk 5 is de in vivo bioditributie van G23-polymersomen in de hersenen en 
overige organen in detail bestudeerd (muis studies). Deze resultaten zijn in een directe 
studie vergeleken met transferrin antilichaam gefunctionaliseerde polymersomen. 
Transferrin antilichaam, met een molecuul gewicht van ~90.000 Dalton, wordt 
momenteel gezien als de gouden standaard. Onze resultaten laten zien dat het G23- 
peptide, met een molecuulgewicht van slechts 1.640 Dalton, vergelijkbare resultaten 
geeft. Echter, we zagen ook een grootte specifieke toename van G23-polymersomen in 
het longweefsel. Dit zou onderdrukt kunnen worden door aangpaste toediening van de 
polymersomen, of in het voordeel gebruikt kunnen worden voor medicijn afgifte in de 
longen. 
 
De laatste twee hoofdstukken (6 en 7) laten een meer fundamentele studie naar design 
en functionalisering van polymersomen zien. Wederom is het polymeer polybutadiene- 
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poly(ethylene glycol) gesynthetiseerd, maar dit maal zijn beide delen door een hydrazon 
binding met elkaar verbonden. Hydrazon bindingen zijn dynamische bindingen met een 
pH gevoeligheid in een fysiologisch relevante range (pH 5-8).  
 In hoofdstuk 6 wordt de pH gevoeligheid van deze binding in polymersomen 
bestudeerd. We tonen aan dat deze polymersomen stabiel zijn bij een pH van 7.4 (bloed) 
en hun colloïdale stabiliteit verliezen wanneer de pH verlaagd wordt naar 6.4 en lager 
(endosoom). Door het inmengen van verschillende hoeveelheden van het stabiele 
polymeer uit hoofdstuk 2 konden polymersomen met verschillende PEGyleringsgraden 
worden verkregen. De minimum hoeveelheid poly(ethyleen glycol) die nodig is om de 
colloïdale stabiliteit van polymersomen te behouden is 5 procent. 
Tot slot wordt in hoofdstuk 7 een studie gepresenteerd waarin polymersomen met een 
hydrazon binding stabiel gehouden worden bij pH 7.4. Dit maal werden de aniline 
gekatalyseerde dynamische eigenschappen van de hydrazon binding gebruikt om 
functionele groepen te introduceren door middel van oppervlakte uitwisseling. Dit 
resulteerde in asymmetrische membranen met verschillende functionele groepen aan de 
binnen- en buitenzijde van de polymersomen. Daarnaast werd aangetoond dat 
uitwisseling van functionele groepen tussen polymersomen mogelijk is. Deze resultaten 
openen nieuwe mogelijkheden voor de constructie van complexe multifunctionele 
polymersomen met controle over hun grootte en colloïdale stabiliteit. 
8.2 Visie 
Dit gehele proefschrift is gebaseerd op het polymeer polybutadiene-poly(ethylene 
glycol). Dit polymeer werd gekozen vanwege zijn lage glastransitie temperatuur 
(vervormbaar bij kamertemperatuur) en biologische tolerantie. Echter, dit polymeer is 
niet biologisch degradeerbaar op een tijdschaal van dagen. Toch hebben we voor dit 
polymeer gekozen, omdat het ons in staat stelt om een relatief simpel polymersome 
model te bestuderen met goede controle over de structuur. Daarnaast zou 
biodegradeerbaarheid een extra complexiteit met zich mee brengen, namelijk het uit 
elkaar vallen van de structuur tijdens de studies. Echter, het is juist de robuustheid van 
ons model dat in een klinische toepassing zeer ongewenst is. Daarom moet de factor 
degradeerbaarheid in vervolgstudies zeker geïntroduceerd worden.  
 Daarnaast zijn alle in vitro en in vivo studies zijn uitgevoerd met lege polymersomen 
om belangrijke inzichten te krijgen in bijvoorbeeld de bloedcirculatie en biodistributie 
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van polymersomen. Echter, ook dit is een versimpelde weergave van een polymersome 
medicijn-afgifte systeem. In hoofdstuk 2 werden kort enkele experimenten beschreven 
die aantonen dat polymersomen beladen kunnen worden met 1 procent van een model 
drug. Deze belading veranderd de stijfheid van het membraan en zal wellicht een 
invloed op de bloedcirculatie en biodistributie hebben. Een mogelijke verandering als 
gevolg van medicijn belading wordt momenteel dan ook onderzocht.  
 Het onderzoek als beschreven in hoofdstuk 4 en 5 zijn zeer veel belovend voor 
toekomstige biomedische toepassingen. De muizen leken niet te leiden onder de 
polymersome injecties en zowel de in vitro als in vivo resultaten laten een zeer hoog 
transport van polymersomen over de bloed-hersenbarrière zien. Zeker in vergelijking 
tot de meeste reeds bekende systemen. Hierbij moet ook aangemerkt worden dat het 
ontwikkelen van de polymersomen, het identificeren van G23-peptiden en het in vitro/in 
vivo testen binnen vier jaar is uitgevoerd. Een extra optimalisatie itteratie zou zeker tot 
nog betere resultaten leiden, want ook deze hoofdstukken laten vragen onbeantwoord. 
Zou een andere grootte polymersomen in deze setting andere resultaten geven 
(combinatie van de factoren grootte en functionalisatie), hoe kunnen we een medicijn 
vrijgeven als de polymersome in het hersenweefsel is aangekomen en is er een 
therapeutisch effect in een ziektemodel? Daarnaast moeten we aantekenen dat, hoewel 
ons systeem nu al efficiënt is vergeleken met andere onderzoeken, er nog altijd minder 
dan 1 procent van de  geïnjecteerde dosis in het hersenweefsel terecht komt. Er is dus 
nog veel ruimte voor verbetering en het ontwikkelen van betere inzichten ten aanzien 
van het gebruik van polymersomen in biomedische toepassingen en in het gebied van 
“polymer therapeutic” in het algemeen. 
 
In 1999 werd door Discher een eerste systematische studie naar de structuur van holle 
sferische polymeer structuren uitgevoerd. In deze publicatie noemt hij deze structuren 
polymersomen, naar analogie van liposomen die reeds meer dan 50 jaar bekend en 
bestudeerd werden. Tegenwoordig worden liposomen gevonden in medicijnen die 
goedgekeurd zijn voor gebruik in de kliniek. In dat opzichte hebben studies naar 
liposomen in biomedische toepassingen een voorsprong van meer dan 40 jaar. Echter 
als je de literatuur vandaag de dag bestudeerd wordt duidelijk dat in ruim tien jaar alles 
wat ooit gedaan is met liposomen ook met polymersomen is gedaan. Daarnaast blijkt 
steeds weer dat in veel (maar niet alle) toepassingen polymersomen beter presteren dan 
Chapter 8 
 
148 
liposomen omdat er veel meer design vrijheid is. Daarom is de introductie van de eerste 
medische toepassingen van polymersomen in mijn optiek voor de hand liggend en 
slechts een kwestie van tijd. Ik ben er dan ook van overtuigd dat in de nabije toekomst 
bestaande therapieën gebaseerd o.a. liposomen vervangen worden door polymersome 
analoge, maar de grootse potentie ligt in enorme diversiteit van polymeren en 
structuren die mogelijk zijn voor polymersomen en “polymer therapeutics” in het 
algemeen om aan specifieke criteria te voldoen. De creativiteit van de chemici is slechts 
de beperkende factor om formuleringen te verbeteren nadat wetenschappers uit andere 
disciplines hun input terug hebben gegeven. Het is deze flexibiliteit die “polymeric 
therapeutics” ver boven conventionele methoden uit tilt. Polymeric therapeutics zal 
biomedische oplossingen blijven bieden waar conventionele therapieën geen antwoord 
hebben. 
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Doorlopend in dit proefschrift heb ik geprobeerd steeds in de wij-vorm te schrijven, 
want het moge duidelijk zijn dat ik dit werk zeker niet alleen heb gedaan. Op de 
werkvloer kon ik rekenen op de steun van mijn collega’s, de vaste staf en natuurlijk een 
klein legertje studenten die veel werk voor mij hebben uitgevoerd. Thuis kon ik op de 
steun van familie en vrienden rekenen. Helaas kan ik niet iedereen persoonlijk noemen, 
toch zijn een aantal mensen die ik hieronder kort wil benoemen. 
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bedanken voor het vertrouwen dat jullie in mij hadden op het moment dat jullie mij een 
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zakelijke vragen terecht, maar ook de meer organisch chemische vragen werden door 
jou beantwoord. Ik ben jullie beide zeer dankbaar voor de goede begeleiding en denk 
met warme gevoelens terug aan de vier jaar die ik in jullie labs heb mogen doorbrengen. 
 
Veel van het werk beschreven in hoofdstukken 4 en 5 is in samenwerking met Julia, 
Katica, Inge en Dick Hoekstra van de UMC Groningen uitgevoerd. Julia en Katica, I really 
enjoyed working with the two of you. I think our joined efforts lifted the level of our 
research. Julia, I like your straight forward and efficient approach. Next time we meet we 
should have a cup of hot chocolate! Katica, you are one of the strongest women I have 
ever met and yet you are so warm hearted. A nice combination which I admire in you. 
Inge, als begeleider van Julia en Katica wil ik ook jou bedanken voor onze geslaagde 
samenwerking. Dick Hoekstra, niet alleen hebben wij in het beschreven onderzoek 
samengewerkt, maar je bent ook lid van de manuscriptcommissie. Ik wil je hartelijk 
bedanken voor deze dubbele rol, maar ook voor de interesse die je altijd in mijn werk 
hebt getoond. 
 Iets dichter bij huis in het UMC Nijmegen hebben Peter Laverman en Otto Boerman 
mij geholpen met de experimenten als in hoofdstuk 3 beschreven. Peter, samenwerken 
met jou is ontspannen en doelgericht. We hebben een mooie publicatie geproduceerd en 
zullen elkaar in de toekomst nog vaker zien. Otto Boerman, jou wil ik bedanken voor het 
steunen van deze samenwerking en natuurlijk voor het plaatsnemen in de 
manuscriptcommissie. 
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Ik heb het genoegen gehad om met een groot aantal collega’s samen te mogen werken in 
zowel de Bio- Organische als Synthetisch- Organische groep. Een persoon die er dan 
meteen uitspringt is Hans Adams, de “peptide master”. Hans, jij bent niet weg te denken 
uit de dankwoorden in Nijmeegse chemie proefschriften. Dat is niet voor niets, want ook 
in dit proefschrift heb jij een behoorlijke peptide afdruk achter gelaten. Hans, ik zeg 
altijd maar zo, dat op een gegeven moment iedereen jouw verhalen echt zal gaan missen. 
Daarom wil ik je bij deze bedanken voor je hulp en gezelschap. Ook gaat er een woord 
van dank uit naar de vaste staf en in het bijzonder de secretaresses Jacky, Marieke, Paula 
en Desiree. In het lab heb ik samen mogen werken met vele collega promovendi en 
postdocs. Jullie hebben er allen voor gezorgd dat ik iedere dag weer met plezier naar 
Nijmegen ben gereisd om in een goede sfeer aan het werk te gaan. In het bijzonder wil ik 
Jorgen, Henri en Ferdi bedanken. Regelmatig denk ik nog terug aan de fantastische 
transdolomiti die wij hebben gefietst, een prestatie en ervaring die ik niet snel zal 
vergeten.  
 
Wellicht is de grootste bijdrage aan dit proefschrift geleverd door de studenten die ik 
heb mogen begeleiden. Hoewel niet al hun werk in de publicaties of dit proefschrift 
terecht is gekomen zijn het hun resultaten die geleid hebben tot de experimenten die 
uiteindelijk in dit boekje zijn opgenomen. Kelly, Berry, Sander, Jos, Sanne, Taco, Frank en 
Ruoyu ik heb veel van jullie mogen leren. 
 Kelly en Berry, jullie hebben een grote bijdrage geleverd in het begin van mijn 
onderzoek. Dankzij jullie inspanningen is de chemie, zoals beschreven in hoofdstuk 2, tot 
stand gekomen. Kelly, ik kan ik me de beelden van een meisje van ~1.5 meter dat staand 
op een krukje een bijna even zo grote kolom tot een goed einde brengt nog levendig voor 
me halen. Berry, jij was mijn eerste en meest eigenwijze student ooit. Echter, jouw werk 
aan de anionische polymerisatie van polyethyleen glycol was zeker niet makkelijk. Een 
deelonderzoek waarin je eigenwijze karakter goed van pas is gekomen. 
 Sander en Jos, ook jullie hebben tegelijk stage gelopen en hoewel ik soms helemaal 
gek werd van jullie drukte was dit een topjaar. Sander, als jij je mond opent volgt er een 
spraakwaterval die geen einde lijkt te krijgen. Je enthousiasme is enorm en uit zich dan 
ook in een brede interesse van synthetische chemie via stijldansen tot biologie. Jos, jij 
was verreweg de meest speelse student die ik heb gehad. Hoewel het daardoor soms 
moeilijk was om je op je werk te laten focussen heb je de basis weten te leggen voor een 
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mooie publicatie. Een co-auteurschap doet recht aan jouw inspanningen waar je trots op 
mag zijn.  
 Sanne en Taco, ook tussen jullie stage zat veel overlap en ik denk dat er een mooie 
vriendschap tussen beide uit is ontstaan. Taco, jij werd als HBO-student in mijn schoot 
geworpen. In de eerste instantie wilden ik jou “handige moleculen” voor de hele groep 
laten synthetiseren. Echter, binnen twee weken zag ik dat dit een grove onderschatting 
van jouw kunnen was. Dat jij ook zeer uitdagende projecten tot een goed einde weet te 
brengen komt dan ook naar voren in twee co-auteurschappen. Sanne, jouw vrolijke 
karakter en gedrevenheid om goede resultaten te behalen zijn onophoudelijk. Hoewel 
dit een van je sterke punten is, merkte ik dat je soms ook te veel hooi op je vork neemt 
en heb daarom geprobeerd om je ruimte te geven. Tijdens jouw ministage zag ik dat je 
zelfstandig ideeën ontwikkeld en je inzet en doorzettingsvermogen niet verminderd als 
het merendeel van de experimenten mislukt. Dit is een unieke eigenschap! Het is dan 
ook niet voor niets dat ik je heb gevraagd om ook een lange stage bij mij (en Hanneke) te 
lopen.  
 Frank, als natuurwetenschapper kwam jij precies op het juiste moment langs voor 
een ministage. Je hebt heel wat tijd achter de confocal microscoop doorgebracht en hebt 
perfect uitgezocht hoe de verschillende polymersome samples op fluorescentie 
geanalyseerd dienen te worden. Ondanks dat je na een week al wist dat dit type 
onderzoek niet jouw toekomst zal zijn, heb je extra tijd in je stage gestoken om het 
project volledig af te ronden. Jij staat model voor een geduldige, serieuze, doordachte en 
resultaat gerichte onderzoeker. 
 Ruoyu Xing, I thought I would have no more students yet you came to do an 
internship with me, although you knew I would leave before you would finish. You are a 
unique student in the sense that you want to learn chemistry while being a biology 
student. Besides your study you enjoy life and your stay in the Netherlands to the fullest. 
Not afraid to meet new people you travelled with couch surf friends to Deventer to visit 
the Charles Dickens festival, where we also had a few drinks. 
 
Dan zijn er nog een aantal mensen/groepen die ik kort wil benoemen, gewoon omdat ze 
er zijn of zijn geweest. Te beginnen met het hele team van TI pharma project T5-105 met 
in het bijzonder nog Hanneke. Ook mijn vrienden waar ik regelmatig mee op trek wil ik 
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bedanken. Mijn vrienden hebben jarenlang saaie scheikunde verhalen moeten aanhoren, 
daarom heb ik speciaal voor jullie een Nederlandse samenvatting geschreven. 
 De liefde voor scheikunde en zin om een studie chemie te studeren is ontstaan in de 
scheikunde lessen op het voortgezet onderwijs. Jan Legebeke (alias LEGObeke), hoewel 
u niet mijn eerste scheikunde docent was, was u wel de docent die mijn liefde voor 
chemie heeft aangewakkerd en gevoed. Jouw lessen hebben de basis gelegd voor mijn 
zeer geslaagde keuze om chemie te studeren en in de chemie te promoveren.  
 
Twee mensen hebben mij altijd en onvoorwaardelijk gesteund in keuze als kind, jong 
volwassene en zelfs nu nog. Dat zijn mijn ouders! Er wordt wel eens gezegd dat een kind 
een product van de opvoeding is. Hoewel ik het daar niet altijd mee eens ben weet ik 
zeker dat ouders die alle “tools” aanreiken om iets van je leven te maken het maximale 
hebben gegeven. Papa en mama, ik ben zeer blij met alle mogelijkheden die jullie mij 
hebben gegeven en zie steeds vaker in wat jullie jezelf daar voor ontzegd hebben. Ik wil 
jullie, maar ook mijn beide zussen Ingrid en Ester dan ook speciaal benoemen. 
 Sinds kort heb ik er officieel een tweede familie bij, de familie Bosch. Zij hebben mij 
het mooiste geven wat zij in huis hadden; Lisette. Na exact 10 jaar mag ik je nu mijn 
vrouw noemen. Vrijwel mijn hele studie en promotie heb jij meegemaakt en gesteund. 
Het is fijn om bij jou thuis te komen en te merken dat je naar mijn verhalen luistert. 
Liesje, ik hou van jou. 
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